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1 Introduction
ANESTHESIA has profound eﬀects on the respiratory control system. It has long been
known that anesthesia may diminish pulmonary ventilation, and hypercapnia is com-
monplace if spontaneous breathing is preserved. Studies looking at the incidence of
postoperative respiratory complications show that hypoxemia is a common problem at
the emergence of anesthesia in the postanesthesia care unit (PACU).76,90 During recov-
ery from anesthesia, hypoxia, hypercapnia, and acidosis have several causes: residual
anesthetic and analgesic drugs at their eﬀect site, atelectasis, reduced cardiac output,
upper airway obstruction, analgesic/sedative medication, pain/stress, and underlying
disease. The patient may continue to breathe during a hypoxemic episode, but hypoxia
and hypercapnia have further eﬀects. They cause sympathetic nervous system activity,
which can lead to tachycardia, hypertension and ischemic ECG changes. Aﬀerent input
from the peripheral chemoreceptor is an important stimulus to arousal, the clearing of
upper airway obstruction and the subsequent hyperventilatory response to correct any
hypoxia, hypercapnia and acidosis. Therefore it is of utmost importance to understand
the eﬀect of anesthetics and analgesics on cardiorespiratory control and the mechanism
of action of these agents.
Control of Breathing
Breathing results from activity of the respiratory centers in the brainstem and is well ad-
justed to the metabolic and non-metabolic needs of the body. Optimal adjustments are
possible by incorporating information from various sites in the body. With respect to
the metabolic control of breathing, the chemical composition of arterial blood primar-
ily regulates breathing through eﬀects on the peripheral and central chemoreceptors.
The peripheral chemoreceptors in the carotid bodies are sensitive to changes in arterial
pH, PCO2 and PO2. The central chemoreceptors on the surface of the ventral medulla
are sensitive to changes in brain tissue PCO2 and pH. To maintain a chemical equi-
librium in the body, the metabolic ventilatory control system makes use of two reﬂex
pathways. The peripheral chemoreﬂex loop consists of the peripheral chemoreceptors,
the sinus nerve, sites in the brain stem that receive and process aﬀerent input from the
carotid bodies, the brainstem respiratory centers and the neuromechanical link between
brainstem and ventilation (phrenic nerve, spinal motorneurons, diaphragm, intercostal
nerves and muscles, lungs). The central chemoreﬂex loop involves the central chemore-
ceptors, and neuronal connection between these receptors and the brainstem respira-
tory centers and the above mentioned link between respiratory centers and ventilation
(i.e., the pathway common to both chemoreﬂex loops).37,169,196
Pure chemical control of breathing operates only during non-rapid-eye-movement
(non-REM) sleep and anesthesia (in spontaneous breathing patients). During wakeful-
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ness and REM-sleep, another equally important system, the behavioral control system,
will inﬂuence breathing and may even temporarily override the chemical system. Be-
havioral control of breathing allows for adjustment of breathing to speciﬁc situations
such as speech, singing, reading, eating, diving, et cetera.211 In the postoperative pa-
tient various other systems will inﬂuence breathing, such as the pain-related control of
ventilation and the stress response to surgical stimulation. Clinical and experimental
studies show that pain and surgical stimulation act as a chemoreﬂex-independent res-
piratory stimulant in the awake, sedated and anesthetized states.109,163,173
The aim of this thesis is to increase our insight in the cardiorespiratory control of peri-
operative patients. Studies were performed in animals, volunteers and patients. They
were designed to answer the following questions:
1. What is the role of the carotid body in the control of breathing in man?
2. What is the mechanism of anesthesia-induced depression of the peripheral chemo-
reﬂex loop and are we able to develop cheap and eﬀective regimens to prevent
depression of this vital chemoreﬂex?
3. How do intravenous and inhalational anesthetics and opioids, given alone and in
combination, aﬀect cardiorespiratory control?
4. Is the depression of anesthetics and analgesics on respiration, counterbalanced
by the stimulatory eﬀects of pain and stress?
• In Chapters 2 and 3, items 1 and 2 are addressed. In Chapter 2 respiratory studies
were performed in healthy volunteers as well as in unilateral and bilateral carotid
body resected patients in order to quantify the inﬂuence of the carotid bodies
on the control of breathing. Studies performed are multiple steps into and out
of hypercapnia according to a multifrequency binary sequence (MFBS) recently
developed in Oxford to optimize the study of the peripheral chemoreﬂex loop.144
• In Chapter 3 hypoxic studies were performed in healthy volunteers in the absence
and presence of antioxidants (iv ascorbic acid and oral α-tocopherol) during the
inhalation of the potent volatile anesthetic halothane. Halothane, at already sub-
anesthetic concentrations (0.05–0.1 end-tidal %) causes profound depression of
the carotid bodies and consequently of the ventilatory response to hypoxia.47 This
protocol was developed to test the ability of antioxidants to prevent halothane-
induced depression of the hypoxic ventilatory response. The administration of
antioxidants makes sense taking into account the vast literature showing the in-
volvement of free radical species in oxygen sensing at the carotid bodies, and the
production of radicals species from halothane due to its reductive metabolism.95,96
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• In Chapters 4 and 5, the inﬂuence of the intravenous anesthetic propofol on car-
diorespiratory control is discussed. The results of experiments on various car-
diorespiratory and EEG parameters such as the acute and sustained hypoxic ven-
tilatory response, dynamic carbon dioxide ventilatory response (MFBS), heart rate
and bispectral index of the EEG are reported. Furthermore, the possible site of ac-
tion of propofol within the chemical ventilatory control system is discussed (item
3).
• In Chapters 6 and 7, the eﬀect of combining opioids and anesthetics on the car-
diorespiratory control system is described. The nature and magnitude of interac-
tion of an anesthetic-opioid combination on resting ventilation, resting end-tidal
carbon dioxide concentration, blood pressure, heart rate and bispectral index of
the EEG and the steady-state ventilatory responses to carbon dioxide and acute
hypoxia is assessed using the technique of response surface modeling (item 3).
• In Chapter 8, the inﬂuence of tramadol on ventilatory control in the anesthetized
cat is discussed. To examine the involvement of the µ-opioid receptor in tramadol
eﬀects on respiration, the ability of naloxone, an opioid-antagonist, to reverse the
respiratory eﬀects of tramadol was studied (item 3).
• Finally, in Chapter 9, the complex of factors that interact on the cardiorespira-
tory control system in postoperative patients is examined. Respiratory studies
are performed in patients shortly after major abdominal surgery as well as weeks
to months later so that these subjects could serve as their own control. Breath-
ing was tested by applying ramp-like increases in end-tidal PCO2 combined with
concomitant ramp-like decreases in end-tidal PO2. This stimulus was chosen to
mimic the changes in arterial gas composition that occur during upper airway
obstruction (item 4).

SECTION 1
Physiology

2 Modeling the ventilatory response to carbon dioxide in
humans after bilateral and unilateral carotid body
resection (CBR)
IT IS AXIOMATIC that the respiratory chemoreceptors sense and respond to changes
in the composition of their immediate microenvironment.78 In humans, the ventilatory
response to a step change in end-tidal CO2 yields a fast (τ ∼10 s) and a slow component
τ ∼120 s).12,40 Two sets of chemoreceptors are thought to elicit these two components:
the peripheral chemoreceptors, causing the fast component and located in the carotid
bodies at the bifurcation of the common carotid artery, and the central chemoreceptors,
causing the slow component and located in the ventral medulla.12,40,55 Validation of the
(carotid body)-origin of the fast component in humans is a diﬃcult task and has not
been accomplished satisfactorily as yet. Studies in animals,55 and patients who have
had bilateral carotid body resection (CBR) for the relief of asthmatic symptoms,12,91
or bilateral carotid endarterectomy for transient cerebral ischemia,208 suggest that the
fast component of the ventilatory response to CO2 arises from carotid body activity.
However, it is questionable whether animal studies apply directly to humans, and in
case of patients with underlying disease of the vessels and lungs, it is also possible that
the eﬀect on the V˙i-CO2 response was related to any underlying process.
In this study, we sought to examine the ventilatory response to CO2 of adult human
subjects who had undergone bilateral and unilateral carotid body resection for carotid
body tumors. Testing in patients with carotid body tumors prior to resection had re-
vealed that the carotid body function had not been altered by the tumor formation.
Furthermore, all of the tested subjects were otherwise healthy with normal lung and
cardiovascular function.
METHODS
Patients and Volunteers
We recruited 14 patients and 7 volunteers after approval of the protocol was obtained from the
LUMC ethics committee. Patients had undergone unilateral or bilateral resection of the carotid
body 1 (2000) to 26 (1976) years before testing but were otherwise healthy. These patients
had developed tumors of one or two carotid bodies (glomus tumor or chemodectoma), most of
them due to a mutation of the SDHD gene on chromosome 11q23, as part of the head and neck
hereditary paraganglioma. SDHD (succinate-ubiquinone oxireductase subunit D) is a small part
of cytochrome b588 of the mitochondrial respiratory chain complex II. In the majority of Dutch
patients (all part of the Dutch founder families) a missense mutation that changes ASP92 ⇒ Tyr
was found.93, 203 Control patients were healthy volunteers matched for age and sex (table 1).
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Table 1. Patient and volunteer characteristics
male/female age (yrs) age range weight (kg) height (cm)
bilateral CBR 4/3 46 ± 8 28–51 73 ± 10 174 ± 16
unilateral CBR 4/3 41 ± 10 30–56 78 ± 18 177 ± 13
control 4/3 48 ± 11 31–59 73 ± 11 175 ± 9
Values are mean ± SD.
Apparatus
The subjects were comfortably seated in a hospital bed and breathed through a face mask (Vi-
tal Signs, Totowa, NJ). The gas ﬂows were measured with a pneumotachograph connected to a
pressure transducer and electronically integrated to yield a volume signal. The volume signal
was calibrated with a motor-driven piston pump (stroke volume 1 l, at a frequency of 20 min−1).
Corrections were made for the changes in gas viscosity due to changes in oxygen concentration
of the inhaled gas mixtures. The pneumotachograph was connected to a -piece. One arm of
the-piece received a gas mixture with a ﬂow of 50 L/min from a gas mixing system, consisting
of three mass ﬂow controllers (Bronkhorst High Tech BV - F202, The Netherlands) with which
the ﬂow of O2, N2 and CO2 could be set individually at a desired level. A Personal Computer
provided control signals to the mass-ﬂow controllers so that the composition of the inspired
gas mixtures could be adjusted to force end-tidal oxygen and carbon dioxide concentrations
(PETO2 and PETCO2) to follow a speciﬁed pattern in time, independent of the ventilatory re-
sponse. The in- and expired O2 and CO2 concentrations and the arterial hemoglobin-O2 sat-
uration (SPO2) were measured with a Datex Multicap gas monitor (near the mouth) and Datex
Satelite Plus pulse oximeter, respectively (Datex-Engstrom, Helsinki, Finland). The gas moni-
tor was calibrated with gas mixtures of known concentration delivered by a gas-mixing pump
(Wösthoﬀ, Bochum, Germany). PETO2, PETCO2, tidal volume, respiratory frequency, inspired
minute ventilation (V˙i) and SPO2 were collected and stored on disc for further analysis. The
data steering and acquisition software was custom build (RESREG and ACQ) by Erik Kruyt and
Erik Olofsen and displays the ventilation data on-line in real time.
Study Design
Each subjects rested for 30 min after arriving in the laboratory. Next, two hypercapnic studies
were performed at the background of normoxia, followed by a 20-min hypoxic study (PETO2 7
kPa), and, ﬁnally two hypercapnic studies at the background of mild hypoxia (PETO2 10 kPa).
Hypercapnic Studies: The end-tidal PCO2 was varied according to a multi-frequency binary
sequence (MFBS) that involved 13 steps into and 13 steps out of ﬁxed PETCO2 levels (low and
high CO2: 2 mmHg and 12 mmHg above the subjects normal air breathing value for PETCO2)
altogether lasting 1408 s (23 min and 28 s).144 See ﬁgure 1 of chapter 6 for a schematic diagram
of the PETCO2 input function.∗ The MFBS experiments were performed at a background of nor-
moxia or moderate hypoxia (to cause a more potent stimulus to the peripheral chemoreceptors)
The hypoxic CO2 studies started 20 min after the initiation of hypoxia, which was done to allow
time for hypoxic ventilatory decline to develop prior to investigating the response to CO2 (cf.
Chapter 4).
∗See for the rationale of using MFBS rather than step CO2 input functions Chapter 5.
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Sustained Hypoxic Studies: The PETO2 was forced as follows: (1) 10 min at 15 kpa, (2) a
rapid decrease to 7 kPa, (3) 20 min at 7 kPa (SPO2 ∼87%), (4) a rapid increase to 10 kPa (after
which the last two hypercapnic studies were performed).
Data Analysis
Hypercapnic Study: In order to determine whether both the fast and slow components could
be identiﬁed in the ventilatory response to PETCO2, both single and a two-compartment model
were ﬁtted to the data. Both models were based on that of Bellville et al.12 and Dahan et
al.40 The two-compartment model, describing central and peripheral chemoreﬂex parameters
is given by:
τc
d
dt
V˙c(t)+ V˙c(t) = Gc[PET ,CO2(t − Tc)− Bk](1)
τp
d
dt
V˙p(t)+ V˙p(t) = Gp[PET ,CO2(t − Tp)− Bk](2)
V˙c(t) and V˙p(t) are the outputs of the central and peripheral chemoreﬂex loops.
PETCO2(t - Tc) is the stimulus to the central chemoreﬂex loop delayed by the central transport
delay time, PETCO2(t - Tp) the input to the peripheral chemoreﬂex loop delayed by the peripheral
transport delay time. The parameters GC and τC are the CO2 sensitivity and time constant of
the central chemoreﬂex loop. The corresponding parameters of the peripheral chemoreﬂex
loop are denoted by GP and τP . Bk is the apneic threshold or extrapolated PETCO2 of the
steady-state V˙i-PETCO2 response at zero V˙i.
The noise corrupting the data is modeled through an external parallel pathway (V˙n).114 In
most experiments a drift in the ventilation was present. We therefore decided to include a
drift term in our model (C · t). The total ventilatory response is made up of the sum of the
contributions of the central and peripheral chemoreﬂex loops, the external noise, the drift
term and the measurement noise term (W(t)):40
V˙i(t) = V˙c(t)+ V˙p(t)+ V˙n(t)+ C · t +W(t)(3)
The two-compartment model reduces to the one-compartment model by ﬁxing GP and thus
component V˙P to zero. This results in the simple model:
V˙i(t) = V˙c(t)+ V˙n(t)+ C · t +W(t)(4)
The estimation of the parameters of the one- and two-compartment model was performed
with an one-step prediction error method.144
Sustained Hypoxic Studies: Mean values of the breath-to-breath data were chosen over iden-
tical time segments. Period A is the 1-min period before the 15-min of hypoxia; Period B the
3rd min of hypoxia; Period C the 20th min of hypoxia. Diﬀerences in V˙i between Periods A and
B were deﬁned as the acute hypoxic response or AHR. Diﬀerences in V˙i between periods B and
C were used as measure of the hypoxic ventilatory decline or HVD. The V˙i responses are ex-
pressed as the change in V˙i per percentage change in SPO2 (units: L min−1 %−1).
Statistical Analysis
The variance ratio test (F ratio test) was used to compare the goodness of ﬁt among the one-
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and two-compartment models. This test indicates whether, after allowing for the diﬀerence
in the number of parameters between the nested models, the larger model still provides a
statistically signiﬁcant improvement in the ﬁt to a common data sequence, compared with the
smaller model. The F -statistic was calculated as follows:2
F = (RSS1 − RSS2)/(df1 − df2)
RSS2/df2
∼ F(df1 − df2, df2)(5)
where RSS1 and df1 refer to the residual sum of squares and degrees of freedom of the smaller
model and RSS2 and df2 refer to the residual sum of squares and degrees of freedom of the
larger model. Note that the F -ratio assumes that the residuals are uncorrelated (white or close
to white). This was obtained by modeling the noise using the parallel noise pathway.144
On the parameters obtained from the two-compartment model we performed a paired (nor-
moxia versus hypoxia) and unpaired (the eﬀect of carotid body resection) analysis of variance.
The eﬀect of CBR on the AHR and HVD was tested by one-way analysis of variance. Values
are mean ± SD. P-values < 0·05 were considered signiﬁcant.
RESULTS
Hypercapnic Studies
An example of a ventilatory response to two subsequent MFBS CO2 inputs of a bilateral
CBR patient is given in ﬁgure 1. The ﬁt of the two-compartment model to the data is
given (line through the data points).
Model Comparison.
• For the normoxic CO2 data in bilateral CBR patients the two-compartment model
did not provide a statistically signiﬁcant improvement over the one-compartment
model. For the hypoxic CO2 data an improvement occurred in 1 out of 7 subjects.
• For the unilaterally resected patients, the two-compartment model ﬁtted the data
signiﬁcantly better than the one-compartment model for 6 out of 7 subjects under
both conditions of normoxia and hypoxia.
• For control subjects, the two-compartment model ﬁtted the data signiﬁcantly bet-
ter than the one-compartment model for 5 out of 7 subjects under both O2 back-
ground conditions.
Model Parameters. The mean parameter values are given in table 1. The statistical
analysis was performed on the parameters of the two-compartment in order to test
the eﬀect of the protocol for each of the three subjects groups (paired anova). For
bilaterally CBR patients parameter GP remained unaﬀected by hypoxia. The increase of
GP in hypoxia seen in unilaterally resected patients was not signiﬁcant. Only in control
subjects didGP increase signiﬁcantly with hypoxia (P< 0·05). All other parameters were
unaﬀected by hypoxia, with the exception of GC in control subjects which increased
signiﬁcantly (P < 0·05).
In order to investigate the eﬀect of carotid body resection on model parameters, an
unpaired anova was performed on the parameters of the two-compartment model as
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Table 2. Model parameters of the two- and one-compartment models
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Figure 1. Two-compartment model ﬁt to the normoxic CO2 data of a bilaterally CBR patient. Shown
is the response to 2 subsequent MFBS CO2 inputs. Each dot is one breath. The line through the data
points is the sum of the peripheral component (V˙P ), central component (V˙C ), parallel noise (V˙n),
measurement noise (W ) and a trend term (C). Only components V˙P and V˙C are shown.
a factor between the three subject groups. This eﬀect showed a signiﬁcant diﬀerence
across groups of GC and GP (P < 0·05). This is, a lower GC and GP for the bilateral
CBR patients compared to the unilateral CBR patients; and also a lower GC and GP for
the unilateral CBR compared to control (see also ﬁg. 2). There was also a signiﬁcant
decrease in Bk in both bilaterally and unilaterally resected patients compared with the
control group (P < 0·05). There was no signiﬁcant interaction between the carotid body
condition and the protocol (hypoxia eﬀect), probably due to the lack of hypoxic eﬀect
in unilaterally CBR patients, as observed in the paired comparison.
Inspection of the noise pathway revealed that successive breaths are less correlated
in the absence of carotid bodies.
Hypoxic Studies
The acute hypoxic response increased signiﬁcantly from bilaterally to unilaterally CBR
patients and control subjects: 0·12 ± 0·09, 0·53 ± 0·43 (P = 0·03 vs. bilateral CBR), and
1·33 ± 0·80 L min−1 %−1 (P = 0·03 vs. unilateral CBR and P < 0·01 vs. bilateral CBR).
The magnitude of HVD did not diﬀer among the three groups although there was trend
towards a greater HVD with a greater AHR (ﬁg. 3): bilateral CBR 0·35 ± 0·27, unilateral
CBR 0·46 ± 0·34 and control 0·83 ± 0·65 L min−1 %−1 (P = 0·11).
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Figure 2. Mean values ± SD of the gain’s of the two-compartment model for bilateral and unilateral
CBR patients and control subjects. See text for the result of the paired (eﬀect of hypoxia) and
unpaired comparisons (diﬀerences among the three groups).
DISCUSSION
This study provides additional data on human subjects who have undergone CBR. Our
ﬁndings in otherwise healthy patients using MFBS CO2 inputs to the ventilatory con-
trol system are in the general direction predicted from previous studies in humans
and animals.12,40,55,78,91,208 The main ﬁnding of our study is the need for only a one-
compartment model when ﬁtting normoxic and hypoxic CO2 data in patients after bi-
lateral CBR (i.e., the absence of a signiﬁcant improvement in ﬁt in the two-compartment
model). When a signiﬁcant improvement in ﬁt does occur with the introduction of a
second, fast component, it is associated with the presence of a peripheral chemoreﬂex
response. This occurred in unilaterally CBR patients and control subjects. Our data
indicate that the peripheral component (GP ) arises from the carotid body.
Central–Peripheral Ventilatory Chemoreflex Interaction
The value of GC increased in hypoxia in control subjects (table 2). This may suggest
central–peripheral interaction (that is, the modulation of the central gain of the res-
piratory controller by the peripheral drive from the carotid bodies). The ﬁnding that
GC increased from bilateral to unilateral CBR patients to control subjects (especially in
hypoxia) is further proof for this form of interaction.
In the work of Bellville et al. there are some indications for such an interaction in the
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Figure 3. The acute hypoxic response (AHR) versus the hypoxic ventilatory decline (HVD). The
continuous line is the linear regression. On the bottom the mean ± 95% conﬁdence interval AHR-
values for the three groups is given.
human respiratory control system.12 They found in normal subjects an increased central
CO2 sensitivity in hypoxia compared to normoxia and, like we did, in subjects who had
undergone CBR a decreased CO2 sensitivity was obtained. On the other hand, Ward &
Bellville found no signiﬁcant reduction of the central CO2 sensitivity after intravenous
infusion of dopamine, which caused a large decrease of the peripheral CO2 sensitivity.209
Results of Robbins may also point into the direction of an interaction.159 He compared
hypoxic steps against a background of normocapnia at the peripheral chemoreceptors
and initial hypercapnia at the central chemoreceptors with hypoxic steps against a back-
ground of normocapnia at both sets of chemoreceptors. Two of his three subjects
showed an increased ventilatory response to steps into hypoxia when central PCO2 was
high. The issue of central–peripheral interaction has also been pursued by others using
a similar protocol as that of Robbins.32,33,188 Their results do not lend much support for
inclusion of central–peripheral interaction in the model of the chemoreﬂexes.
Dahan et al. observed the reduction of the central gain with hyperoxia which reduced
GP by > 70%.40 However, in an attempt to ﬁt normoxic step CO2 response curves using
an central–peripheral interaction model, they observed that the model was overparam-
eterized.
While our current study is entirely convincing regarding the origin of the peripheral,
fast component, V˙P , the existence of central–peripheral interaction remains a challeng-
ing issue for further research. So far, the data conﬁrming central–peripheral interac-
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tion comes mostly from data involving CBR (cf. ref. 12 and this study). It may well be
that after CBR transient or permanent changes in central chemoreﬂex function occurs
(plasticity).139 We followed one patient for over one year after CBR and observed a large
but over time variable depression of GC relative to pre-operative conditions. This sug-
gests a change in the central chemoreﬂex loop which had not reached a steady-state as
yet. Finally, our results as well those of others may direct also towards central O2-CO2
interaction.
Characteristic of Components
We did observe an increase in GP and AHR among the three groups, suggesting that
each of the carotid bodies have an additive eﬀect on the peripheral contribution to CO2-
and hypoxia-stimulated breathing. Although the magnitude of the hypoxic ventilatory
decline did not diﬀer among the three groups, there was a clear trend of increased HVD
with increased AHR (ﬁg. 3). This suggests the need for AHR in the development of HVD.
This is in agreement with a previous observation where we observed that despite central
hypoxia (i.e., within the CNS), but absence of peripheral drive, HVD did not develop.50
The very small but signiﬁcant AHR in bilaterally resected subjects was surprising
(ﬁg. 3) but may be due an eﬀect of hypoxia on central O2-sensitive chemosensors.198
Taken into account the CO2 data, we do not believe that the small AHR reﬂects the
return of peripheral chemoreception (e.g., at the end of the cut sinus nerve or at arterial
chemoreceptors).
We observed 0·3 to 0·5 kPa lower Bk values after uni- and bilateral CBR relative to
control subjects. This suggest only a minor addition of the peripheral chemoreﬂex to
ventilatory drive when the system is not stimulated by CO2. Whether this is also true
under conditions other than the awake state (for example sleep or propofol anesthesia†)
deserves further study.
The central chemoreﬂex gains in the unilaterally CBR patients and control subjects
obtained under conditions of normoxia as well as all the other ’normoxic’ parameters
are in close agreement with previous observations in a group of healthy young volun-
teers (18–21 years).40 This suggests the absence of age eﬀect, at least over the age range
studied, on the dynamics of the ventilatory control system.
In conclusion, we give additional proof that, in humans, the quantitative contribution of
the peripheral and central respiratory chemoreﬂexes to CO2-stimulated breathing, un-
der conditions of constant background PETO2, (and the eﬀect of pharmacological agents
on these chemoreﬂexes) is reliably assessed using the two-compartment model of the
ventilatory control system as previously suggested by Bellville et al.12 and Dahan et al.40
†see Chapters 4 and 5

3 Antioxidants prevent depression of the acute hypoxic
ventilatory response by subanesthetic halothane
A MAJOR DEFENSE of the mammalian body to acute hypoxia is a rapid increase in pul-
monary ventilation called the acute hypoxic response (AHR). This vital chemoreﬂex is
primarily mediated by the carotid bodies located at the bifurcations of the common
carotid arteries80 During the past decade considerable progress has been made in unrav-
eling the cascade of events within carotid body type I cells upon exposure to a hypoxic
environment, although there are still many areas of controversy.80,118
The general pictures emerging from most studies is that low oxygen decreases the
open probability of potassium channels which causes membrane depolarisation and
inﬂux of Ca2+ ions. In several species, various types of potassium channels are de-
scribed that may serve as oxygen sensing element that initiates the transduction cas-
cade in hypoxia, for example Kv channels in rabbit, 146,148 and Maxi-K and TASK chan-
nels in rat.25,158 Although it is known that potassium channels confer redox sensitivity
and are sensitive to changes in the concentration of reactive oxygen species (ROS) it is
unclear by what mechanism low oxygen is able to decrease the conductance of these
channels.102,105,118
Volatile anaesthetics such as halothane can open potassium channels in various cell
types such as TASK channels in rat carotid body.25,143,184,140,141 At the same time, volatile
anaesthetics, particularly halothane, are known to depress the acute hypoxic response,
an eﬀect that may be mediated through a preferential and potent action on the carotid
bodies.100,47 It is unknown if opening of potassium channels by halothane might occur
through changes in the cell redox state and/or changes in ROS. It is known, however, that
during hypoxia halothane undergoes a reductive metabolism in the liver bywhich radical
species are produced and lipid peroxidation is initiated; this reductive metabolism of
halothane is thought to be responsible for it’s mild hepatotoxic eﬀect.56,57,95,187 In guinea
pig liver, peroxidation of lipids following halothane administration can be inhibited by
antioxidant treatment with vitamin E.177
The above ﬁndings on the sensitivity of potassium channels to ROS, the ability of
halothane to produce radical species and to open potassium channels and ﬁnally the
role of potassium channels in the hypoxic response raise the question if halothane may
reduce the hypoxic response by producing ROS or by inﬂuencing the redox state of the
carotid body. The aim therefore of the present studies in humans was to examine the
inﬂuence of the potent antioxidants a-tocopherol and ascorbic acid on the acute hypoxic
ventilatory response.
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METHODS
Subjects and Apparatus
Thirty-two healthy, non-smoking, male subjects (age 20 to 35 yr) were recruited after proto-
col approval by the Leiden University Medical Center Committee on Medical Ethics. None of
the volunteers was taking any medication or ever had surgery under general anaesthesia. All
subjects performed a series of test experiments to familiarize them with the apparatus and
experimental procedures. The subjects were instructed not to eat or drink for at least 8 hours
prior to the study. They were not instructed about respiratory physiology, anesthesia and the
intensions of the study. All gave oral and written informed consent before their participation.
After arrival at the laboratory, an intravenous catheter was inserted in the left or right ante-
cubital vein for drug infusion. Subsequently electrodes for EEG monitoring (BisSensor, Aspect
Medical Systems, Newton, MA) were placed on the head at AT1-FP1 as speciﬁed by the manufac-
turer, and the subjects rested for 20 to 30 min. Next a facemask was applied over the mouth
and nose.
The EEG was recorded using an Aspect A-2000 EEG monitor (software version 3.3). The
monitor computed the bispectral index (BIS), an objective measure of hypnosis,164 over 2-s
epochs. We averaged the BIS values over 1 min-intervals and used data points obtained at
3-min intervals for further analysis.
SeeMETHODS section Apparatus of Chapter 2 for a description of the procedure and appara-
tus. Part of the nitrogen (5 L/min) passed through a halothane vaporizer (Dräger 19·2, Lubeck,
Germany). During the initial part of the study (control experiments), the vaporizer was kept
in the "oﬀ"-position. Dräger Nederland BV calibrated the vaporizer prior to its use in this study.
Study Design
In the ﬁrst set of studies, which was designed to test the eﬀect of antioxidant pre-treatment
on the depression by halothane of the acute hypoxic response (AHR), two separate groups of
8 subjects underwent a control hypoxic study, followed by a halothane hypoxic study, and
ﬁnally by a halothane hypoxic study after pre-treatment with a cocktail of antioxidants (study
1) or placebo (study 2). In a second set of studies, which was designed to study the eﬀect of
antioxidant pre-treatment on the hypoxic ventilatory response in the absence of halothane, two
separate groups of 8 subjects underwent a control hypoxic study, followed by a sham halothane
hypoxic study, and next followed by a sham halothane study after pre-treatment with a cocktail
of antioxidants (study 3) or placebo (study 4). While the design of the halothane administration
was randomised and blinded to the subjects only, both subjects and researchers were blinded
to the pre-treatment with anti-oxidants or placebo.
After each hypoxic study blood was drawn from the capillary bed of a hyperaemic ﬁnger for
the determination of blood acidity (A˙strup equilibration technique, Radiometer, Copenhagen,
Denmark).
TheHypoxic Study. Hypoxia was induced with a dynamic end-tidal forcing system:39,45 steps
from normoxia (PETO2 15 kPa) into hypoxia (PETO2 6·2 kPa obtained within 4 to 6 breaths) were
applied. Since peak hypoxic responses occur within three min,39 hypoxia was maintained for
three min, after which hyperoxia was introduced for 5 min (FiO2 > 0·5). The PETCO2 was
maintained just above individual resting values.
Halothane. During the appropriate studies, the subjects inhaled halothane (Fluothane, Zeneca
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Ltd, Macclesﬁeld, UK). By manipulating the settings of the vaporizer, the subjects inhaled
0·11% end-expiratory halothane for 10 min before the hypoxic study started. Inhaling 0·11%
halothane for 10 min results in a MAC equivalent of 0·13 (assuming an age adjusted MAC
of 0·84% in our young subjects).83 Note that because of the short (10 min) exposure time to
this end-tidal level of halothane, the brain concentration is less than 0·11%, preventing the
occurrence of signiﬁcant central eﬀects (i.e., within the central nervous system) of halothane.
The subjects were under the impression that halothane was given during the sham halothane
studies by manipulating an empty vaporizer.
The Antioxidant Cocktail (AOX). The antioxidant cocktail consisted of 200 mg of oral α-
tocopherol (Organon, Oss, The Netherlands) given 1-h prior to the start of the appropriate
hypoxic study, which was ingested with a cup of yoghurt and two 1 gram intravenous doses
of ascorbic acid (Ascorbinezuur CF, 5 ml, Centrafarm, The Netherlands) given 10 and 4 min
before the appropriate hypoxic study. Placebos consisted of cellulose tablets and 0·9% NaCl
manufactured by the local pharmacy). The oral placebo was also ingested with yoghurt.
Data and Statistical Analysis
Analysis was performed on a blinded data set. The breath-to-breath data of the last 10 breaths
of normoxia and the last 10 breaths of hypoxia were averaged. Since the relationship between
ventilation and arterial oxygen saturation is found to be linear,45 we calculated the diﬀerence
between the mean V˙i- and the SPO2-data points and expressed the acute hypoxic ventilatory
response (AHR) or sensitivity as follows:45
AHR = [V˙i(hypoxia) – V˙i(normoxia)] / [SPO2(normoxia) – SPO2(hypoxia)]
(units L/min per % desaturation). The statistical analysis was performed using SPSS v10.0
for Windows. To detect the signiﬁcance of diﬀerences among the three treatment groups of
each study, a two-way analysis of variance was performed. Post-hoc analysis was by least-
signiﬁcant diﬀerences and Bonferroni tests. To assess the eﬀect of antioxidant-versus placebo-
pre-treatment, Student t-tests were performed on the appropriate treatment levels of studies
1 and 2 and studies 3 and 4. Values reported are mean ± SD. P-values < 0·05 were considered
signiﬁcant.
RESULTS
All subjects completed the protocols without side eﬀects. During all studies PETCO2
values were kept constant 0·1 to 0·2 kPa above individual resting values, with no diﬀer-
ences between baseline (pre-hypoxia) and hypoxic PETCO2 values and pH. In all hypoxic
studies SPO2 values were 82 ± 2%.
The values of baseline ventilatory parameters and the control ventilatory responses
to hypoxia are in agreement with earlier observations (table 1; refs. 48,45). We ob-
served no eﬀect from low dose halothane on baseline ventilation. Similarly, antioxidant
and placebo pre-treatment had no signiﬁcant eﬀect on baseline parameters (table 1).
Halothane (0·11% end-tidal) decreased the ventilatory response to hypoxia by more
than 50%. As shown in ﬁgure 1, this eﬀect was completely prevented by pre-treatment
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Table 1. Inﬂuence of antioxidant and placebo pretreatment on halothane- and sham-halothane-
induced depression of the ventilatory response to hypoxia
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with the antioxidant cocktail (study 1) but not by placebo pre-treatment (study 2). Sham
halothane did not aﬀect any of the ventilatory baseline and hypoxic parameters, neither
did antioxidant (study 3) or placebo (study 4) pre-treatment (table 1 and ﬁg. 2)). The 95%
conﬁdence intervals of antioxidant eﬀect relative to halothane or sham-halothane (ratio
AOX+halothane/halothane in study 1, and ratio AOX+sham halothane/sham halothane
in study 3) did not overlap: 1·7, 3·1 and 0·6, 1·1 in studies 1 and 3, respectively (ﬁgure
3). This indicates that the eﬀect of AOX to abolish halothane’s depressant eﬀect cannot
be explained by an increase of the AHR by the antioxidants per se.
Bispectral index values did not diﬀer among control, halothane, sham-halothane, an-
tioxidant pre-treatment and placebo pre-treatment studies (table 1), indicating that
there were no diﬀerences in the subjects’ level of arousal across the various runs of
all four studies.
DISCUSSION
We have found that while an antioxidant cocktail had only a small, statistically not
signiﬁcant, eﬀect on the acute hypoxic response (ﬁg. 3), it did reverse the large depres-
sion in the hypoxic response caused by low dose halothane. To place this result into
context, we need to discuss methodological considerations; the modulating role of reac-
tive oxygen species (ROS) in the chemoreception process; and the mechanism by which
halothane depresses the hypoxic ventilatory response and how this eﬀect might depend
on the redox state in (the membrane of) chemoreceptors cells. The measurement of the
hypoxic ventilatory response requires isocapnia both across drug treatments as well
as during the hypoxic test. As seen in table 1 the mean diﬀerences in PETCO2 for the
diﬀerent treatment conditions in the four studies were closely matched and did not
contribute to the changes in the measured AHR.
Although we attempted to achieve blinding, the subjects were probably aware of when
the halothane was being inhaled. The depression, however, of the AHR by halothane
is large and consistent across subjects (ﬁg. 1) while the changes in the AHR with the
sham-halothane are variable and similar to the variation expected with repeated hypoxic
tests. In testing the eﬀects of inhalational anaesthetics, the experimental conditions are
very important. We have previously shown that arousing the subject with audio visual
stimulation can reverse the depression of the AHR by isoﬂurane.200
In the present experiments, the subjects were awake but left undisturbed. Because
we did not see any inﬂuence of either halothane or the antioxidants on the bispectral
index (table 1), we have no observational evidence of an inﬂuence of the subject’s level
of arousal on our results. While we believe that the antioxidant cocktail that we utilized
was eﬀective in altering the intracellular or extracellular redox state, we have no direct
measurement of their eﬃcacy in our subjects. We rationalize the use of an antioxidant
cocktail as follows. We had to take into account that the eﬀects of halothane could be
located at several sites: at the outer face of the membrane, within the membrane or in
the cytosol or possibly at the mitochondrial level. For this reason we used the water-
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Figure 1. Hypoxic ventilatory responses of individual subjects of studies 1 and 2. Study 1: Control,
run 1, and halothane hypoxic ventilatory responses, run 2, and inﬂuence of antioxidant, run 3
pretreatment on halothane-induced impairment of the hypoxic drive. Study 2: Control, run 1,
and halothane hypoxic responses, run 2, and inﬂuence of placebo pre-treatment on halothane-
induced impairment of the hypoxic drive, run 3. Note the ability of antioxidant but not placebo
pre-treatment to prevent depression of the hypoxic response by halothane.
soluble ascorbic acid which is a particularly potent anti-oxidant in plasma and in the
cytosol27,74 and α-tocopherol which, due to its lipid solubility, may be the most impor-
tant free radical and lipid peroxide scavenger in membranes.26 Furthermore, it is known
that the combined eﬀectiveness of ascorbate and α-tocopherol is synergistic, with the
net result that radicals originating from the membrane are removed using two diﬀerent
antioxidants.134,138 Combined administration of α-tocopherol (2000 I.U. i.m.) and ascor-
bic acid (2 g i.v.) has been shown to reduce lipid peroxidation in patients undergoing
cardiac bypass operation.9 The oxygen transduction cascade in the carotid body (as in
the similarly oxygen sensitive pulmonary artery smooth muscle and the pulmonary neu-
ral epithelial cell bodies) has been subject to considerable research over the past decade
and while a much clearer picture of the process has emerged, there are many areas of
considerable controversy.80,118 The most generally accepted model is that low oxygen
decreases the open probability of potassium channels in the membrane of carotid body
type I cells which results in depolarisation. This membrane depolarisation opens volt-
age gated calcium channels with the resulting inﬂux of Ca2+ causing neurotransmitter
release, which activates the synaptically adjacent carotid sinus nerve. Currently, much
interest has focused on the oxygen sensitive potassium channels in the carotid bodies
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Figure 2. Hypoxic ventilatory responses of individual subjects of studies 3 and 4. Study 3: Con-
trol, run 1, and sham halothane hypoxic ventilatory responses, run 2, and inﬂuence of antioxidant
pretreatment on the hypoxic drive during inhalation of sham halothane, run 3. Study 4: Control,
run 1, and sham halothane, run 2, and the inﬂuence of placebo pre-treatment on the hypoxic drive
during inhalation of sham halothane, run 3.
of several species.149,113 The rat and the rabbit have been most commonly studied and
they appear to have diﬀerent types of oxygen sensitive potassium channels. The rat
appears to have both TASK,25 and Maxi-K channels,158 that are oxygen sensitive, while
in the rabbit Kv channels seem to serve this role.146,148 However, within this general
model, it is not determined how low oxygen closes the potassium channel that seems
to initiate the cascade. Several studies have shown that potassium channels show re-
dox sensitivity and considerable sensitivity to levels of ROS.102,105,142,117 It is unsettled
whether potassium channels possess intrinsic oxygen sensitivity, or, alternatively, are
inﬂuenced or modulated by other O2 sensing elements in the cascade, for example by
(membrane associated) cytosolic redox couples . Intrinsic oxygen sensitivity could exist
in the form of reduction/oxidation of thiol containing free cysteine residues in b sub-
units that are required for hypoxic sensitivity.147 One proposed redox model associated
with enzymatic production of ROS that may inﬂuence potassium channel conductance
is the cytochrome P-450 system that utilizes NAD(P)H as an electron donor. Inhibition
of this enzyme system has been shown to prevent the hypoxic inhibition of potassium
channels87 but this has not been found in all model systems.165
It is clear that within this general framework of hypoxic chemoreception there is con-
siderable variety in speciﬁc sensor elements and couplings. Particularly when channels
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are expressed in heterologous systems, all the elements for the in vivo cascade may not
be present. In addition, there may be substantive diﬀerences between sensing elements
of the cascade between the diﬀerent oxygen sensitive tissues. Thus, it has been diﬃcult
to verify the role for ROS in carotid body chemotransduction in more physiologically in-
tact preparations. In fact, there is considerable controversy as to whether ROS increases
(pulmonary arterial smooth muscle)111,214 or decreases (carotid body)108 with hypoxia
in oxygen sensitive cells. Experiments in which the redox state of carotid body cells
was altered would seem to indicate that ROS may not be a direct link between hypoxia
and the membrane depolarisation initiated by the closure of the K+ channel.165,167 Ex-
ogenous reductants, on the other hand, have been shown to mimic the eﬀect of hypoxia
on O2 sensitive potassium channels in carotid body cells.11 Thus, whatever the precise
mechanism, there is likely to be at least a modulating role for the redox state of the
type-I cell in O2 sensing. The depressant eﬀect of subanesthetic halothane in humans
on ventilation during hypoxia may occur via a preferential and potent action on the
carotid bodies.47,100 The mechanism for this depression is unknown but inhalational
anaesthetics can directly open two-pore domain potassium (TASK) channels in various
cell types,140,142,143,184 and in particular in the rat carotid body.25 The action ion of inhala-
tional anaesthetics on TASK channels may be located at a speciﬁc region at the junction
between the ﬁnal transmembrane domain and the cytoplasmic C-terminus.143,192 This
site is also involved in neurotransmitter inhibition of the channel but does not contain
a motif that is known to be involved in cell signalling mechanisms.192 How changes in
ROS or redox state could alter the properties of this binding site is unknown. In the lung
carcinoma cell line H146, a representative model for pulmonary oxygen-sensitive neu-
roepithelial body cells, halothane transiently reverses hypoxic inhibition of potassium
currents, similar to the reversal caused by the reactive species H2O2.86 The metabolism
of halothane itself may also change the redox status of cells. In hypoxia, halothane un-
dergoes a reductive metabolism that in the liver is catalysed by isoforms of cytochrome
P450 but in other tissues possibly also by other heme-containing proteins.57,95,187 Reduc-
tion of halothane yields CF3CHCl radicals able to inactivate cytochrome P450 by covalent
binding, or, alternatively, to remove hydrogen from polyunsaturated lipids thus initiat-
ing lipid peroxidation.56,95 In guinea pig, the hepatotoxic eﬀect caused by this reductive
metabolism of halothane can be prevented by antioxidant treatment.176 In humans, in-
duction with hemin of heme oxygenase-1, which has an antioxidant role in oxidative
stress, has been shown to be eﬀective against halothane-induced liver damage.136 The
susceptibility of halothane’s depressant eﬀect to antioxidant treatment that we found
in this study indicates that the cellular redox state inﬂuences the eﬀect of halothane
on the oxgyen sensing mechanism. This could be explained by a modulation by ROS
of the coupling of halothane to the potassium channel (or other channels). Whether
or not the ROS was generated from halothane’s metabolism or from other intracellular
processes,214 the reduction in ROS with antioxidant treatment could reduce the cou-
pling of halothane to the channel and prevent it from opening it. An alternative way to
explain our ﬁndings would be to suggest that an increase in the concentration of ROS
has an inhibitory eﬀect on the mechanism involved in the acute hypoxic response. In
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Figure 3. The eﬀect of the antioxidant cocktail or placebo on halothane or sham-halothane induced
depression of the acute hypoxic response. Values are the ratio of the third hypoxic run (antioxidants
or placebo) over the second hypoxic run (halothane or sham halothane) of studies 1 to 4. ◦ is mean,
the triangles depict the 95% conﬁdence intervals (c.i.). A value of 1 indicates no eﬀect of the AOX
or placebo pre-treatement on the acute hypoxic ventilatory response. Note that the 95% c.i.’s of
studies 1 (AOX + halothane) and 3 (AOX + sham-halothane) do not overlap.
this scenario, the cellular redox state or the signalling from a particular ROS would be
the coupling from low oxygen to potassium channel closure. In this model , an NAD(P)H
oxidase has been proposed as the membrane bound source of oxygen sensitive ROS im-
plying a decrease in ROS in hypoxia.94,96,106,181 The increase in local ROS caused by the
reductive metabolism of halothane in hypoxia would thus counter the hypoxia- induced
decrease in ROS and prevent the hypoxic closure of the K+ channel. This eﬀect would
be most noticeable in hypoxia since halothane’s reductive metabolism is increased in
hypoxia.
In animal species, the eﬀect of halothane on the hypoxic ventilatory response is vari-
able. In the goat, for example, an end-tidal concentration of 0·5% does not signiﬁcantly
depress it.104 In the rabbit and cat, 0·5-1% halothane reduces the hypoxic response,
the eﬀect in the latter species being larger.52,150 As shown in this and previous stud-
ies, the eﬀect of 0·1 MAC in man is to reduce hypoxic sensitivity by more than 50%.
These species diﬀerences could originate from the diﬀerences in the type of oxygen
sensitive potassium channel that initiates the transduction cascade (e.g., TASK versus
Kv) and their diﬀerences in anaesthetic sensitivity or in splice variants of the expressed
channel. An alternative explanation could also lie in species diﬀerences in the defence
against ROS. Goats produce large quantities of ascorbic acid,31 and may thus be bet-
ter protected against the adverse eﬀects of free radicals produced by halothane. To a
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lesser degree this may also be the case for rabbits. Cats produce low quantities of ascor-
bic acid,31 and this might explain their higher susceptibility to halothane than rabbits.
Humans have lost the ability to synthesize ascorbic acid and may therefore be more
vulnerable to the adverse eﬀects of reactive species that are produced by halothane. It
is worth mentioning that in a previous study we were not able to demonstrate a clear
depression of the normocapnic AHR by desﬂurane.45 This volatile anaesthetic has a low
metabolism, with little production of free radicals.103 In Chapters 4 and 5 we show that
low dose propofol, which is known to have antioxidant properties,58 neither depressed
the CO2 sensitivity of the peripheral chemoreﬂex loop nor the fast - carotid body me-
diated - component of the acute hypoxic response. Together with the present ﬁndings,
these previous data suggest that the (lack of) depressant eﬀects of anaesthetics on the
hypoxic response may be related to their pro-oxidant (antioxidant) properties, but fur-
ther studies are needed to support this hypothesis. From the data that we presented in
this study we conclude that changing the cellular redox state can modulate the depres-
sant eﬀect of halothane on the acute hypoxic response. Further, although our results do
not supply direct evidence for an inhibitory role of ROS in the acute hypoxic response,
they could be explained by ascribing at least a modulating role to radical species in the
AHR. Our observation that anti-oxidant pre-treatment markedly reduces the depressant
eﬀect of halothane on the AHR demonstrates a speciﬁc pharmacological reversal of an
anaesthetic eﬀect. Further work will be needed in both humans and animal preparations
to clarify the interaction of cellular redox status, inhalational anaesthetics and oxygen
sensitive potassium channels in the carotid body.
SECTION 2
Pharmacology

4 Propofol for monitored anesthesia care: implications on
hypoxic control of cardiorespiratory responses
DURING MONITORED anesthesia care, in which anesthetics or analgesics are used as ad-
juvant to regional anesthesia, ventilatory control is predominantly metabolic or chemi-
cal in nature. Because hypoxia (especially episodic or intermittent hypoxia) is frequently
associated withmonitored anesthesia care,168,186 we investigated the inﬂuence of propo-
fol, a popular hypnotic for sedation during such care, on the ventilatory responses to
acute, sustained, and episodic isocapnic hypoxia.
Hypoxia has a dual eﬀect on the ventilatory control system. A short episode of hy-
poxia (duration < 5 min) causes an increase in the hypoxic drive from the peripheral
chemoreceptors of the carotid bodies.206 Hypoxia of longer duration causes depres-
sion of the respiratory centers in the brain stem.206,210 The net eﬀect of these op-
posing phenomena is that the ventilatory response to sustained hypoxia is biphasic:
an initial period of hyperventilation, the acute hypoxic response (AHR), is followed
within 3 to 5 min by a slow hypoxic ventilatory decline (HVD). A steady-state in ven-
tilation (V˙i) is obtained after 15 to 20 min.50,67 The mechanism of the hypoxic depres-
sion of V˙i (HVD) is unknown. During moderate hypoxia (oxygen saturation 80–90%)
the accumulation and release of inhibitory neurotransmitters or modulators, such as
γ-aminobutyric acid (GABA) or adenosine, is thought to play a major role in the devel-
opment of HVD.49,50,67,68,124 A consequence of the hypoxia-related central depression is
that the recovery of the hypoxic response is not immediate (i.e., after prolonged hypoxia
subsequent hypoxic responses remain depressed).50,67
Recent studies indicate that several general anesthetics, including propofol, inter-
act with or modulate the GABAA receptor complex.51,107,126 At clinical concentrations,
propofol enhances GABA-evoked chloride currents and causes direct activation of the
receptor in the absence of GABA.51,107 GABAA receptors are thought to be involved in the
generation of HVD,49,50,67,206,210 and hence there may be an important role for propofol
in modulating/enhancing HVD.
Clinically, hypoxia is often episodic or periodic, especially during sleep or sedation.162,186
We therefore further examined the interaction of propofol and periodic hypoxia on V˙i
and the development of HVD. Apart from assessing ventilatory responses we measured
heart rate (HR) responses and the bispectral index (BIS) of the electroencephalogram
(EEG). The BIS will inform us on the central nervous system arousal state of the partici-
pants, which is relevant because it may be an important factor in the study outcome.
METHODS
Subjects and Apparatus
Ten healthy male volunteers (aged 18–25 yr) participated in the protocol after approval was
38 Chapter 4 •
obtained from the Leiden University Medical Center Human Ethics Committee. The subjects
were healthy and did not have a history of tobacco or illicit drug use. They were instructed not
to eat or drink for at least 8 h before the study.
After arrival at the laboratory, two intravenous catheters were inserted in the left and right
cubital vein (one for propofol administration and one for blood sampling). Subsequently stan-
dard electrodes for EEG measurement (BisSensor, Aspect Medical Systems, Natick, MA) were
placed and the subjects rested for 20 to 30 min. Next a face mask was placed and the experi-
ments started.
See METHODS section Apparatus of Chapter 2 for a description of the procedure and appa-
ratus. The EEG and electromyelogram were recorded using an Aspect (Natick, MA) A-2000 EEG
monitor. The monitor computed the bispectral index (BIS) over 4-s epochs. We averaged the
BIS values over 1 min-intervals.
Study Design
Two diﬀerent hypoxic tests (sustained hypoxia and hypoxic pulses) were performed without
and with propofol. Control studies preceded propofol studies. The order of hypoxic tests was
randomized. Between tests there was ample time for resting. Control and drug hypoxic studies
were performed at identical PETCO2’s, 5–7 mmHg above awake resting values. This was done
to balance an eﬀect of the increase in PETCO2 resulting from depression of V˙i by propofol.
Sustained Hypoxic Test. The PETO2 was forced as follows: (1) 10 min at 110 mmHg, (2) a
rapid decrease to 50 mmHg, (3) 15 min at 50 mmHg, (4) a rapid increase to 110 mmHg, (5) 2
min at 110 mmHg, (6) a rapid decrease to 50 mmHg, (7) 3 min at 50 mmHg, (8) at least 5 min
at more than 300 mmHg.
Hypoxic Pulses. The PETO2 waveform was as follows: (1) 10 min at 110 mmHg, (2) a rapid
decrease to 50 mmHg, (3) 3 min at 50 mmHg, (4) a rapid increase to 110 mmHg, (5) 2 min at 110
mmHg. The hypoxic-normoxic sequence (steps 2–5) was repeated ﬁve times. This procedure
yields six 3-min hypoxic pulses separated by 2 min of normoxia.
Propofol Administration, Sampling and Assay. A Psion (London, United Kingdom) palm-
top computer programmed with a three compartment propofol pharmacokinetic data set,34
was used to control a Becton Dickinson infusion pump (St. Etienne, France) for the intravenous
administration of propofol. The propofol target concentration was set at 1 µg/ml and was kept
constant during both propofol hypoxic studies. After BIS values had reached a steady level, but
at least twenty minutes after the target had been reached, the hypoxic studies started. Propofol
blood samples (5 ml) were obtained 5 min before the ﬁrst hypoxic study (T1), at the end of the
ﬁrst hypoxic study (T2) and at the end of the second hypoxic study (T3). The samples were col-
lected in syringes containing potassium oxalate. The propofol concentrations were determined
by reverse-phase high performance liquid chromatography.207
Data Analysis
Sustained Hypoxic Test. Mean values of the breath-to-breath data were chosen over identical
time segments (see ﬁgure 1). Period N is the 1-min period before the 15-min of hypoxia; period
H1 the 3rd min of hypoxia; period H2 the 15th min of hypoxia; and period H3 the 3rd min of the
second hypoxic bout. Diﬀerences in V˙i between Periods N and H1 were deﬁned as the ﬁrst AHR
(AHR1), between Periods N and H2 as the sustained hypoxic response, and between Periods
N and H3 as the second AHR (AHR2). The diﬀerence between AHR1 and sustained hypoxic
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Figure 1. Control and propofol ventilatory responses to the sustained hypoxic test of one subject.
TOP. End-tidal pressure of oxygen input to the subject. BOTTOM. Ventilatory responses above
normoxic baseline (V˙i data are averaged over six breaths). Period N is the 1-min period before the
15 min of hypoxia; period H1 min 3 of hypoxia; period H2 min 15 of hypoxia; and period H3 min 3
of the second hypoxic bout. Continuous line = control; dashed line = propofol.
response was used as measure of the HVD. The V˙i responses are expressed as the change in V˙i
per percentage change in SPO2 (unit: L min−1 %−1).
Hypoxic Pulses. We tested the occurrence of HVD by comparing the hypoxic response to the
ﬁrst hypoxic pulse with the response to the last hypoxic pulse. In order to do so, mean values
of the breath-to-breath data of the last min of normoxia before the ﬁrst hypoxic pulse (period
A) and the third min of the ﬁrst (period B) and last hypoxic pulse (period C) were calculated.
Diﬀerences in V˙i between periods A and B were deﬁned as the ﬁrst AHR (AHRﬁrst), and between
periods A and C as the last AHR (AHRlast).
Statistical Analysis
A two-way analysis of variance was performed on the diﬀerent periods (N, H1, H2 and H3) of
the sustained hypoxic test. Because peak heart rate responses occurred at period H1 + 3 min
(see Results), for hypoxic HR sensitivities a comparison was made among periods H1 + 3 min,
H2 and H3. Diﬀerences between periods were tested with the Student-Newman-Keuls test. A
paired-t-test was performed to compare ventilatory and heart rate responses to the ﬁrst and
sixth hypoxic pulse. To detect the signiﬁcance of diﬀerence between the control and propofol
studies, a paired-t-test was performed on individual parameters of the hypoxic studies. P val-
ues < 0.05 were considered signiﬁcant. All values are mean ± SD.
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RESULTS
Propofol Concentrations and BIS Values.
Blood propofol concentrations and BIS values varied considerably among subjects but
were constant over time within subjects. Over time, blood propofol concentrations were
0·61 ± 0·30 µg/mL at T1, 0·56 ± 0·23 µg/mL at T2, and 0·58 ± 0·23 µg/mL at T3 (not
signiﬁcant). Mean coeﬃcient of variation over time was 14·6% (range 7–34%). Because
of technical problems, the collection of BIS data was not achieved in one subject. Aver-
aged control BIS values were 97 ± 2 and 96 ± 2 for the sustained hypoxic and hypoxic
pulses studies, respectively. During propofol, the mean BIS values were 76 ± 14 for
the sustained hypoxic study (range among subjects 53–91; mean coeﬃcient of variation
over time = 7%), and 76 ± 10 for the hypoxic pulses study (range among subjects 66–91;
mean coeﬃcient of variation over time 8%).
Ventilatory Responses
Sustained Hypoxic Test. Propofol reduced normoxic baseline V˙i by about 15% (P <
0·001; table 1). In ﬁgure 1, examples of a control and propofol hypoxic study of one
subject are shown. In all subjects, in both control and propofol studies, the hypoxic
ventilatory responses were biphasic and the recovery of the hypoxic response was not
immediate (ﬁgures 1, 2, table 1). Propofol decreased AHR1 by 50% from 1·74 ± 1·22
to 0·89 ± 0·70 L min−1 %−1 (P < 0·001), the sustained hypoxic response by 60% from
1·11 ± 0·80 to 0·33 ± 0·30 L min−1 %−1 (P = 0·002) and AHR2 by 60% from 1·04 ±
0·48 to 0·39 ± 0·33 L min−1 %−1 (P < 0·001). The absolute magnitude of HVD did not
diﬀer between control and propofol (0·63 ± 0·51 versus 0·56 ± 0·52 L min−1 %−1, not
signiﬁcant). Propofol increased the ratio HVD/AHR1 bymore than 50% from 0·35± 0·16
to 0·54 ± 0·16 (P = 0·02), and caused more depression of the second hypoxic response:
The ratio AHR2/AHR1 was 0·67 ± 0·16 for control and 0·51 ± 0·22 for propofol (P <
0·05).
Hypoxic Pulses. BIS values and control of end-tidal gas concentrations are listed
in table 2. In ﬁgure 3, examples of a control and propofol study of one subject are
shown. In the control study, V˙i in Periods B and C increased to 197 ± 78% and 200 ±
63% of baseline, respectively. Corresponding values in the propofol study were 154 ±
27% (period B) and 144 ± 37% (period C). In control and propofol studies AHRﬁrst did
not diﬀer from AHRlast: control 1·35 ± 0·84 versus 1·35 ± 0·67 L min−1 %−1 (not sig-
niﬁcant; ﬁgure 4); propofol 0·64± 0·39 versus 0·58± 0·25 L min−1 %−1 (not signiﬁcant).
Heart Rate Responses
Because of technical problems, the collection of heart rate data failed in one subject.
Propofol decreased normoxic HR by 8–10 beats/min (table 1). In control and propofol
sustained hypoxic studies, peak heart rate responses occurred at period H1 + 3 min
(ﬁgure 2). Control heart rate sensitivity decreased from its peak by 20% in period H2
(not signiﬁcant) and by 35% in period H3 (P < 0·05). Propofol heart rate sensitivity
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Table 1. The Ventilatory, Heart Rate and Bispectral Index Responses to Sustained Hypoxia before
and during Propofol Administration
Period N Period H1 Period H2 Period H3
V˙i (L/min) control 19·2 ± 5·2 37·6 ± 14·4* 31·0 ± 11·3† 30·8 ± 11·1†
propofol 16·0 ± 8·4 25·4 ± 13·3* 19·8 ± 10·0† 20·4 ± 10·9†
V˙i (% of baseline V˙i) control 100 195 ± 54* 162 ± 28† 158 ± 21†
propofol 100 160 ± 29* 127 ± 16† 127 ± 10†
VT (mL/breath) control 1145 ± 201 1755 ± 296* 1578 ± 305† 1559 ± 324†
propofol 913 ± 368 1287 ± 426* 1104 ± 373† 1097 ± 371†
RR (breaths/min) control 17 ± 4 22 ± 10* 20 ± 6 20 ± 6
propofol 16 ± 3 19 ± 5* 17 ± 3‡ 18 ± 4‡
Heart Rate (beats/min) control 69 ± 10 83 ± 16* 83 ± 14* 81 ± 12*
propofol 58 ± 11 68 ± 16* 68 ± 15* 66 ± 14*
BIS control 96 ± 2 97 ± 1 97 ± 2 97 ± 2
propofol 78 ± 11 79 ± 9 74 ± 19 74 ± 17
PETCO2 (mmHg) control 46·8 ± 2·9 46·6 ± 3·0 46·9 ± 3·0 46·7 ± 2·9
propofol 46·6 ± 2·7 46·5 ± 3·1 46·8 ± 2·9 46·7 ± 2·9
PETO2 (mmHg) control 112·0 ± 0·8 49·1 ± 0·8* 49·1 ± 0·4* 49·0 ± 0·8*
propofol 112·8 ± 1·1 49·1 ± 0·5* 48·4 ± 0·4* 49·0 ± 0·7*
SPO2 (%) control 98 ± 1 87 ± 4* 87 ± 4* 87 ± 4*
propofol 98 ± 1 86 ± 4* 85 ± 3* 86 ± 3*
Values are mean ± SD.
N = the last normoxic min before the 15-min hypoxic period; H1 = min 3 of initial hypoxia;
H2 = min 15 of initial hypoxia; H3 = min 3 of the 2rd hypoxic episode.
∗ P < 0·05 versus Period N. † P < 0·05 versus Period N and H1. ‡ P < 0·05 versus Period H1.
decreased from its peak by 21% in period H2 (P < 0·05) and by 38% in period H3 (P <
0·05). Compared with control, propofol decreased hypoxic heart rate sensitivities in
periods H1 + 3 min, H2 and H3 by 27 ± 36%, 36 ± 22 % and 38 ± 34%, respectively (not
signiﬁcant). Heart rate responses during the hypoxic pulses test did not diﬀer between
the ﬁrst and sixth hypoxic pulse and between control and propofol studies.
DISCUSSION
Influence of Propofol on the Ventilatory Response to Acute Hypoxia
In this study we observed that, in a healthy, young group of male volunteers, propo-
fol, at a sedative concentration (mean BIS value 76), caused a ∼50% reduction of the
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Figure 2. The mean ventilatory (left ) and heart rate (right ) responses to the sustained hypoxic test
expressed as change in V˙i or heart rate per percent in arterial hemoglobin-oxygen saturation (SPO2).
For periods N, H1, H2, and H3 see legend of ﬁgure 1. The data points between periods H1 and H2
are one minutes averages of minutes 6 (i.e., H1 + 3 min), 9 and 12 of hypoxia. Values are mean ±
SD.
ventilatory response to acute hypoxia. Two previous studies examined the inﬂuence
of propofol on the hypoxic ventilatory response. Blouin et al.20 tested the inﬂuence of
propofol at a blood concentration of 2 µg/mL on a ramp hypoxic test. They observed an
80% depression of the ventilatory response in eight male volunteers. However, because
the ramp hypoxic test is a mixture of AHR and HVD,195 their ﬁnding is best compared
with our observation of propofol-induced reduction of the sustained hypoxic response
by about 60%. Nagyova et al.130 showed a reduction of the AHR by 21, 23 and 60%
at respective propofol blood concentrations of 0·5, 1 and 2 µg/mL. This is less than
our ﬁnding of 50% depression at 0·6 µg/mL. However, in the study by Nagyova et al.’s
study, diﬀerences between the level of consciousness in awake and drug studies were
minimized by encouraging the subjects to watch television. There is now ample evi-
dence that this induces behavioral control of breathing. As a consequence additional
(nonchemical) drives increase responses mediated via the carotid bodies.46
Our study gives little information on the site of action of propofol with respect to its
eﬀects on normoxic resting ventilation and AHR. Propofol may aﬀect ventilatory control
at four possible sites: at the peripheral or central chemoreceptors; at the respiratory
centers in the brain stem; at the neuromechanical link between brain stem and ventila-
tion (this includes spinalmotorneurons, respiratorymuscles, lungs and airways); at sites
in the central nervous system involved in behavioral-state control (for example the brain
stem reticular system). In cats and rabbits, Ponte and Sadler151 showed that a high dose
propofol infusion (18 to 35 mg/kg per h) into the carotid artery abolished chemorecep-
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Figure 3. Control and propofol ventilatory responses to intermittent 3-min hypoxic episodes (six
hypoxic pulses) of one subject. In between hypoxia there are 2-min normoxic periods. TOP. End-
tidal pressure of oxygen input to the subject. BOTTOM. Ventilatory responses above normoxic
baseline (V˙i data are averaged over six breaths). Period A is the 1-min period before the ﬁrst hypoxic
episode; period B is min 3 of the ﬁrst hypoxic episode; period C is min 3 of 6th hypoxic episode.
Control = continuous line; propofol = dashed lines.
tor discharge in normoxia and prevented an increase during hypoxia. In humans Dow
and Goodman62 showed that during propofol anesthesia, sudden exposure to hyper-
oxia reduces V˙i. This suggests that the peripheral chemoreceptors remain active during
propofol anesthesia but does not exclude some depression. In anesthetized cats, an
inhibitory eﬀect of propofol on cells in the dorsomedial and ventrolateral medulla me-
diating pressor eﬀects has been observed.215 Both sites are involved in respiratory con-
trol and may contain central chemoreceptors.198 We suggest that, in our study, propofol
decreased AHR by depression of the peripheral chemoreﬂex loop, either directly by en-
hancing GABAergic inhibition of respiratory centers within the brain stem or indirectly
by changing the behavioral state of the subjects. At this time, we are unable to exclude
an eﬀect of propofol at the peripheral chemoreceptors.
The EEG data gives some evidence for an eﬀect of propofol on ventilatory control via
sites involved in behavioral-state control. We used the BIS of the EEG as measure of
the state of sedation/ or hypnosis. Among subjects, we observed a large variability in
blood propofol concentrations and BIS values. We relate this to the relatively large in-
terindividual variability in pharmacokinetics and dynamics of intravenous anesthetics.
For the BIS, we relate this further to the occurrence, at least in some subjects, of natural
sleep on top of drug-induced sedation. Non-rapid eye movement and slow-wave sleep
cause further decreases in BIS.185 In ﬁgure 5, we plotted the BIS values of individual
subjects (x-axis) versus the depression of the AHR (y-axis, AHR as percentage of con-
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Figure 4. The mean ventilatory responses to hypoxic pulses expressed as change in V˙i per per-
centage in arterial hemoglobin oxygen saturation. Hypoxic duration of each pulse is 3-min. For
both control and propofol, the response to the last hypoxic pulses (no. 6) is not diﬀerent from the
response to the ﬁrst pulse. Values are mean ± SD.
trol and obtained from both hypoxic studies). The data suggest the existence of two
(behavioral and respiratory) states in our subjects. Subjects were either awake (control
studies [open squares in the right part of ﬁgure 5], and propofol studies with little to
no eﬀect on AHR [open circles in the right part of ﬁgure 5]) or sedated or asleep with
50 to 60% depression of AHR (closed circles in the right part of ﬁgure 5). In the latter
group, variations in the level of sedation or hypnosis (as measured by the BIS) had little
further eﬀect on AHR.
Influence of Propofol on Hypoxic Ventilatory Decline
In humans, the mechanism of the secondary decline in V˙i during hypoxia of longer
duration (> 3 min) is still under debate. The following observations with respect to
HVD are of importance to our study and may provide some insight into the mechanism
of HVD:
1. Moderate hypoxia causes an increase in cerebral blood ﬂow (CBF).98 Because of the
increase in CBF, the carbon dioxide tension within the central nervous system and
hence the central ventilatory drive are decreased. As a consequence a signiﬁcant
part of HVD may be related to an increase in CBF.
2. When HVD develops, its inﬂuence on V˙i does not dissipate immediately upon the
termination of hypoxia. Subsequent hypoxic responses remain depressed (ratio
AHR2/AHR1 < 1) and one hour of air breathing is necessary for a full recovery
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Figure 5. Left. The relationship between blood propofol concentration and bispectral index (BIS).
Note the twofold larger range in propofol concentration data compared with BIS data. The squares
are data points obtained before propofol administration, the circles during propofol infusion. The
line through the data is linear regression. Right. Inﬂuence of the sedative or hypnotic state as mea-
sured by the BIS of the electroencephalogram on the depression by propofol of the acute hypoxic
ventilatory response (expressed as percentage of awake values). Squares = control data; open cir-
cles = propofol data in "awake" subjects as judged by their BIS values and acute hypoxic response.
To guide the eye, a sigmoid function (the Hill equation) was ﬁtted to the data. The BIS value at
which 50% of the eﬀect occurred is 89.
of AHR (AHR2/AHR1 = 1).50,67 These observations have led to hypothesis that the
accumulation or release of neurotransmitters or modulators with net inhibitory
inﬂuences on V˙i is quantitatively the more important contributor to HVD. The most
important neurotransmitters candidates are GABA and adenosine.49,50,67,124,206,210
On the termination of hypoxia, their turnover is not immediate and therefore the
depressant eﬀects of hypoxia wane slowly. Animal studies give further proof for
a role of central inhibition from GABA. Bicuculline, a GABAA receptor antagonist,
reverses HVD in the anesthetized cat.124
3. Among and within subjects, the ratio HVD/AHR1 is constant with changing values
of AHR1.50,67 This is explained by a modulatory eﬀect of the hypoxic drive of the
peripheral chemoreceptors on the central (i.e. within the central nervous system)
development of HVD.50
In our study, propofol did not aﬀect the absolute magnitude of HVD. However, rela-
tive to AHR1, HVD did increase, causing an increase in ratio HVD/AHR1. Furthermore,
the ratio AHR2/AHR1 decreased during propofol infusion. Because propofol concen-
trations and BIS values were constant over time, we argue that these observations in-
dicate that propofol enhanced the development of HVD. Recent studies indicate that
propofol acts at GABAA receptors and enhances GABA-ergic transmission.51,107,145 We
therefore suggest that the relative increase in HVD is related to propofol’s action at the
GABAA receptor complex. Other GABAA receptor agonists such as midazolam cause
similar eﬀects on the ratio HVD/AHR1.49 Although these observations support a role
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for GABAergic neurons in the inhibition of brain stem respiratory centers during sus-
tained hypoxia, they do not exclude the involvement of other receptor systems such as
adenosine and opioid receptors. For example, Cartwright et al.29 showed an increase of
the ratio HVD/AHR1 by the µ-receptor agonist alfentanil. Aminophylline, an adenosine-
receptor blocker, reduces the ratio HVD/AHR1.68 These ﬁndings illustrate that HVD
development is modulated by various agents commonly used in anesthesia. Studies in
humans on the inﬂuence of propofol on CBF indicate that propofol reduces CBF con-
comitant with a reduction in cerebral metabolic rate, and maintains the cerebrovascular
response to changes in arterial PCO2.73 Although no studies on the inﬂuence of propofol
on changes in arterial PO2 are available, it seems improbable that propofol increased
the CBF response to hypoxia.
In contrast to 15 min of sustained hypoxia, 15 min of intermittent hypoxia, without
and with propofol, were unable to generate HVD. Because in our studies the level of
hypoxia was relatively mild (inspired oxygen concentration 10%), a limited number of
hypoxic pulses were applied, and the duration of the pulses was relatively short, we
are unable to predict the impact of repeated episodes of deeper, longer or more fre-
quent periods of hypoxia on V˙i. Only limited data are available on ventilatory changes
during repeated hypoxia. We recently studied the inﬂuence of 0.25% sevoﬂurane on
the the ventilatory response to four to six 3-min hypoxic episodes (SPO2 84%) separated
by 2 min of normoxia in humans.175 Hypoxic V˙i remained constant over time. In this
respect, the behavior of sevoﬂurane is identical to propofol. In anesthetized pigs, rep-
etition of 12-min of deep hypoxia (inspired oxygen concentration, 7%) was associated
with cardiorespiratory depression during the second hypoxic episode.115 Further animal
studies are required to study the interaction of repetitive (deep) hypoxia and anesthet-
ics/hypnotics on V˙i and hemodynamics.
Influence of Propofol on the Heart Rate Responses to Hypoxia
The Heart Rate response to acute hypoxia depends on the eﬀects of hypoxia at various
sites in the body. Decreased heart rate may result from a direct eﬀect of hypoxia on
the sinoatrial node or hypoxic stimulation of the carotid bodies resulting in stimulation
of the vagal centers in the medulla; increased heart rate may result from activation of
aortic chemoreceptors, lung receptors (stimulated via an increase in V˙i), or sites within
the central nervous system. These factors interact in a complex fashion.115 In normal
breathing subjects, mild to moderate hypoxia is generally associated with tachycardia.
Bradycardia is often observed if hypoxia coincides with apnea or at deeper levels of
hypoxia.53,84
In both control and propofol studies, the peak heart rate response to hypoxia oc-
curred 6 min after the initiation of hypoxia (ﬁgure 2). The reason for the relatively slow
dynamics of the heart rate response (compared with the V˙i response) is unknown but
may be related to the complex interaction of the various components responsible for
the heart rate response, all with their own dynamics. The results of our study give little
evidence for an important role of GABA-mediated hypoxic depression of centers in the
brain stem involved in heart rate control. In contrast to the V˙i data, propofol did not
• Propofol and Hypoxic CardioRespiratory Control 47
enhance heart rate decline during sustained hypoxia or increase depression of the heart
rate response to a hypoxic episode after 15 min of hypoxia. Furthermore, the decline
of heart rate responses in periods H2 or H3 (compared with period H1 + 3 min) may be
caused by the decrease in V˙i. Further studies are needed (for example a protocol that
allows for a ﬁxed V˙i level) to elucidate the mechanism by which propofol aﬀects heart
rate responses to hypoxia.
It is not appropriate to simply extrapolate our data (obtained in healthy young male
subjects, using imposed isohypercapnic hypoxic stimuli [mean SPO2, 86%], without the
occurrence of obstructive apnea) to patients under monitored anesthesia care. Studies
in patients with sleep apnea indicate that if hypoxia is related to obstructive apnea, ini-
tial bradycardia is followed, upon the relief of apnea, by brisk tachycardic responses.176,216
In light of the clinical importance of this issue,161 further studies are warranted to exam-
ine the inﬂuence of sedatives and analgesics on the chronotropic response to hypoxia,
especially if upper-airway obstruction is involved.

5 Respiratory sites of action of propofol: absence of
depression of peripheral chemoreﬂex loop by
low dose propofol
PROPOFOL is frequently used as a monoanesthetic-sedative for various diagnostic or
small surgical procedures in patients who breathe spontaneously or is combined with
regional anesthesia techniques for larger surgical procedures. Therefore, knowledge
on the ventilatory eﬀects of this agent is of importance. In Chapter 4 we showed that
propofol, at a sedative concentration (mean BIS value 76), caused a ∼50% reduction
of the ventilatory response to acute hypoxia. However the site of action of propofol
within the ventilatory control system remains unknown. Propofol may aﬀect breath-
ing at peripheral sites (e.g., peripheral chemoreceptors, lung, diaphragm), central sites
(e.g., central chemoreceptors, respiratory centers) or at both sites. All halogenated
volatile anesthetics, already at subanesthetic concentrations (0·05–0·2 minimum alveo-
lar concentration (MAC); BIS values∼70–80), cause a selective depression of oxygen (O2)
and carbon dioxide (CO2) responses mediated by the peripheral chemoreceptors (selec-
tive with regard to responses mediated by the central chemoreceptors, which remain
unaﬀected).45,47,100,175,202 In this study, we investigated whether propofol has eﬀects on
the peripheral CO2 response similar to those of the inhalational anesthetics. We studied
the inﬂuence of two concentrations of propofol on the dynamic ventilatory response to
hypercapnia in healthy volunteers. Using the dynamic end-tidal CO2 forcing technique,
the ventilatory responses were separated into a fast component originating at the pe-
ripheral chemoreceptors and a slow component at the central chemoreceptors.12,38 Note
that hypoxic studies are unable to resolve the issue of eﬀect-site of a certain agent –
anesthetic or analgesic– within the ventilatory control system. The dynamic end-tidal
CO2 forcing technique is especially developed to quantify the contributions of the pe-
ripheral and central chemoreﬂex loops to inspired minute ventilation (V˙i) in a noninva-
sive fashion and has been validated extensively in cats and humans.12,38,55
We made two important adaptations in comparison with our earlier studies on the
inﬂuences of anesthetics and opioids on the dynamic ventilatory response to carbon
dioxide. First, to cause a more potent stimulus to the peripheral chemoreceptors, we
performed experiments at the background of moderate hypoxia (oxygen saturation 85-
90%).38 Second, To increase the precision of the estimation of parameters related to
the peripheral chemoreﬂex loop, we used a multi-frequency binary sequence (MFBS) in
end-tidal partial pressure of carbon dioxide (PCO2) input involving 13 steps into and 13
steps out of hypercapnia.144
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Figure 1. The PETCO2 multifrequency binary sequence. The y-axis represents the increase in PETCO2
above the individual subjects’ resting PETCO2 values.
METHODS
Subjects and Apparatus
Ten healthy volunteers aged 18–25 yr (7 men and 3 women) participated in the protocols after
approval was obtained from the local Human Ethics Committee. The subjects were healthy and
did not have a history of tobacco or illicit drug abuse.
After arrival at the laboratory, two intravenous catheters were inserted in the left and right
cubital vein (one for propofol administration and one for blood sampling). Subsequently, elec-
trodes for electroencephalographic measurement (BisSensor; Aspect Medical System, Newton,
MA) were placed on the head as speciﬁed by the manufacturer, and the subjects rested for
20–30 min. Next a face mask was placed and the studies started.
See METHODS section Apparatus of Chapter 2 for a description of the procedure and appa-
ratus. The electroencephalogram was recorded using an Aspect A-2000 EEG monitor (Aspect
Medical Systems; software version 3·3). The BIS values were averaged over 1 min-intervals.
Study Design
The end-tidal PCO2 was varied according to a MFBS that involved 13 steps into and 13 steps out
of ﬁxed PETCO2 levels (low and high CO2: 2 mmHg and 12 mmHg above the subjects‘ normal
air breathing values for PETCO2) altogether lasting 1408 s (23 min and 28 s). Figure 1 shows
a schematic diagram of the PETCO2 input function. The MFBS experiments were performed at
a background of moderate hypoxia (PETO2 = 70 mmHg) and started 20 min after the initiation
of hypoxia. This was done to allow time for hypoxic ventilatory decline to develop prior to
investigating the response to CO2.
Drug Administration and Sampling
A Psion palm-top computer (London, England) programmed with a three compartment propo-
fol pharmacokinetic data set was used to control a Becton Dickinson infusion pump (St. Eti-
enne, France) for intravenous administration of propofol.79 Each subject performed two control
MFBS experiments, two during low dose propofol infusion (Plow; target plasma concentration,
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0·75 µg/ml) and two during high dose propofol infusion (Phigh, target plasma concentration,
1·5 µg/ml). Control studies preceded propofol studies, and low dose propofol experiments
preceded high dose propofol experiments. MFBS studies started 15 min after plasma target
concentrations had been reached. The duration of propofol infusion was 150 min (75 min for
Plow and 75 min for Phigh).
Six venous propofol samples were obtained before and after each of the MFBS experiments.
The samples were collected in syringes containing potassium oxalate, and propofol concentra-
tions were determined by reverse-phase high performance liquid chromatography.
Data Analysis
Thedata were analyzed by ﬁtting the breath-to-breath ventilatory responses to a two-compartment
model, as described previously.12,38,55,171 The steady state relation of V˙i to PETCO2 at constant
PETO2 in humans is described by:
V˙i = (Gp +Gc) · [PETCO2 − Bk](1)
where Gp = the carbon dioxide sensitivity of the peripheral chemoreﬂex loop, Gc = the carbon
dioxide sensitivity of the central chemoreﬂex loop and Bk = the apneic threshold or extrapolated
PETCO2 of the steady state ventilatory response to carbon dioxide at zero V˙i. The sum of Gp
and Gc is the total carbon dioxide sensitivity (GT ). To describe the delay in eﬀect and dynamics
of the peripheral and central ventilatory responses to CO2, time delays (T) and time constants
(τ) are incorporated in the model. The deterministic model parameters are as follows: Bk, Gc ,
Gp, time constant of the peripheral chemoreﬂex loop (τP ), time constant of on-response the
central chemoreﬂex loop, i.e., at high PETCO2 (τON ), time constant of the oﬀ-response of the
central chemoreﬂex loop, i.e., at low PETCO2 (τOFF ), time delays of the central and peripheral
chemoreﬂex loops (TC and TP ), and a linear trend term.38 The noise corrupting the data was
modeled through an external pathway with ﬁrst order dynamics.38 Estimation of the parame-
ters was performed with a one-step prediction error method.116
Sensitivity Analysis
We performed an a posteriori sensitivity analysis. Sensitivity analysis enabled us to deter-
mine whether the parameter values could be estimated with ﬁnite precision from the actual
data.37,42,212 The analysis was performed by ﬁxing one parameter (i.e., by not allowing it to
be estimated) at a time to a series of values (–100% to +100%) around the ‘optimum’ value (in
terms of the ‘cost’ function or residual sum of squares of the diﬀerence between measured and
estimated ventilation). The other parameters were estimated by minimizing the residual sum
of squares. The shape of the relation between parameter and residual sum of squares informed
us of whether parameters were estimable using the speciﬁc PETCO2 and PETO2 inputs.37,42,212
Furthermore, because we performed the sensitivity analysis on actual data (and not on simu-
lated data), we were informed whether local minima existed.
Statistical Analysis
The estimated parameters of control and propofol experiments were subjected to a two-way
analysis of variance and post hoc least signiﬁcant diﬀerences tests. P-values less than 0·05
were considered to be signiﬁcant. All values reported are mean ± SD.
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Table 1. Estimated Model Parameters, Propofol Concentrations and Bispectral Index (BIS) Values
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Figure 2. Control, left, and propofol, right, ventilatory responses to carbon dioxide of one subject.
TOP: PETCO2 input function is shown and is varied according to a multi-frequency binary sequence
that involved 13 steps into and 13 steps out of hypercapnia. BOTTOM: Each circle represents one
breath. The thick line through the breaths is the deterministic part of the model, which is the sum
of the outputs of the peripheral (V˙p) and central (V˙c) chemoreflex loops and a trend term. Estimated
control parameter values are as follows: Bk, 36·8 mmHg, Gp , 0·40 L·min-1·mmHg-1, and Gc , 1·61
L·min-1·mmHg-1. Estimated propofol parameter values are as follows: Bk, 36·5 mmHg, Gp , 0·35
L·min-1·mmHg-1 and Gc , 0·75 L·min-1·mmHg-1.
RESULTS
All subjects terminated the protocol without side eﬀects. Because of propofol, the
arousal state of the subjects decreased with Bispectral Index values of 84 ± 8 at low
dose propofol infusion and 67 ± 14 at high dose propofol infusion. The concentration
of propofol remained constant over time during the two infusion schemes (table 1).
Examples of a control and a propofol MFBS experiment (propofol target = 1·5 µg/ml)
and model ﬁts of one subject are given in ﬁgure 2. Only the deterministic part of
the model is shown. It shows a large eﬀect of propofol on the output of the central
chemoreﬂex loop (a 55% reduction of Gc) with only a minor eﬀect on the output of the
peripheral chemoreﬂex loop (a 12% reduction of Gp).
The averaged model parameters are collected in table 1. At all three treatment lev-
els, the estimated model parameters did not diﬀer between the ﬁrst and second CO2
response. Propofol reduced the total CO2 sensitivity (GT ) by approximately 20% at a
propofol target of 0·75 µg/ml and by approximately 34% at a target of 1·5 µg/ml. At
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Figure 3. Influence of propofol on the ventilatory carbon dioxide (CO2) sensitivities relative to con-
trol values for peripheral CO2 sensitivity (Gp), central CO2 sensitivity (Gc) and total CO2 sensitivity
(GT ). values are mean ± SD.
both propofol concentrations, the reduction of GT was caused by a reduction of the
output of the central chemoreﬂex loop by 20% and 40% at low and high dose propo-
fol, respectively, without aﬀecting the output of the peripheral chemoreﬂex loop. As
a consequence the ratio Gp to Gc is increased relative to the control state (ﬁgure 3).
The apneic threshold (B) showed a small but signiﬁcant reduction during propofol infu-
sion (table 1). The time constants and time delays of both chemoreﬂex loops remained
unaﬀected by propofol (data not shown).
Figure 4 shows the results of the sensitivity analysis of the model parameters in one
subject. A well deﬁned minimum of the residual sum of squares was observed for all
parameters, indicating that they could be identiﬁed with acceptable accuracy (including
parameters TP and TP , not shown). The most accurately estimated parameters were Bk
and Gp, as shown by the steepness of the increase in residual sum of squares at param-
eter values above and below the optimum. The shape of the curves for Gc , τP , τON , and
τOFF are markedly asymmetric, indicating that the estimation may be less accurate at
values higher than the optimum. As expected, the steepness of the increase in residual
sum of squares of Gp is less when this parameter is estimated from single step CO2
input function (broken line in ﬁg. 4). This indicates that Gp is estimated with greater
accuracy from an MFBS input function relative to a single step input. Gc is well esti-
mated from an MFBS and step input. However, the analysis indicates somewhat greater
accuracy using a single CO2 step for values above its optimum and an MFBS input for
values below its optimum.
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DISCUSSION
We used a multifrequency binary sequence in PETCO2 to quantify the eﬀect of propofol
on ventilatory control. The MFBS was designed by Pedersen et al.144 to spread its power
over the frequency range of interest for identiﬁcation of both peripheral and central
chemoreﬂex responses and to optimize identiﬁcation of the peripheral chemoreﬂex re-
sponse. Using a single step, the peripheral response is determined from only a limited
portion of the data (2 min of the 15–20 min of a CO2 study). Using an MFBS, this in-
creases signiﬁcantly (19·5 min of a 24 min experiment). Consequently, the precision of
estimation parameters related to the peripheral chemoreﬂex loop is greater when de-
rived from MFBS compared with single steps. Indeed, our sensitivity analysis indicates
the improvement of the estimation of the peripheral CO2 sensitivity compared with a
step PETCO2 function without compromising the accuracy of estimation of central CO2
sensitivity (ﬁg. 4).
We used a target-controlled infusion system to administer propofol. Fifteen minutes
after target plasma concentrations of propofol were attained, the respiratory studies
started. Estimation of the eﬀect-site propofol concentration indicated that this time
was ample for equilibrium between blood and eﬀect-site. Wemeasured venous propofol
concentrations, whichmay not reﬂect arterial or eﬀect-site concentrations. However, we
observed no time eﬀect on venous propofol concentrations or on parameter estimates
at Plow or Phigh. This indicates stable arterial and eﬀect-site propofol concentrations
and suggests a small gradient between venous and arterial propofol concentrations.
With respect to the control of breathing propofol may have an eﬀect at the central
or peripheral chemoreceptors, at the respiratory centers in the brainstem, at the neu-
romechanical link between brainstem and ventilation (V˙i), or at sites in the central ner-
vous system involved in behavioral state control. The exact location of the central
chemoreceptors is unknown but they are probably located in the dorsomedial medulla,
the rostroventrolateral medulla, or both.198 The peripheral chemoreceptors are located
in the carotid bodies, which are strategically situated at the bifurcation of the common
carotid arteries and have an important role in oxygen delivery to the brain. The periph-
eral chemoreceptors respond to changes in arterial oxygen tension (PaO2) and arterial
carbon dioxide tension (PaCO2).14,15
We observed that propofol, at doses causing a decrease in Bispectral Index to approx-
imately 70, has an important eﬀect on the control of breathing. Speciﬁcally, propofol
reduced Gc but had little inﬂuence on Gp. This indicates the absence of a (selective) ef-
fect of low-dose propofol on the peripheral chemoreﬂex loop. In this respect, propofol
stands in sharp contrast to the modern volatile halogenated anesthetics.45,50,175,202 Our
ﬁndings are in agreement with studies from the literature. Dow and Goodman showed
in humans that during propofol anesthesia, the carotid bodies retain their ability to
respond to hyperoxia.62 In anesthetized cats, propofol displayed an inhibitory eﬀect on
areas of the dorsomedial and ventrolateral medulla, which possibly contain the central
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Figure 4. Results of the sensitivity analysis for the model parameters of the empirical carbon
dioxide model of the ventilatory controller in one subject. The data are control data obtained using
a multifrequency binary sequence input function (continuous lines). For comparative reasons, we
added the sensitivity analysis on Gp and Gc obtained from a single step input function of the same
subject (subject 936, broken lines). The x-axis gives the optimal parameter value (100%) ± 100%;
the y -axis gives the increase in residual sum of squares (∆residual SSQ) from the optimal value
(residual SSQ set at 0).
chemoreceptors.198,215 Evidently, our data do not preclude some depressant eﬀect of
higher doses of propofol than used by us on the carotid bodies or its aﬀerent pathways.
For example, animal data show that high dose propofol infusion, 18–35 mg/kg per h,
causes the cessation of carotid body chemoreceptor activity.150
Eﬀect of Propofol on Peripheral CO2 versus O2 Responses
Our ﬁnding of the absence of an eﬀect of propofol up to plasma concentrations of 1·25
µg/mL on the peripheral CO2 response seems in disagreement with our observation in
Chapter 4 of a 50% depression of the acute hypoxic V˙i response by 0·6 µg/mL propofol.
Because the acute hypoxic ventilatory response originates at the peripheral chemore-
ceptors of the carotid bodies,206 some depression of the peripheral CO2 response was
anticipated from our earlier results. Apart from the possibility thatO2- and CO2-sensing
at the carotid bodies are diﬀerentially aﬀected by propofol, there are three conceivable
explanations for this discrepancy.
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1. Carotid body depression by anesthetics is dependent on stimulus intensity. For
example, Ponte and Sadler showed that relative to a mild hypoxic stimulus, a
more intense stimulus (PO2 < 40 mmHg) is able to overcome volatile anesthetic-
induced depression of the carotid bodies.151 In analogy, the stimulus in this study
(a hypercapnic-hypoxic stimulus of PETCO2 13 mmHg above resting and SPO2 88–
90%) may oﬀset depression of the carotid bodies by propofol as observed previ-
ously using a less intense hypoxic stimulus (a hypercapnic-hypoxic stimulus of
PETCO2 5 mmHg above resting and SPO2 ∼87%). Interestingly, when assessing
the eﬀect of low dose volatile anesthetics on ventilatory control, we observed de-
pression of carotid body mediated responses even when intense stimuli, such as
used in this study, were applied.45,175 This suggests a diﬀerence in stimulus inten-
sity needed to overcome carotid body depression caused by propofol and volatile
anesthetics.
2. In cats, Berkenbosch et al. studied the peripheral V˙i response dynamics to hypoxic
stimulation while the PaO2 of the medulla oblongata was kept constant using the
technique of artiﬁcial brainstem perfusion.15 Mathematically, the responses were
best described by two components: a fast component with a time constant of ap-
proximately 2 s and a slow component with a time constant of approximately 73 s.
The fast component was considered to originate at the carotid bodies, whereas it
was argued that the slow component was due to central modulation of the carotid
body response (i.e., neuronal dynamics).15 Interestingly, in the same animal prepa-
ration, the response of the peripheral chemoreﬂex pathway to changes in end-tidal
PCO2 does not show a slow component.15 This indicates that although peripheral
hypoxic stimulation activates central neuronal dynamics, peripheral hypercapnic
stimulation does not. Also, in humans, the hyperventilatory response to hypoxia
is well-described by a fast and a slow component.97 In Chapter 4 we studied the
eﬀect of 0·6 µg/ml propofol on the ventilatory responses to 3 min hypoxic pulses,
we reanalyzed the data using the two-component model as described by Berken-
bosch et al.15 All control curves were best described by two components as judged
by the Akaike criterion,1 with time constants of 3 and 100 s for the fast and slow
components, respectively. Propofol did not aﬀect the gain (i.e., hypoxic sensitivity)
of the fast component (ratio Gpropofol/Gcontrol = 0·95), but caused a signiﬁcant
reduction of the gain of the slow component (ratio Gpropofol/Gcontrol = 0·45, P
< 0·05). If we assume that the fast response reﬂects the carotid body response
to hypoxia and the slow component central neuronal dynamics,15,39 these results
suggest that propofol aﬀects central neuronal dynamics but has little eﬀect on the
carotid bodies or their output, and thus does not reduce Gp. This is in contrast to
the eﬀect of inhalational anesthetics. We previously studied the eﬀect of sevoﬂu-
rane, 0·25% end-tidal (∼0·15 MAC), on the ventilatory responses to 3 min hypoxic
pulses,175 and reanalyzed the data using the two-component model as described
above. Sevoﬂurane reduced the fast and slow component by 25 and 60%, respec-
tively (P < 0·05), an indication for an eﬀect of sevoﬂurane on the carotid bodies
and on central neuronal dynamics.
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3. Apart from a stimulatory eﬀect at the carotid bodies, hypoxia causes depression
of ventilation via central mechanisms, i.e., within the central nervous system.48
The central eﬀect of hypoxia on V˙i is already apparent after 1 min of hypoxic
exposure,39 therefore, any measured hypoxic V˙i response is the mixture of carotid
body and central eﬀects on V˙i. Because propofol enhances the magnitude of the
central depressant eﬀects of hypoxia in humans,∗ greater depression by propofol
of the measured ventilatory response to hypoxia relative to the measured periph-
eral CO2 response is expected.
These three mechanisms should be taken into account when comparing our current
results on the eﬀect of propofol on the peripheral and central chemoreﬂex loops with
our results of Chapter 4 and studies from the literature on the eﬀect of propofol on the
ventilatory response to acute,130 and subacute hypoxia.20
Inﬂuence of Propofol versus Inhalational Anesthetics on Peripheral CO2 Response
The discrepant eﬀects of propofol and sevoﬂurane on the carotid body response to
CO2 is striking and may be explained by diﬀerences in molecular sites of action of
intravenous and halogenated inhalational anesthetics. We believe that propofol, like in-
halational anesthetics, aﬀects breathing through enhancement of γ-aminobutyric acid-
mediated transmission and reduction of glutamatergic activity in the brainstem.190
This may have induced the depression of Gc in our study. Furthermore, inhalational
anesthetics activate background K+ channels in the peripheral and central nervous
system.25,143,184 These channels are involved in tonic inhibition of cellular excitabil-
ity, and activation by volatile anesthetics may be the cause of some major side eﬀects
such as depression of cardiac function and respiratory depression. Buckler et al. re-
cently showed the existence of an oxygen-, acid- and inhalational anesthetic (halothane)-
sensitive background K+ channel in the carotid body chemoreceptor cells,25 which pos-
sibly is an important link in the cascade leading to CO2- and O2-sensing in the carotid
bodies and the selective site of inhalational anesthetic depression of carotid body func-
tion†. Further studies are needed to show how anesthetics (including propofol) modu-
late the pH-PO2 sensitivity of these background channels.
∗see chapter 4
†see also Chapter 3
6 Response Surface Modeling of Alfentanil–Sevoﬂurane
Interaction on Cardiorespiratory Control and
Bispectral Index
ONE OF THE ADVANTAGES of combining an opioid and an anesthetic over the use of
single agents is the synergistic increase in desired anesthetic eﬀect, such as absence of
movement in response to a painful stimulus as deﬁned by the minimal alveolar concen-
tration (i.e., anesthetic potency).110 The consequence of this mechanism is the need for
less drugswith possibly less side eﬀects. Anesthesiologistsmake use of these fortuitous
interactions by combining opioids and anesthetics during anesthesia. Because respira-
tory depression is a serious side eﬀect of anesthetics,47,48 hypnotics,49 and opioids,43,171
even at low doses, it is surprising that few studies in humans addressed the issue of
the impact of drug combinations on respiration. Especially, the nature of the interac-
tion (additive versus synergistic) of an anesthetic–opioid combination on the control of
breathing remains unknown. Therefore, we studied the inﬂuence of the opioid alfen-
tanil and the inhalational anesthetic sevoﬂurane on ventilatory control, heart rate (HR),
bispectral index (BIS),as measure of the hypnotic state of the subjects, and the ventila-
tory and HR responses to hypoxia. The ability of the ventilatory control system to cope
adequately with hypoxic episodes is of importance because hypoxic periods frequently
occur perioperatively.
The alfentanil–sevoﬂurane interaction on ventilatory control, HR and BIS was assessed
by response surface modeling.82,191,129 This approach enables us to construct three di-
mensional representations of the concentration-response relation among combinations
of alfentanil and sevoﬂurane and assess the nature of the interaction (additive, synergis-
tic or antagonistic) over the whole surface area (it is possible for the response surface to
include all of these interactions in diﬀerent regions).82,191,129 This approach is superior
to the construction of isoboles (or iso-eﬀect curves), which allows assessment of the in-
teraction at drug combinations yielding a constant eﬀect, such as 25% or 50% reduction
in eﬀect parameter (i.e., C25 and C50).
In this study we used the dynamic end-tidal forcing technique.38 This technique
enables us to assess the eﬀect of drug combinations on ventilatory control at identi-
cal end-tidal partial pressures of carbon dioxide (PETCO2’s). Consequently, this makes
a comparison among the respiratory eﬀects of diﬀerent drug combinations possible
because the results are not confounded by changes in PETCO2.
METHODS
Subjects and Apparatus
Nine healthy male volunteers (aged 18–25 yr) participated in the protocol after approval was
obtained from the local human ethics committee (Commissie Medische Ethiek, Leiden Univer-
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Table 1. Total Number of Paired Hypoxic Studies at Each of the Treatment Concentrations
Target Alfentanil Conc. (ng/ml)
0 10 20 30 40 50
0 18 4 9 3 9 2
0·05 1 1 2 2 – –
0·1 9 5 9 2 5 –
0·2 9 3 7 2 1 –
0·3 9 3 3 – – –
E
T
se
vo
ﬂ
u
ra
n
e
(%
)
0·4 2 – – – – –
sity Medical Center, 2300 RC leiden, The Netherlands). Oral and written consent was obtained
from all volunteers. The subjects were healthy and did not have a history of tobacco or illicit
drug use.
After arrival at the laboratory, two intravenous catheters were inserted in the left and right
antecubital vein (one for alfentanil administration and one for blood sampling). Subsequently
electrodes for electroencephalographic measurement were placed on the head as speciﬁed by
the manufacturer and the subjects rested for 20–30 min. Next, a face mask was applied over
the mouth and nose and the experiments started.
See METHODS section Apparatus of Chapter 2 for a description of the procedure and appa-
ratus. The electroencephalograph was recorded using a monitor that computed the BIS over
2-s epochs. We averaged the BIS values over 1 min-intervals and used data points obtained at
3-min intervals.
Study Design
The ventilatory response to isocapnic hypoxia (acute hypoxic response) was assessed during in-
halation of sevoﬂurane, infusion of alfentanil and the combined administration of both agents.
Initially, two hypoxic control studies (i.e., studies without the administration of any agent) were
obtained. Next inhalation of sevoﬂurane was started, and hypoxic studies were performed dur-
ing inhalation of sevoﬂurane. To achieve blood-brain equilibrium, sevoﬂurane hypoxic experi-
ments were preceded by a 12-min equilibration period.137 In table 1, the various imposed target
end-tidal sevoﬂurane concentrations are given. After this set of studies, the subject rested for
30–45 min, and another two control studies were obtained. Next, intravenous infusion of alfen-
tanil was started, and hypoxic studies were performed at various blood target concentrations
(table 1). Subsequently, hypoxic studies during the combined administration of sevoﬂurane
and alfentanil were performed (table 1). The sevoﬂurane and alfentanil target concentrations
were chosen in such a way that at least 60% depression but preferably 80% depression, of the
ventilatory response to hypoxia was achieved. All experiments were performed on a single day,
starting at 08:30 AM.
The Isocapnic Hypoxic Study
The PETO2 waveform was as follows: (1) 10 min at 110 mmHg; (2) a rapid decrease to 50mmHg;
(3) 3 min at 50 mmHg; and (4) 4–5 min at 110 mmHg. At each treatment level (control, various
concentrations of sevoﬂurane, alfentanil, and sevoﬂurane plus alfentanil), two hypoxic studies
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Figure 1. LEFT. The inﬂuence of plasma alfentanil concentration (x-axis) at ﬁxed concentrations of
end-tidal sevoﬂurane concentration on the hypoxic ventilatory response (y-axis) in one subject (sub-
ject 926). Note the parallel displacements of the alfentanil dose–hypoxic response curve caused by
sevoﬂurane. RIGHT. A three dimensional graph of the individual Bayesian estimate of the response
surface of subject 926 for the hypoxic ventilatory response. The surface gives an impression of
the nature of the interaction at all possible drug combinations, which in this case is additive.
were obtained.
All hypoxic studies were performed at identical end-tidal PCO2 concentrations, ∼5–7 mmHg
more than awake resting values. This high value was chosen to oﬀset an increase in end-tidal
PCO2 caused by the alfentanil-sevoﬂurane-induced ventilatory depression.
Alfentanil Administration, Blood Sampling, and Assay.
A target controlled infusion was used for the administration of alfentanil. A palm-top computer
programmed with the population pharmacokinetic data set, reported by Maitre et al.119 was
connected to a syringe pump, which was ﬁlled with alfentanil (0.5 mg/ml). This system allows a
theoretical plasma concentration of alfentanil to be achieved rapidly and maintained. Hypoxic
studies were performed 5–10 min after blood alfentanil concentrations reached their target
levels. Because this equals 5–10 times the alfentanil blood-brain equilibration half-life of 1
min,179 we assume that brain and blood alfentanil concentrations were in equilibrium.
Before and after changes in target alfentanil concentration, 3 ml blood samples for the mea-
surement of alfentanil were collected. A capillary gas chromatographic technique was used to
determine the plasma concentration.
Data Analysis and Statistics
Averaged values of the breath-to-breath data were chosen over identical time segments. Nor-
moxic data points were the mean of the 10 breaths before the 3-min hypoxic period. Hy-
poxic data points were mean of the last 10 breaths of the hypoxic episode. Analysis was
performed on the following variables: normoxic V˙i, normoxic VT , normoxic RR, normoxic HR,
normoxic BIS, normoxic and hypoxic end-tidal PCO2, normoxic and hypoxic end-tidal partial
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pressure of oxygen (PO2); and the change in V˙i, VT , RR and HR from normoxia to hypoxia
relative to the absolute changes in arterial oxygen saturation (i.e., ∆V˙i/∆SPO2, ∆VT /∆SPO2,
∆RR/∆SPO2 and ∆HR/∆SPO2). Hypoxic sensitivities usually are deﬁned as follows: [E(hypoxia)
– E(normoxia)]/∆SPO2, where ∆SPO2 is [100 – SPO2 (hypoxia)], and E the value of a measured
parameter. Instead of 100, we used the actual SPO2-value measured during normoxia to cal-
culate ∆SPO2. This deﬁnition results in positive hypoxic sensitivity values when the measured
parameter E increases upon the introduction of hypoxia (i.e., E(hypoxia) > E(normoxia)). Only
when the eﬀect parameter decreases because of hypoxia (i.e., E(hypoxia) < E(normoxia)), will
the value of the hypoxic sensitivity be negative. The data sets (sevoﬂurane concentration,
alfentanil concentration, E parameter) were analyzed using a pharmacodynamic model which
can be visualized in three-dimensional space as a ‘response surface’. We used the following
pharmacodynamic model:
f(x) = α · (1− xγ)(1)
By substituting E0, which is the baseline value (i.e., pre-drug administration value) of a variable,
for α and substituting Uγ/2 for xγ and U = C/C50, where C50 is the concentration causing 50%
decrease of E, E a measured variable and C the concentration of one drug we obtain:
E(C) = E0 · (1−Uγ/2)(2)
Pure additive interactions of two drugs (alfentanil and sevoﬂurane) are modeled as follows:
E(CA, CS) = E0 · (1− (UA +US)γ/2)(3)
UA = CA/C50,A(4)
US = CS/C50,S(5)
CA is the alfentanil plasma concentration, CS the end-tidal sevoﬂurane concentration, C50,A is
the alfentanil concentration causing a 50% decrease of E, C50,S is the sevoﬂurane concentration
causing a 50% decrease of E.
To include non-additive interactions in the model, an interaction, term I(Q), is introduced:
E(CA, CS) = E0 · (1− [(UA +US)γ]/2 · I(Q))(6)
I(Q) is a smooth function (spline) of Q (see Appendix 1). Following Minto et al.,129
Q = UA/(UA +US)(7)
Q ranges from 0 (sevoﬂurane only) to 1 (alfentanil only) and is the drug concentration ratio of
alfentanil and sevoﬂurane normalized by their respective C50s or potencies (equations 4 and
5). The smooth function has two parameters, Imax and Qmax . Imax is the maximum value of
the interaction term, and Qmax is the value of Q (i.e., concentration ratio) for which I attains
Imax . When Imax equals 1, the interaction is purely additive. An Imax of less than 1 denotes
antagonism and an Imax of more than 1 denotes synergy.
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The model was ﬁtted to the data with NONMEM (conditional estimation method), version
V, level 1·1 (a data analysis program for non-linear mixed eﬀects modeling)∗ using a popula-
tion approach. The interindividual variability of each of the model parameters is characterized
by the percentage coeﬃcient of variation, which is a parameter derived from the variance of
the logarithm of the individual model parameters. Likelihood-ratio tests were performed to
determine whether γ did not equal 1 and whether Imax did not equal 1. The intraindividual
variability was quantiﬁed by the standard deviation of the residuals. P-values of less than 0·01
were considered signiﬁcant.
RESULTS
A total of 109 paired hypoxic responses were obtained at various treatment levels (table
1). The duration of the experiments ranged from 5 to 6 hours. In ﬁgure 1, an example of
the various drug combinations applied in a single subject is shown. This graph further
illustrates that the maximum depression of the hypoxic drive (= ∆V˙i/∆SPO2) was 70 to
80%, obtained at multiple drug combinations. This level of depression was one of the
aims of the study protocol, which was met in all subjects.
End-tidal carbon dioxide values were equal in normoxia and hypoxia (PETCO2 nor-
moxia 48·3 ± 0·5 mmHg (mean ± SEM) versus hypoxia 48·2 ± 0·6 mmHg). These
values are 6–7 mmHg more than individual resting values. The measured plasma alfen-
tanil values averaged to 12·7 ± 0·9 ng/ml, 21·3 ± 1·6 ng/ml, 27·4 ± 1·2 ng/ml and
35·6 ± 2·4 ng/ml for target concentrations of 10, 20, 30 and 40 ng/ml, respectively.
A three dimensional graph of the conditional Bayesian estimate of the response sur-
face of one subject for ∆V˙i/∆SPO2 is given in ﬁgure 1 (right). The value of γ was not
diﬀerent from 1. This indicates a linear relation between alfentanil, sevoﬂurane, and
eﬀect. The surface gives an impression of the nature of the interaction at all possible
drug combinations, at least within the dose ranges tested, which, in this case, is ad-
ditive in all regions of that part of the surface. It further predicts the interaction at
concentrations higher than those we applied. Assuming that the concentration-eﬀect
relation remains linear, the model predicts the complete loss of the hypoxic response
(i.e., ∆V˙i/∆SPO2 = 0) in this subject at combinations of alfentanil and sevoﬂurane on a
line on the surface connecting the points (alfentanil = 55 ng/ml, sevoﬂurane = 0 ET%)
and (alfentanil = 22 ng/ml, sevoﬂurane = 0·4 ET%).
The population estimates of the response surfaces are given in table 2 and ﬁgures
2–4. The model ﬁt the data well. For all variables, the model ﬁts yielded values of γ not
signiﬁcantly diﬀerent from 1. This indicates that alfentanil and sevoﬂurane, and com-
binations of alfentanil and sevoﬂurane at ﬁxed ratios, cause changes of the measured
variables in a linear manner. The C25 and C50 values (the concentrations causing 25%
and 50% reduction of eﬀect) are given in table 2. Note the absence of eﬀect of alfentanil
on BIS (table 2 and ﬁg. 4) and of sevoﬂurane on normoxic breathing frequency (table 2;
∗NONMEM User’s Guides, 1999, SL Beal & LB Sheiner (Eds.) NONMEM Project Group, University of
California at San Francisco, San Francisco.
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see also below).
Pure additive interactions were found for the following parameters: ∆V˙i/∆SPO2, VT ,
∆VT/∆SPO2, ∆RR/∆SPO2, ∆HR/∆SPO2. Inert interactions were observed for RR and BIS.
This leads to straight isoboles or iso-eﬀect curves (the isoboles are shown in ﬁgs. 2–4
Right ). Alfentanil, over the dose range studied, caused a modest reduction of normoxic
breathing frequency. The C25 was 81·5 ng/ml, clearly outside the dose range we studied
(table 2). Sevoﬂurane had no eﬀect on RR when increasing from 0 to 0·4 ET%. Sevoﬂu-
rane caused a linear reduction of BIS with an EC25 of 0·45 ET% (table 2). The eﬀect of
sevoﬂurane on the BIS was independent of the alfentanil concentration.
Synergistic interactions were found for normoxic V˙i and HR (table 2 and ﬁgs. 2 and
3). In ﬁgure 5, the relations between Q (i.e., the alfentanil–sevoﬂurane concentration
ratio) and I(Q) (i.e., the interaction) are given. For V˙i and HR, synergistic interactions
were observed, with maximum synergistic interactions (Imax in table 2) occurring at Q
values of approximately 0·7 (Qmax in table 2). Depression of V˙i by 25% occurred at an
alfentanil concentration of 38 ng/ml and at a sevoﬂurane concentration of 0·7 ET%.
The combinations of sevoﬂurane and alfentanil causing 25, 50, and 75% reduction in
V˙i are given in ﬁgure 2 (TOP Right). The synergy is obvious from the concave form of
the isoboles. One possibility for 25% reduction is 13·4 ng/ml alfentanil plus 0·12 ET%
sevoﬂurane (I(Q) ∼1·9 at a Q of ∼0·7).
DISCUSSION
The main ﬁndings in this study are as follows: (1) Alfentanil, (up to a plasma concentra-
tion of 50 ng/ml), and sevoﬂurane (from 0 to 0·4 ET%), when administered separately,
depress ventilation, HR, and the ventilatory and HR responses to acute hypoxia in a
dose-dependent linear manner; (2) When combined, their depressant eﬀect on ventila-
tion and HR is synergistic, whereas their eﬀect on the hypoxic responses is additive; (3)
Relative to normoxic baseline parameters (V˙i, VT , RR and HR), the responses to hypoxia,
show greater sensitivity to the eﬀects of alfentanil and sevoﬂurane (i.e., depression oc-
curs at lower drug concentrations), when drugs are administered separately and when
combined (C25 values diﬀer by 2–8 times); (4) The bispectral index is sensitive to sevoﬂu-
rane but not alfentanil, even when these agents are combined (inert interaction).
The Pharmacodynamic Model
Although the relation between drug concentration and respiratory eﬀect has been mod-
eled previously using an inhibitory sigmoid Emax model,42 we refrained from such an
approach. In contrast, we chose the function f(x) = a(1 − xγ), which allows for lin-
ear and non-linear concentration-eﬀect relationships (see ﬁg. 6). This was done for the
following reasons:
1. Asymmetric sigmoidal relations between drug and eﬀect may occur in complex
systems, such as the ventilatory control system. For example, at high drug concen-
trations (higher than those studied by us), nonlinear threshold values may cause
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Table 2. Model Parameter Estimates for Ventilation (V˙i), Tidal Volume (VT ), Respiratory frequency
(RR), heart rate (HR), the hypoxic sensitivities (∆E/∆SPO2) and bispectral index (BIS)
V˙i ∆V˙i/∆SPO2 HR ∆ HR/∆SPO2
L/min L min−1 %−1 min−1 min−1 %-1
Baseline 18·4 ± 1·5 1·04 ± 0·27 60·7 ± 2·4 1·10 ± 0·10
%CV 22 74 11 24
C25 Alfentanila 37·7 ± 11 15·7 ± 1·4 155 ± 90 19·1 ± 3·0
C50 Alfentanila 75·3 ± 23 31·3 ± 2·8 310 ± 180 38·2 ± 6·1
%CV 48 17 108 20
C25 Sevoﬂuraneb 0·73 ± 0·44 0·14 ± 0·05 1·92 ± 1·35 0·25 ± 0·11
C50 Sevoﬂuraneb 1·46 ± 0·88 0·27 ± 0·05 3·85 ± 2·60 0·50 ± 0·23
%CV 106 41 ∗ 70
Imax 1·92 ± 0·28 2·47 ± 0·90
Qmax 0·68 ± 0·11 0·69 ± 0·13
SD of Residuals 2·99 0·21 3·67 0·33
VT ∆VT /∆SPO2 RR ∆ RR/∆SPO2 BIS
ml ml %−1 min−1 min−1 %-1
Baseline 1150 ± 50 46 ± 11 16·1 ± 1·1 0·25 ± 0·07 96·3 ± 0·8
%CV 11 62 16 86 2·1
C25 Alfentanila 37·0 ± 6·5 18·4 ± 2·6 81·5 ± 24·7 11·6 ± 0·4 ∗
C50 Alfentanila 74·0 ± 13·0 36·8 ± 5·2 163·0 ± 49·3 23·2 ± 0·7 ∗
%CV 30 28 ∗ ∗ ∗
C25 Sevoﬂuraneb 0·39 ± 0·18 0·15 ± 0·05 ∗ 0·24 ± 0·02 0·45 ± 0·08
C50 Sevoﬂuraneb 0·79 ± 0·36 0·29 ± 0·10 ∗ 0·49 ± 0·04 0·90 ± 0·17
%CV 80 70 ∗ ∗ 53
SD of Residuals 80 10·9 2·49 0·18 3·32
Values are population estimate± SE and the percentage coeﬃcient of variation (%CV ), which
is a measure of the interindividual variability, as derived from the NONMEM analysis;
Baseline is the control parameter value (i.e., before drug administration);
a and b: C25 and C50 denote concentrations of alfentanil (in ng/ml) or sevoﬂurane (in end-
tidal concentration or ET%) giving 25% and 50% reductions in E;
∗ parameter not included in the statistical model;
Imax and Qmax are interaction parameters: Imax values not signiﬁcantly diﬀerent from 1 are
not included in the table (in these cases the alfentanil–sevoﬂurane interaction is additive)
and Imax values greater than 1 indicate synergy;
SD (standard deviation) of the residuals is a measure of goodness of ﬁt.
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the respiratory oscillator to stop abruptly andmay cause irregular or cyclic breath-
ing and apnea.190 In our model eﬀect becomes zero at the concentration C50 · 2
1
γ
(ﬁg. 6).
2. Some respiratory parameters, such as hypoxic sensitivity (∆V˙i/∆SPO2), may be-
come negative above certain drug concentrations. For example, we previously
observed in one male subject that although hypoxia caused an increase in V˙i dur-
ing alfentanil infusion (target, 40 ng/ml) in the awake state, it caused an im-
mediate decrease in ventilation when the subject was asleep (i.e., [V˙i(hypoxia) –
V˙i(normoxia)]/[SPO2(normoxia) – SPO2(hypoxia)] < 0).170 Our model predicts such be-
havior at concentrations > C50 ·2
1
γ (ﬁgure 6). In some of the subjects in this study
negative responses were observed for ∆VT/∆SPO2, ∆ RR/∆SPO2 and ∆ HR/∆SPO2
at high alfentanil concentrations.
3. Within a limited dose range (such as the range studied by us) some respiratory
dose-response relations appear linear or almost linear. For example, halothane
and isoﬂurane, over the dose range from 0 to 0·2 MAC, cause a linear decrease of
the hypoxic ventilatory response (at 0·2 MAC ∆V˙i/∆SPO2 is approximately 20% of
control).47,201 In our model, a linear function is obtained when γ = 1 (ﬁg. 6). In-
terestingly, for all parameters our model, ﬁts yielded values of γ not signiﬁcantly
diﬀerent from 1. This indicates that, at least within the dose range we tested, the
data are well-described by a linear relation between drug (sevoﬂurane or alfen-
tanil) and eﬀect. This is also true for combinations of both agents, but only at
ﬁxed concentration ratios (Q). Incorporation of higher doses might have yielded
values of γ signiﬁcantly diﬀerent from 1. This may be especially true for the BIS-
sevoﬂurane relation.137
Response Surface Modeling The response surface modeling method, as recently re-
ported by Minto et al.,129 is based on two ideas. First, there is the notion that the
combination of two drugs should be regarded as a new drug with its own properties,183
with the concentration-eﬀect relation E = f(CA/C50,A+CS/C50,S;ψ)where the parameter
vector ψ (in our model I(Q)) controls the properties of the interaction and speciﬁcally
how it deviates from pure additivity. Second, ψ is assumed to depend only on the ra-
tio of the concentrations of the two administered drugs.28 These two ideas are crucial
because they allow for a greatly reduced number of parameters necessary to describe
a surface and thus make them estimable from a study of reasonable size.129 A proper
choice of ψ and f may further reduce the number of parameters while describing the
concentration-eﬀect relation in the range measured. We made two modiﬁcations to the
model speciﬁed by Minto et al.. First, interaction was taken into account by the function
I(Q) for which we chose a spline with two, interpretable parameters (see Appendix 1
for details). Second, for f we chose equation 1.
Although visual inspection of the residuals did not show remaining structure, other
possibilities of modeling the concentration-eﬀect relation and the nature of the inter-
• Alfentanil–Sevoﬂurane Interaction 67
0
5
10
15
20
0.00
0.10
0.20
0.30
0.40
10
20
30
40
50
60
n
o
rm
o
xi
c 
ve
nt
ila
tio
n 
(L/
mi
n)
sev
oflur
ane 
(%)
alfentanil (ng/ml)
sevoflurane (%)
0.0 0.1 0.2 0.3 0.4
a
lfe
nt
an
il (
ng
/m
l)
0
10
20
30
40
50
60
Normoxic Ventilation
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.00
0.10
0.20
0.30
0.40
10
20
30
40
50
60
hy
po
xic
 v
en
tila
to
ry
 re
sp
on
se
 
 
(L/
mi
n p
er 
%)
sev
oflur
ane 
(%)
alfentanil (ng/ml)
sevoflurane (%)
0.0 0.1 0.2 0.3 0.4
a
lfe
nt
an
il (
ng
/m
l)
0
10
20
30
40
50
60
Hypoxic Ventilatory Response
25%
50%
75%
25%
50%
75%
100%
Figure 2. TOP. Left: Response surface modeling of the inﬂuence of plasma alfentanil concentra-
tion and end-tidal sevoﬂurane concentration on normoxic ventilation (V˙i) at a ﬁxed PETCO2. Right:
Individual data points and isoboles of 25, 50, and 75% depression of V˙i. Open circles denote data
points above the surface, closed circles denote data points below the surface (control data points
not shown). The area of the circles is proportional to the distance from that data point to the sur-
face area. A 25% reduction of V˙i occurred at: an alfentanil concentration of ∼38 ng/ml when no
sevoﬂurane was present, at a sevoﬂurane concentration of ∼0·73% when no alfentanil was present,
and at ∼0·1% sevoﬂurane when 15 ng/ml alfentanil was present. This indicates synergistic interac-
tion (I(Q) ∼1·9 at Q of ∼0·7; P < 0·01). BOTTOM. Left: Response-surface modeling of the inﬂuence
of alfentanil and sevoﬂurane on the ventilatory response to acute hypoxia at a ﬁxed PETCO2 (i.e.,
the hypoxic drive). Right: Individual data points and isoboles of 25, 50, 75 and 100% reduction of
hypoxic drive. A 25% reduction of hypoxic drive occurred at an alfentanil concentration of ∼16
ng/ml when no sevoﬂurane was present, at a sevoﬂurane concentration of ∼0·14% when no alfen-
tanil was present, and at ∼0·05% sevoﬂurane when 10 ng/ml alfentanil was present. This indicates
additive interaction.
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Figure 3. TOP. Left: Response surface modeling of the inﬂuence of plasma alfentanil concentra-
tion and end-tidal sevoﬂurane concentration on normoxic heart rate (HR) at a ﬁxed PETCO2. Right:
Individual data points and isoboles of 10, 20, and 30% reduction of HR. Open circles denote data
points above the surface, closed circles denote data points below the surface (control data points
not shown). The area of the circles is proportional to the distance from that data point to the sur-
face area. BOTTOM. Left: Response-surface modeling of the inﬂuence of alfentanil and sevoﬂurane
on the HR response to acute hypoxia at a ﬁxed PETCO2. Right: Individual data points and isoboles
of 25, 50, 75, and 100% reduction of the HR response to acute hypoxia at a ﬁxed PETCO2.
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action could be explored, for example, by using the function:157,†
f(x) = α
(1+ δ · xγ)1/δ(8)
Now a spectrum of linear, sigmoidal, and asymmetric sigmoidal concentration-eﬀect
relations is possible with varying values of γ and δ. However, because in our analysis γ
never signiﬁcantly diﬀered from 1, inclusion of additional nonlinear parameters, such
as in equation 8, does not seem necessary. Finally, when synergistic interactions were
detected (i.e., for V˙i and HR), the standard deviations of the estimated parameters did
not warrant a more complex form of I(Q).
V˙i and HR versus ∆V˙i/∆SPO2 and ∆ HR/∆SPO2
We observed synergistic alfentanil–sevoﬂurane interactions on V˙i and HR. This indi-
cates that the eﬀect of the drug combination was greater than expected from the dose-
response curves of sevoﬂurane alone and alfentanil alone. Our analysis shows that for
both variables, maximum synergy occurred at Q values of approximately 0·7. This in-
dicates that, taking into account their respective C50 values, concentrations that give
maximal synergy on reduction of V˙i are at fractions (or multiples) of 26·7 ng/ml for
alfentanil and 0·24 ET% for sevoﬂurane (maximum synergy causing 25% reduction of ef-
†Note that when δ is ﬁxed to –1, equation. (8) reduces to eqn. 1.
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Figure 4. LEFT. Response surface modeling of the inﬂuence of plasma alfentanil concentration and
end-tidal sevoﬂurane concentration on the Bispectral Index (BIS). RIGHT. Individual data points and
isoboles of 10, and 20% reduction of the BIS. Open circles denote data points above the surface,
closed circles denote data points below the surface (control data points not shown). The area of
the circles is proportional to the distance from that data point to the surface area. A 25% reduction
of the BIS occurred at a sevoﬂurane concentration of ∼0·43% (table 2), but no decrease was seen
with increasing doses of alfentanil, even in the presence of sevoﬂurane.
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Figure 5. The relations between Q (i.e., the alfentanil–sevoﬂurane concentration ratio) and I(Q) (i.e.,
the interaction) for ventilation (left ) and heart rate (right ). For both eﬀects, synergistic interac-
tions were observed over the range of concentration ratios from 0 to 1, with maximum synergistic
interactions (Imax in table 2) occurring at Q values of about 0·7 (Qmax in table 2).
Figure 6. Three examples of the concentration–eﬀect relation predicted by the pharmacodynamic
model f (x) = E0(1− xγ) where xγ = Uγ/2 and U = C/C50, obtained at three ﬁxed values of γ (0.2,
1 and 4). when γ = 1, the model becomes linear. At all three γ values, negative eﬀects are possible
at drug concentrations x > C50 · 2
1
γ . Note that the values for C50 and γ were chosen in such a way
that the zero crossing for all three examples occurred at the same value of C. As a consequence the
values of C causing 50% of the eﬀect (i.e., C50) occur at diﬀerent values of C (C1 through C3 are the
C50 values for the three diﬀerent curves). Diﬀerent values for C50 and γ would result in the zero
crossing at diﬀerent values of C. E0 = baseline eﬀect, E50 = 50% depression of eﬀect.
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fect occurs at 13·4 ng/ml alfentanil + 0·12 ET% sevoﬂurane, maximum synergy causing
50% reduction occurs at 26·7 ng/ml alfentanil + 0·24 ET% sevoﬂurane, and maximum
synergy causing 100% reduction occurs at 53·4 ng/ml alfentanil + 0·48 ET% sevoﬂu-
rane).‡ For HR these concentrations are fractions of 86·6 ng/ml for alfentanil and 0·48
ET% for sevoﬂurane (= C50 values). Because we explored only a relatively small part
of the response surface for V˙i and HR, C50 and C100 values are extrapolations. As indi-
cated above, nonlinearities of the ventilatory controller may cause apnea at concentra-
tions higher than those explored in our protocol but lower than those estimated from
our analysis. Moreover, we may have underestimated the magnitude of synergy in our
study. Therefore, our results apply to the portion of the response surface analyzed and
extrapolation should be performed with caution (especially for those surfaces that are
explored only marginally, e.g., HR). The mechanism of the observed synergistic inter-
actions remain elusive. Further studies (e.g., identifying shared central eﬀect-sites for
opioid- and anesthetic-induced respiratory depression) are needed to understand the
synergistic eﬀects of alfentanil and sevoﬂurane on ventilation and heart rate.
We observed additive alfentanil-sevoﬂurane interactions on∆V˙i/∆SPO2 and∆HR/∆SPO2.
This indicates that the eﬀect of the sevoﬂurane-alfentanil combination is expected from
the concentration-response curve of the individual agents. The absence of synergy
may be related to the diﬀerent pathways through which sevoﬂurane and alfentanil de-
press the hypoxic response (inhalational anesthetics depress hypoxic response at sites
within the peripheral chemoreﬂex loop,47,201 and opioids depress the hypoxic response
through eﬀects at the brainstem). Another possibility is that because of the great sen-
sitivity of the hypoxic response to both agents and consequently the early loss of the
hypoxic response (i.e., ∆V˙i/∆SPO2 = 0 occurring at 60 ng/ml alfentanil and 0·5 ET%
sevoﬂurane), we are unable to unearth any synergy from the data.
The observation that the hypoxic drive, relative to resting V˙i, is more sensitive to the
eﬀects of an opioid and an inhalational anesthetic, suggests that the hypoxic test is
the more sensitive tool to assess the eﬀects of anesthetics and opioids on ventilatory
control.
One of the many determinants of HR at rest and during hypoxia is stimulation and
depression of lung receptors by increases/ and decreases in V˙i (i.e., HR eﬀects are
secondary to V˙i-eﬀects).§ This may explain the agreement in the nature of alfentanil-
sevoﬂurane interactions for V˙i and HR and ∆V˙i/∆SPO2 and ∆ HR/∆SPO2.
Bispectral Index and Respiration
In contrast to sevoﬂurane, alfentanil, in the absence and presence of sevoﬂurane, had
no eﬀect on BIS. This indicates that the algorithm for calculating the BIS is not sensi-
tive to the changes in arousal level from opioids and the combination of opioids and
anesthetics (at least within the dose-ranges we evaluated). Because we did not obtain
other measures of sedation during the study (such as the subjective observers’ assess-
‡These values are obtained by simultaneously solving equations 6 and 7, with E/E0 = 0·75 for 25%
reduction, E/E0 = 0·5 for 50% reduction and E/E0 = 0 for 100% reduction.
§see Chapter 4
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Figure 7. The inﬂuence of alfentanil on ventilation (left.) Values are % of control) and hypoxic drive
(right.) Values are % of control) at constant bispectral index (BIS) values (so called iso-BIS curves).
The BIS values are in italic and range from 95 to 65. The BIS values were ﬁxed by inhalation of
constant concentration of sevoﬂurane. Note that the hypoxic drive is more vulnerable than V˙i for
the eﬀects of alfentanil at all tested BIS values.
ment of alertness and sedation score) we remained uninformed on the level of arousal
during the alfentanil-sevoﬂurane studies. However, because clinicians and researchers
use BIS monitoring, we constructed iso-BIS curves (equivalent to iso-eﬀect curves, ﬁg.
7). We now are informed about the steady-state relation between alfentanil and V˙i and
∆V˙i/∆SPO2 at varying BIS levels. Further studies are needed to examine whether these
steady-state relations are independent of sevoﬂurane and also apply to other agents
that aﬀect the BIS (such as propofol, isoﬂurane, dexmedetomidine, midazolam), or that
separate BIS-opioid-V˙i-relations exist for each anesthetic/hypnotic.
Study Limitations
Somemethodologic issues deserve further comment. We used an isohypercapnic design
(PETCO2 ﬁxed to ∼48 mmHg). This enables the comparison of the eﬀect of various drug
concentrations on V˙i without the confounding inﬂuence of variations in PETCO2. How-
ever, because every drug eﬀect on V˙i is conditional on a certain PETCO2 value, other re-
sultsmight be seen at diﬀerent carbon dioxide concentrations. Furthermore, becausewe
performed a steady-state study (drug concentrations, PETO2, and PETCO2 were clamped
during hypoxic testing), the time course of drug-induced variations in blood gases (such
as those that may occur during bolus opioid infusions) and their translation into V˙i and
oxygen delivery were not modeled. Further studies are needed to examine the blood
gas and V˙i dynamics caused by the administration of opioids and anesthetics occurring
in the clinical setting.
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APPENDIX
For the function I(Q) we use a spline with a piece g1(x) between knots at x = 0 and x = Qmax and a
piece g2(x) between knots x = Qmax and x = 1, constrained by the following eight conditions:
g1(0) = g2(1) = 1(9)
g1(Qmax) = g2(Qmax) = Imax(10)
dg1(x)/dx
∣
∣
x=Qmax = dg2(x)/dx
∣
∣
x=Qmax = 0(11)
d2g1(x)/dx2
∣
∣
∣
x=0 = d
2g2(x)/dx2
∣
∣
∣
x=1 = 0(12)
The ﬁrst four constraints (eqns. 9 and 10) deal with the values of I(Q) at the three knots, constraints
ﬁve and six (eqn. 11) make the second knot a maximum (or minimum) and constraints seven and eight
(eqn. 12) are natural boundary conditions at the ﬁrst and last knot and assure the absence of values
outside (1,Imax). Because we specify eight conditions, we can utilize a cubic spline so that each piece
is given by a third-order polynomial:
g(x) = a0 + a1x + a2x2 + a3x3(13)
The parameters ai are such that the above constraints are satisﬁed. Note that they need not be inter-
preted, but are merely functions of Imax and Qmax . For g1(x) we have:
a0 = 1
a1 = −3(1− Imax)/(2Qmax)
a2 = 0
a3 = (1− Imax)/(2Qmax)/Q2max(14)
For g2(1− x), the parameters ai are obtained by substituting (1 – Qmax) for Qmax.

7 Response surface modeling of remifentanil–propofol
interaction on cardiorespiratory control and
bispectral index
THE COMBINED administration of opioids and anesthetics for induction and mainte-
nance of anesthesia is common practice. The anesthetic is given to lose consciousness,
prevent awareness and reduce movement responses, the opioid is given to suppress so-
matic, stress and adrenergic responses to surgical stimulation. An important advantage
of combining an opioid and an anesthetic is the synergistic increase in these desired
eﬀects, with consequently the need for less drugs to attain the goal of adequate anesthe-
sia relative to the amount of drug needed when only a single agent (i.e., an anesthetic)
is given.110 Since this is not only true for patients that are intubated and ventilated
but also for patients that maintain their own breathing, for example during ‘monitored
anesthesia care’, it is of interest to address the issue of the eﬀect of drug combinations
on respiration. While it is known that anesthesia induces many ‘side eﬀects’ it is ac-
knowledged that respiratory depression is potentially life-threatening.123 We therefore
studied the eﬀect of the opioid remifentanil and intravenous anesthetic propofol on
the cardiorespiratory control. This combination of drugs is frequently used in patients
under monitored anesthesia care for minor (without additional regional anesthesia) and
major (with additional regional anesthesia) surgery. Knowledge on the quantitative and
qualitative (additive versus synergistic) nature of their interaction is clinically important
and may lead to speciﬁc dosing regimens aimed at the titration of sedation/analgesia
versus respiratory eﬀect.
To study the remifentanil-propofol interaction, we made use of the technique of re-
sponse surface modeling.82,89,129,191 This technique allows the observation of the con-
centration-eﬀect relation among inﬁnite combinations of remifentanil and propofol over
the whole surface area in three dimensional space. In Chapter 6 we made successful
use of this technique to quantify the interactive eﬀects of sevoﬂurane and alfentanil on
cardiorespiratory control.
METHODS
Subjects
Twenty-two healthy male volunteers (aged 19–25 yr) participated in the protocol after approval
was obtained from the local Human Ethics Committee (Commissie Medische Ethiek, Leiden
University Medical Center, 2300 RC leiden, The Netherlands). Oral and written consent was
obtained from all volunteers.
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Table 1. Results of the bootstrap based model selection
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Apparatus
After arrival at the laboratory, an intravenous catheter was inserted in the left antecubital vein
(for drug infusion) and an arterial line was placed in the right radial artery (for blood sampling).
Subsequently, electrodes for EEG monitoring (BisSensor, Aspect Medical Systems, Newton, MA)
were placed on the head as speciﬁed by the manufacturer and the subjects rested for 20 to 30
min. Next a face mask was applied over the mouth and nose and data collection started.
See METHODS section Apparatus of Chapter 2 for a description of the procedure and appa-
ratus. The EEG was recorded using an Aspect A-2000 EEG monitor (software version 3·3). The
monitor computed the bispectral index (BIS) over 2-s epochs. We averaged the BIS values over
1 min-intervals.
Study Design
Resting ventilation and PETCO2 (i.e., without any inspired CO2), blood pressure, heart rate,
BIS and the ventilatory response to hypercapnia were measured before and during infusion of
remifentanil, propofol and the combined infusion of these agents. Initially control (i.e. without
the administration of any agent) values were obtained. Next the infusion of remifentanil was
started and cardiorespiratory and BIS parameter values were obtained at steady state blood tar-
get concentrations. After this set of studies, the infusion was terminated and the subject rested
for 1 hour. Next the infusion of propofol was started and cardiorespiratory and BIS parameter
values were obtained at steady state blood target concentrations. Subsequently parameter val-
ues were obtained during the combined administration of remifentanil and propofol. In some
subjects two to three studies were performed at diﬀerent propofol-remifentanil combinations.
The subjects were randomly assigned to a ﬁxed scheme of target concentrations of remifentanil
and propofol. The scheme was designed to ensure that, over the applied dose ranges, evenly
spread data points were obtained.
The Ventilatory Response to Hypercapnia
The ventilatory response to CO2 was obtained by using the ‘dynamic end-tidal forcing’
technique.38–40 After assessment of resting variables, 3 to 8 elevations in PETCO2 were ap-
plied to obtain data points for the steady-state ventilatory response. The elevations varied
from 3 to 19 mmHg. The elevated PETCO2 readings lasted at least 8 min. When on-line analy-
sis revealed that a ventilatory steady-state had not been reached, the duration of hypercapnia
was extended. The order of elevations was arbitrarily chosen. All hypercapnic studies were
performed at a background of moderate hyperoxia (PETO2 120 mmHg).
The elevated PETCO2 and the corresponding V˙i breath-to-breath data were averaged over 10-
breaths. Data points were obtained at the end of the PETCO2 elevation. This procedure yielded
3 to 8 steady-state data points. We expressed ventilation as a linear function of PETCO2: V˙i =
S (PETCO2 – Bk), where S is the ventilatory CO2 sensitivity and Bk the extrapolated PETCO2 at
zero V˙i. Parameters S and Bk were determined by linear regression of V˙i on PETCO2.
Remifentanil and Propofol Administration, Blood Sampling and Assays.
Propofol and remifentanil were administered using target controlled infusion (TCI) systems.
For propofol we used a Psion palm-top computer (London, England) programmed with a three
compartment propofol pharmacokinetic (PK) data set to control a Becton Dickinson infusion
pump (St. Etienne, France).70,79 For remifentanil we used a custom build infusion pump which
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Table 2. Population Pharmacodynamic Estimates
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was programmed with a remifentanil pharmacokinetic data set (Remifusor, University of Glas-
gow, Glasgow).128 These systems allow a speciﬁed target plasma concentration of remifentanil
and propofol to be rapidly achieved and maintained. Hypercapnic studies were performed∼10
min after blood remifentanil and propofol concentrations had reached their target levels. Since
this equals >5-10 times the remifentanil and propofol blood–eﬀect-site equilibration half-lifes,
we assumed that brain and blood remifentanil and propofol concentrations were in equilibrium.
Before and after changes in target drug concentrations, arterial blood samples for determi-
nation of remifentanil and propofol concentrations were collected. Blood for propofol determi-
nation was collected in syringes containing potassium oxalate. Propofol concentrations were
determined by reverse-phase high performance liquid chromatography .132 Samples for the de-
termination of blood remifentanil concentrations were collected into tubes containing sodium
heparin and immediately transferred to tubes containing 50% citric acid (to inactivate esterases)
before freezing at –20◦C. The assay method is based on tandem mass spectrometry detection.10
Response Surface Modeling
Analysis was performed on the following parameters: resting inspired minute ventilation (V˙i)
and PETCO2 (i.e., without any inspired CO2), slope of the hypercapnic ventilatory response
(S), ventilation at a ﬁxed PETCO2 of 55 mmHg (V˙55, calculated from S and BK), mean arterial
pressure (MAP), heart rate (HR) and BIS. The basis of the pharmacodynamic (PD) model is similar
to the model described in Chapter 6 The single-drug concentration (C) – eﬀect (E) relationship
is given by
E(C) = E0 ·
{
1− ( C
C50
)
γ
· 1
2
}
(1)
where E0 is the baseline drug eﬀect, C50 the value of C which gives 50% depression, and γ a
nonlinearity parameter; notice that the model is linear when γ= 1. A straightforward extension
for two concomitantly administered drugs (Cr = remifentanil concentration, Cp = propofol
concentration) is obtained by respecting Loewe additivity:13
E(Cr , Cp) = E0 ·
{
1−
[
Cr
C50,r
+ Cp
C50,p
]γ
· 1
2
}
(2)
Note that isoboles in the Cr – Cp plane are straight lines, irrespective of the value of γ. Devia-
tions from additivity can be modeled as:
E(Cr , Cp) = E0 ·

1−
[
Cr
C50,r
+ Cp
C50,p
]γ(Q)
· 1
2
· I(Q)

(3)
with I(Q) a smooth function (spline) with a parameter denoting maximum interaction Imax
at I(Qmax) and Q = Ur/(Ur + Up), Ur = Cr/C50,r , Up = Cp/C50,p. To limit the number of
parameters γ(Q) was either a constant or a linear function going from γr at Q = 1 to γp at
Q = 0. Since the concentration ranges used in the study for most parameters lie below the C50’s,
these parameters will be poorly estimated leading to wide asymmetric conﬁdence intervals. A
remedy would be to useC10’s or C25’s but one doesn’t know the optimal parameters beforehand.
In fact, it is better to use parameters that are centered according to the study design:
E(Cr , Cp) = E0 ·

1−
[
Cr
Ch,r
· λ1/γ(Q)r + CpCh,p · λ
1/γ(Q)
p
]γ(Q)
· I(Q)

(4)
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where Ch,r and Ch,p the values of Cr and Cp midway in the measured concentrations range,
and Q redeﬁned to be Q = Ur/(Ur + Up), Ur = Cr/Ch,r , Up = Cp/Ch,p; λr and λp denote the
degree of depression from E0 when Cr = Ch,r and Cp = 0 and vice versa, respectively. For
parameter PCO2, which increases from E0, the model used was the same as eq. (4), except the
minus sign was replaced by a plus sign.
Parameter Estimation and Model Selection
The above model has the following parameters to be estimated: E0, λr , λp, Imax, Qmax, γr and
γp. The following situations are of special interest:
• Imax = 1, Qmax = 0.5 denoting additivity,
• Imax ≠ 1, Qmax = 0.5 denoting symmetric interaction,
• Imax ≠ 1, Qmax ≠ 0.5 denoting asymmetric interaction.
Notice that when Qmax = 0.5 we could use Minto’s parabolic function of Q instead of the
spline I(Q).129 Furthermore, when two drugs are pharmacodynamically equivalent apart from
a diﬀerence in potency, we would expect a symmetric interaction (since Q is based on normal-
ized concentrations). For each of the above three cases, there are ﬁve situations that describe
(non)linearity:
• γr = γp = 1 denoting linearity,
• γr = γp ≠ 1 denoting nonlinearity described by one parameter,
• γr ≠ 1 and γp = 1 denoting nonlinearity for drug R and linearity for P ,
• γr = 1 and γp ≠ 1 denoting linearity for drug R and nonlinearity for P ,
• γr ≠ 1 and γp ≠ 1 denoting nonlinearity described by two parameters.
This results in a total of ﬁfteen models to be investigated (see ﬁg. 1). NONMEM was used
to estimate the parameter values.135 Since the models are non-nested, the likelihood ratio
criterion is not applicable so Akaike’s Information-theoretic Criterion was used instead:135
AIC = −2LL + 2P , where −2LL is the minimum value of the objective function calculated by
NONMEM and P denotes the number of parameters. The model with the lowest AIC is consid-
ered ‘best’. The population analysis was done under the assumption of lognormally distributed
model parameters and constant relative (except for PCO2 where it was assumed to be additive)
normally distributed intra-individual error.
Model Stability Assessment using the Bootstrap
When, according to AIC criterion, a model is chosen for a certain eﬀect parameter, that choice
is not associated with a measure of conﬁdence in that model. One would like to be more certain
that the choice is not an artifact of particular individuals in the current data set, and that when a
new data set would be obtained, the same model would be chosen. A way to generate surrogate
data sets is given by the method of the bootstrap.69 Basically, a bootstrap data set is formed
by selecting, with replacement, the data from individuals until a set is obtained with the same
total number of individuals. This data set is then subject to the same ﬁtting procedure, and by
repeating the process N times, N parameter estimates are obtained with N selections of one
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M1: γr = γp = 1
M1···5:
{
Imax = 1
Qmax = 0.5
M2: γr = γp = γ ≠ 1
M3: γr ≠ 1; γp = 1
M4: γr = 1; γp ≠ 1 M5: γr ≠ 1; γp ≠ 1
M6: γr = γp = 1
M6···10:
{
Imax ≠ 1
Qmax = 0.5
M7: γr = γp = γ ≠ 1
M8: γr ≠ 1; γp = 1
M9: γr = 1; γp ≠ 1 M10: γr ≠ 1; γp ≠ 1
M11: γr = γp = 1
M11···15:
{
Imax ≠ 1
Qmax ≠ 0.5
M12: γr = γp = γ ≠ 1
M13: γr ≠ 1; γp = 1
M14: γr = 1; γp ≠ 1 M15: γr ≠ 1; γp ≠ 1
Figure 1. Schematic representation of the 15 diﬀerent pharmacodynamic model (M) possibilities.
Models 1 to 5: additive interaction between propofol and remifentanil; models 5 to 10: non-additive
interactions at a value ofQmax equal to 0.5; models 11 to 15: non-additive interactions at a value of
Qmax not equal to 0.5. Models 2, 7 and 12: linear relationships between propofol and remifentanil
concentrations and eﬀect; models 3, 8 and 14: a linear relationship between propofol concentration
and eﬀect, a non-linear relationship between remifentanil concentration and eﬀect; models 4, 9 and
14: a non-linear relationship between propofol concentration and eﬀect, a linear relationship be-
tween remifentanil concentration and eﬀect. Models 5, 10 and 15: Non-linear relationships between
propofol and remifentanil concentrations and eﬀect.
of the ﬁfteen models. From the parameter estimates conﬁdence intervals and histograms can
be constructed. The impact of constraining certain parameters to ﬁxed values, and therefore
identiﬁability, can then be studied visually. The number of times a model is selected is a
measure of our conﬁdence in the model.
The bootstrap procedure was implemented in a C++ program that generates bootstrap data
sets, NONMEM control ﬁles with appropriately ﬁxed parameters, runs NONMEM and reads back
the estimated parameter values and the minimum value of the objective function. When NON-
MEM returned an error status regarding parameter boundary problems (despite carefully cho-
sen initial conditions and boundaries) or rounding errors the model that was ﬁtted was deemed
to be not supported by the data. This, in principle, gives a bias towards the simpler models.
Furthermore, to have a feasible procedure with respect to computer time, we opted not to
investigate all possibilities for the statistical model. Initially, intra-individual variability was
assumed to be present only on parameters E0, λr , and λp. When the number of times the
corresponding variance was estimated to be negligible exceeded N/2, this variability term was
removed and the bootstrap redone. Conﬁdence intervals were obtained in the traditional way
82 Chapter 7 •
PETCO2 (mmHg)
35 40 45 50 55 60 65 70
Ve
n
tila
tio
n
 (L
/m
in
)
0
5
10
15
20
25
30
35
control
propofol (1.5 µg/ml)
remifentanil (1 ng/ml)
remifentanil + propofol
   (1ng/ml)       (1.5 µg/ml)
Figure 2. Four ventilatory carbon dioxide response curves of one subject. The control response
had a slope of 2·4 L/min per mmHg. While propofol decreased the slope to 0·8 L/min per mmHg,
remifentanil caused a parallel shift to higher PCO2 values of about 12 mmHg (slope = 2·2 L/min
per mmHg). The combined administration yielded both a reduction in slope of the response curve
(slope = 0·2 L/min per mmHg) and a rightward shift of about 20 mmHg. These observations suggest
synergy on the slope of hypercapnic response and ventilation at a ﬁxed PETCO2.
(i.e., estimate ± 1.96·SE) and the bootstrap BCa (biascorrected and accelerated) method.69
RESULTS
All 22 subjects completed the protocol without major side eﬀects. A total of 94 re-
sponses were obtained at diﬀerent drug combinations. The range of the measured
arterial remifentanil was 0-2 ng/ml. For propofol all measured concentrations were in
the range of 0-2·0 µg/ml except one (2·6 µg/ml). Consequently Ch,r and Ch,p were set
to 1 ng/ml and 1 µg/ml, respectively, in the pharmacodynamic model
A typical example of respiratory studies in one subject is given in ﬁgure 2. Its shows
the control response (no drugs given) with a slope of 2·4 L min−1 mmHg−1, the eﬀects
of 1·5 µg/ml propofol (a 66% reduction of the slope of the V˙i-CO2 response to 0·8 L
min−1 mmHg−1) and 1 ng/ml remifentanil (a parallel shift of the response curve with a
slope of 2·2 L· min-1·mmHg-1) alone, and the eﬀect of that drug combination, which
was greater than the sum of the eﬀects of either drug alone (a > 90% depression of the
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slope to 0·2 L min−1 mmHg−1).
In table 1 the results of the bootstrap based model selection are given. For all respira-
tory parameters model 7 was best ﬁtted to analyze the data (i.e., non-linear relationship
between drugs and eﬀect, synergistic interaction, Qmax = 0·5, ﬁg. 1). The population
estimates ± SE and 95% conﬁdence intervals, as derived from the NONMEM analysis, of
the response surfaces are given in table 2 and for resting V˙i, resting PETCO2, V˙55 and S
in ﬁgures 3 and 4. At 1 ng/ml and 1 µg/ml, remifentanil and propofol caused ∼28% and
13% depression of resting ventilation, respectively. Combining propofol and remifen-
tanil at these same blood concentrations caused 58% depression (eqn. 4), indicating
the synergistic nature of the interaction. Similar observations were made for resting
PETCO2, V˙55 and S, although the synergistic interaction strength was less (Imax resting
V˙i = 1·9 versus Imax resting PETCO2, V˙55 and S = 1·2–1·3). At the combined infusion of
1 µg/ml propofol and 1 ng/ml remifentanil the depression of V˙55 was 82% (eqn. 4); the
corresponding values for resting PETCO2 and S were 23% and 69%, respectively.
To get an indication of the spread of data points over the surface and of the goodness
of ﬁt, we give bubble plots which show the distance of individual measured data points
from the population surface (i.e., residuals; ﬁgs. 3–5). These plots show evenly spread
data over the tested dose ranges and the absence of overt misﬁts. The values of baseline
MAP and HR indicate that the subjects were free of agitation or stress during the studies
(table 2). The eﬀects remifentanil and propofol on MAP and HR rate were not as remark-
able as their eﬀects on the respiratory parameters: depression at 1 ng/ml remifentanil
and 1 µg/ml propofol ranged from 4 to 12% (table 2). The eﬀect of the combination was
expected from the concentration-response curve of the individual agents (i.e. additive
interaction or Imax = 1, linear dose-eﬀect relationship for MAP, non-linear relationship
for HR, table 1).
The BIS was unable to unearth any sedative eﬀect of remifentanil over the dose range
studied by us (inert interaction, ﬁg. 5). Furthermore, the eﬀect of propofol on the BIS
was independent of the remifentanil concentration. The propofol-BIS relationship was
linear with 19% depression of the BIS at 1 µg/ml plasma level.
DISCUSSION
The main ﬁndings of our study are as follows: (1) Over the dose range tested, remifen-
tanil (0–2 ng/ml) and propofol (0–2.6 µg/ml) caused a dose dependent depression of
respiration, as observed by an increase in resting PETCO2 and decreases in resting V˙i,
slope of the V˙i-CO2 response and ventilation at a ﬁxed PETCO2 of 55 mmHg; (2) While
remifentanil shifts the V˙i-CO2 response curve in a parallel fashion to higher PETCO2 lev-
els, propofol reduces the slope of the response rather than shifting its position (pivot
point at resting V˙i); (3) When combined, the depressant eﬀect of propofol and remifen-
tanil on resting V˙i, resting PETCO2, S and V˙55 is synergistic, with the greatest synergy
observed for resting V˙i; (3) The depressant eﬀect of remifentanil and propofol on blood
pressure and heart rate is modest, when given separately; when combined their depres-
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Figure 3. TOP. Left: Response surface modeling of the interaction of remifentanil and propofol
on resting V˙i. The population response surface shows that the propofol-remifentanil interaction
is synergistic (I(Q) = 1·9 ± 0·2). Note further that the dose-response relationships between drugs
and eﬀect was not linear (for both drugs γ = 0·5 ± 0·1). Right: Individual data points and 25,
50 and 75% isoboles. Open circles denote data point above the surface, closed circles below the
surface (control data points not shown). The area of the circles is proportional to the distance
from that data point to the surface. BOTTOM. Left: Response surface modeling of the interaction
of remifentanil and propofol on V˙i at a ﬁxed PETCO2 of 55 mmHg. The population response surface
shows that the propofol-remifentanil interaction is synergistic (I(Q) = 1·2 ± 0·1). The dose-response
relationships was not linear (for both drugs γ = 0·4 ± 0·1). The model predicted apnea at several
combinations of propofol and remifentanil, e.g., 1·6 ng/ml remifentanil and 2·0 µg/ml propofol or
2·0 ng/ml remifentanil and 1·6 µg/ml propofol. Right: Individual data points and 25, 50, 75 and
100% isoboles.
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Figure 4. TOP. Left: Response surface modeling of the interaction of remifentanil and propofol on
the slope of the V˙i response toCO2 (CO2 sensitivity). The population response surface shows that the
propofol-remifentanil interaction is synergistic (I(Q) = 1·3 ± 0·1). The dose-response relationships
was not linear (for both drugs γ = 0·4 ± 0·1). Note that the eﬀect on slope was predominantly a
propofol eﬀect and to a lesser extend a remifentanil eﬀect. Right: Individual data points and 25,
50 and 75% isoboles. Open circles denote data point above the surface, closed circles below the
surface. The area of the circles is proportional to the distance from that data point to the surface
area. BOTTOM. Left: Response surface modeling of the interaction of remifentanil and propofol on
resting PETCO2. The population response surface shows that the propofol-remifentanil interaction
is synergistic (I(Q) = 1·3 ± 0·2). The dose-response relationships was not linear (for both drugs γ =
0·7 ± 0·1). Note that the x- and y-axes are diﬀerent from the other response surface plots with the
control point now facing the reader. Right: Individual data points and 25% isobole.
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Figure 5. LEFT: Response surfacemodeling of the interaction of remifentanil and propofol on the bis-
pectral index of the EEG (BIS). The population response surface shows that the propofol-remifentanil
interaction is inert since remifentanil had no eﬀet on BIS irrespective of the propofol concentrations.
Over this dose range, propofol causes a linear decrease in BIS with a 25% decrease occurring at 1·4
µg/ml. RIGHT: Individual data points and 25,% isobole. Open circles denote data point above the
surface, closed circles denote data points below the surface. The area of the circles is proportional
to the distance from that data point to the surface area.
sant eﬀect is additive; (4) The BIS is sensitive to propofol but not to remifentanil, even
when these agents are combined.
Pharmacodynamic Modeling
The pharmacodynamic model. In common with the study described in Chapter 6 the
pharmacodynamic model used by us is based on the ’Richards model’ which for one
drug is written as:157 f(x) = α · [(1 + δ · xγ)1/δ]−1. By ﬁxing δ = −1 (cf. eqn. 1) a
model is obtained which may be non-linear (γ ≠ 1) or linear (γ = 1). The advantages of
this approach have been discussed in Chapter 6. In short, in contrast to classical phar-
macodynamic models, such as the inhibitory sigmoid EMAX model, our model predicts
apnea at and above certain drug concentrations; it predicts negative responses above
certain drug concentrations;∗ and ﬁnally, linear respiratory dose-responses may occur
over limited dose ranges.48 Interaction was modeled as suggested by Minto et al.,129
which is based on the following two ideas: (1) the combination of two drugs should be
regarded as one new drug with its own properties, and (2) that these properties depend
only on the concentration ratio Q. As before, interaction was deﬁned by the function
I(Q), for which we chose a spline (for details see Chapter 6). Furthermore, the two
drugs used in this study have dissimilar mechanisms of action so that we would not
∗Negative responses may occur when testing the eﬀect of opioids on the ventilatory response to
hypoxia. See ref. 170 and Chapter 6.
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expect their γ to be equal at equipotent concentrations. Therefore we also included the
possibility of a linear γ(Q). To our surprise γr = γp =γ for all tested parameters.
Parameterization. Frequently, pharmacodynamic models incorporate C50’s to de-
scribe and compare potencies. Since in our study the applied concentration ranges lie
well below the C50’s, these parameters are poorly estimated with wide and asymmetric
conﬁdence intervals. In order to overcome this problem we introduced the parame-
ter λ which is the percentage depression at the concentration midway in the plasma
concentration range (see eqn. 4).
Bootstrap Model Selection. The method of the bootstrap was applied here to assess
the stability of the model selection based on AIC. Conﬁdence in a model is then ex-
pressed as the number of times a model is chosen. Note that this conﬁdence is not
equivalent with the type I or type II error in traditional hypothesis testing. In the space
of two nested models, however, the AIC is closely related to the type I error and the
model selection percentage closely related to the power of the test.178 When NONMEM
produced an error message concerning boundary errors, the model that was tested was
most probably overparameterized and would not be selected by AIC anyway.
Characteristics of Parameter Distributions. Parameter distributions can be esti-
mated by constructing histograms of the estimated parameter values from the boot-
strap runs. With the parameterization utilizing λ’s, their distributions were neither
wide nor skewed so that the conﬁdence intervals (obtained from the NONMEN popula-
tion estimates ± 1·96·SE, table 2) turned out to be equivalent with those obtained from
the bootstrap parameter distributions. For example, for V˙55 the corresponding values
are baseline value 29·0–34·0 L/min, λr 51·0–67·0%, λp 37·0–52·0%, Imax 1·08–1·39 and
γ 0·22–0·50.
Parameter Values
The eﬀects of 1 ng/ml remifentanil and 1 µg/ml propofol on resting V˙i was considerably
less than their eﬀect on V˙55 (the ratio of λ’s is 0·5 for remifentanil and 0·3 for propofol).
This is not surprising taking into account the fact that while resting V˙i is measured
under closed-loop conditions and part of the respiratory depression is oﬀset by the
gradual increase in resting PETCO2, V˙55 is measured under open-loop conditions and the
pharmacokinetics and pharmacodynamic of CO2 (and the eﬀect the tested drugs have
on CO2 PK/PD) have been eﬀectively removed. Recent studies indicate that C50 values
obtained from studies using a ﬁxed PETCO2 input to the chemical control system and
studies on the dynamic eﬀect of drugs on resting ventilation, which do take into account
the dynamics and kinetics of carbon dioxide, were of the same order of magnitude.22
For example, the C50 of alfentanil for depression of ventilation at a raised ﬁxed PETCO2
is about 75 ng/ml,† while the C50 derived from resting ventilation (i.e., without any
inspired CO2) is 60 ng/ml.22
The extrapolated C50 values from this study correspond well with studies from the
literature. For example, the remifentanil C50 of V˙i at a raised and ﬁxed PETCO2 obtained
from a single bolus of 0·5 µg/kg was of the same order of magnitude as our observa-
†see Chapter 6
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tion (1·1 ng/ml versus 0·7 ng/ml in this study, table 2).4 Note that in this latter study
remifentanil concentrations were not measured but obtained from the literature. These
C50 values are a factor of 10 smaller than those observed for changes in spectral edge
frequency of the EEG,128 and 4 to 5 times smaller than those observed for 50% probabil-
ity of adequate anesthesia during abdominal surgery (in combination with 66% nitrous
oxide).65 These ﬁndings indicate the higher opioid sensitivity of CNS sites involved in
ventilatory control compared to sites involved in behavioral state control and suppres-
sion of somatic and autonomic responses. Remifentanil is about 80–100 times more
potent than alfentanil in depressing V˙55.‡ At present we are unaware of any previous
respiratory PK/PD data for propofol.
Clinical Considerations
While response surface modeling provides a compact mathematical formulation for
describing the interactions of two (or more) drugs, it can be diﬃcult to translate this
surface into a clinically useful interpretation. The isoboles (ﬁgs. 3–5) provide a hori-
zontal ‘cut’ through the response surfaces, however, vertical cuts through the response
surfaces may provide a more useful clinical graph. While remifentanil and propofol are
often given at the same time to patients, they are not mixed together and infused at a
constant ratio. General clinical use is for both drugs to be given at a constant rate (re-
sulting in a steady state with constant plasma levels) and then one of the drugs adjusted
up as needed for additional analgesia/sedation or down if less respiratory depression is
important. The parameters of the response surface for resting PETCO2 and ventilation
can be used to predict how these important clinical variables will change with changing
infusion rates. Since PETCO2 is the more easily clinically monitored variable, ﬁgure 6
shows how PETCO2 changes with the infusion rates. In the top panel, the increase in
PETCO2 with changes in propofol plasma concentration at constant remifentanil levels
is shown, while the bottom panel shows the same for constant propofol concentration
and remifentanil is adjusted. The non-linear shape of the response surface results in
marked diﬀerences between these two ﬁgures. Figure 6 predicts that the PETCO2 in-
creases regularly with increasing remifentanil with some potentiation by the addition
of propofol. However, the amount of propofol added does not change the amount of
depression until higher levels of remifentanil are reached. These curves predict that
while remifentanil causes hypercapnia, once beyond an initial additional rise in PETCO2
when the propofol is started, there is little further respiratory depression as the propo-
fol plasma level is increased. These graphs indicate that it might be safer to titrate
the propofol dose with a constant remifentanil background if more or less sedation is
needed, since there should be little change in the amount of respiratory depression,
but if less respiratory depression is required, then the remifentanil would need to be
reduced.
The above applies best to patients who maintain their breathing during anesthesia.
In order to extrapolate our ﬁndings to postoperative patients, we plotted in ﬁgure 7 the
‡see Chapter 6
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Figure 6. TOP. The inﬂuence of the steady-state or eﬀect-site propofol concentration on resting
PETCO2 at various constant remifentanil concentrations. BOTTOM. The inﬂuence of the steady-state
or eﬀect-site remifentanil concentration on resting PETCO2 at various constant propofol concentra-
tions. Changing remifentanil concentrations causes marked increases in resting end-tidal PCO2,
irrespective of the propofol concentration, while changes in propofol concentrations have less of
an eﬀect on resting PETCO2, irrespective of the remifentanil concentrations.
10–60% isoboles of increasing resting PETCO2 with the isobole for 50% probability of re-
gaining consciousness after general anesthesia for abdominal surgery (and the isobole
for 50% probability of no somatic/autonomic response to surgical stimuli).125 This plot
shows (1) the synergistic interaction between propofol and remifentanil on the 50%
probability to ‘wake-up’ after anesthesia (and thus shows in contrast to the bispectral
index data (ﬁg. 5) the sedative/hypnotic eﬀect of remifentanil); (2) whether conscious-
ness has been regained or not, ventilation improves best by reducing the remifentanil
concentration (i.e., the return of the wakefulness drive is of limited importance at least
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Figure 7. Comparison of isoboles of respiratory depression (10–60% isoboles for increases in
PETCO2, data from this study), consciousness and adequate anesthesia (50% probability lines for
consciousness and adequate anesthesia in patients undergoing abdominal surgery, data from ref.
125).
when the subject is not stimulated or reminded to breathe); (3) without the addition
of propofol, remifentanil concentrations up till 2 ng/ml cause only limited respiratory
depression and may be applied for postoperative pain relief.
Because in our study ventilation and plasma drug levels were at steady state when
data points were obtained we did not get information about the time-course of respi-
ratory eﬀects. Furthermore, especially for rapidly acting drugs, such as remifentanil
and propofol, the degree of non-steady-state respiratory depression may be dependent
on the rate of drug infusion. Further studies are needed to study the blood gas and V˙i
dynamics caused by diﬀerent infusion schemes of opioids and anesthetics.
Pharmacological Considerations
In this study we tested two agents with distinct respiratory properties and mechanisms
of action. The opioid remifentanil caused a parallel shift of the V˙i-CO2 response towards
higher PCO2 values with little eﬀect on the slope (ﬁg. 2). On the other hand, the anes-
thetic/sedative propofol caused a reduction of the slope of the V˙i-CO2 response curve (S)
with little to no eﬀect on the position of the curve at resting PETCO2 values (ﬁg. 2). We
consider these eﬀects typical respiratory eﬀects of opioids and anesthetics/sedatives.
The eﬀect of the opioid is because of activation of µ-opioid receptors at sites involved
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in ventilatory control (e.g., the carotid bodies, the preBötzinger complex);44 the eﬀect
of the anesthetic is most probably related to less speciﬁc mechanisms such as changes
in the level of arousal/consciousness and consequently a reduction in input from sites
in the CNS involved in behavioral-state control (e.g., the cortex, brain stem reticular
system) to the ventilatory control system in the brainstem. The observation that the
slope of the V˙i-CO2 response during sedation with propofol was reduced is in agree-
ment with the ﬁnding that the slope of the morphine V˙i-CO2 response is reduced by
physiological sleep.72 Previously, we observed large diﬀerences in the eﬀect of i.v. mor-
phine on the slope of the V˙i-CO2 response in men and women.43,171 with no eﬀect of
morphine on the slope in men but a large reduction in women. Taken into account the
above, it would be appropriate to suggest that in our previous studies morphine pro-
duced greater sedation in women than in men and consequently greater eﬀects on S in
women. Indeed, in a recent study in which we assessed the eﬀect of morphine’s active
metabolite, morphine-6-glucuronide (M6G), on the level of sedation using a numerical
rating score, we found greater sedation in women than men while plasma M6G concen-
trations were equal (unpublished observation). Note however, that our suggestion do
not exclude more fundamental sex diﬀerences in CNS responses to opioids such as sex
diﬀerences in µ-opioid receptor density and aﬃnity in regions involved in ventilatory
control and pain response.174

8 Respiratory depression by tramadol in the cat:
involvement of opioid receptors?
A MAJOR ADVERSE eﬀect of opioid analgesics is respiratory depression which is prob-
ably mediated by an eﬀect on µ-opioid receptors.43,44,166 The analgesic eﬀect of the
centrally acting synthetic opioid tramadol is thought to be mediated through both an
action on µ-opioid receptors and the inhibition of the reuptake of monoamines and/or
stimulation of their release.63,64,153,154 The aﬃnity, however, of tramadol at µ-opioid re-
ceptors is much (> 6000 times) lower than that of morphine,153,154,88 and this makes it
a potentially interesting analgesic with minimal respiratory depression. Indeed several
clinical studies have reported the absence of a signiﬁcant respiratory depression by an
analgesic dose of tramadol.18,71,92,99,127,193,194,205 Some other studies, however, indicate
that under some circumstances tramadol may cause respiratory depression.8,160
A frequently used method to assess the eﬀects of agents on breathing is to measure
respiratory frequency, tidal volume and/or oxygen saturation. Amore sensitive method,
however, to asses ventilatory control is the CO2 response curve because by measur-
ing CO2 sensitivity and the apneic threshold (extrapolated x-intercept of the response
curve) it is possible to anticipate a patient’s ability to respond to sudden hypercapnic
or hypoxic loads, e.g., following an obstructive apnea. Few studies have used the CO2
response to assess tramadol’s eﬀect on breathing. In patients without cardiorespiratory
disease, Seitz et al.180 found a dose-dependent decrease in CO2 sensitivity and mouth
occlusion pressure response after intravenous doses of 1 and 1·5 mg/kg, respectively.
Using the technique of end-tidal CO2 forcing (DEF), we recently found that in healthy
volunteers 100 mg oral tramadol reduced the carbon dioxide sensitivity of the periph-
eral and central chemoreﬂex loops by about 30%, an eﬀect that is similar to that of an
about equal analgesic dose of morphine.131
Thus, it seems that tramadol, at clinical doses, may be able to cause respiratory de-
pression. Whether this depressant eﬀect is mediated by opioid and/or monoaminergic
mechanisms is unknown. The aim of the present study was to examine if tramadol can
cause a dose-dependent respiratory depression in the anesthetized cat. Furthermore,
to investigate a possible opioid mechanism of action, we investigated whether naloxone
could reverse and prevent a possible respiratory depression by tramadol.
METHODS
The experiments were performed after approval of the protocol by the Ethical Committee for
Animal Experiments of the Leiden University Medical Center. Fifteen cats of either sex (body
weight 2·6–5·0 kg) were sedated with 10 mg/kg ketamine hydrochloride. The animals were
anaesthetized with gas containing 0·7–1·4 % sevoﬂurane and 30 % O2 in nitrogen. The right
femoral vein and artery were cannulated, and 20 mg/kg α-chloralose and 100 mg/kg urethan,
were slowly administered intravenously and the volatile anaesthetic was withdrawn. About
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one hour later, an infusion of an a-chloralose–urethan solution was started at a rate of 1·0–1·5
mg/kg per h α-chloralose and 5·0–7·5 mg/kg per h urethan. This regimen leads to conditions
in which the level of anaesthesia is suﬃcient to suppress pain withdrawal reﬂexes but light
enough to preserve the corneal reﬂex. The stability of the ventilatory parameters was studied
at a previous occasion and they were found to be similar to those in awake animals, as indicated
by the fact that they were stable over a period of at least 6 hours.77,197,204
To measure inspiratory and expiratory ﬂow, the trachea was cannulated and connected via
a Fleisch no. 0 transducer (Fleisch, Lausanne, Switzerland), which was connected to a diﬀeren-
tial pressure transducer (Statham PM197, Los Angeles, USA). With the aid of three computer
steered mass ﬂow controllers (HiTec, Veenendaal, The Netherlands) a prescribed composition
of the inspirate from pure oxygen, carbon dioxide and nitrogen could be obtained. The in- and
expiratory fractions of O2 and CO2 were measured with a Datex Multicap gas monitor (Datex-
Engstrom, Helsinki, Finland). Rectal temperature was controlled within 1 oC in each cat and
ranged between cats from 36·5 to 38·5 oC. Femoral arterial pressure was measured with a
strain gauge transducer (Statham P23aC, Los Angeles, CA, USA). All signals were recorded on
polygraphs, converted to digital values (sample frequency 100 Hz) and processed by a PC. Al
signals were stored on a breath-by-breath basis.
Study Design
Three groups of cats consisting of ﬁve animals each were studied.
Group 1: These animals received three doses of tramadol iv up to a cumulative dose of 4 mg/kg
(two consecutive doses of 1 mg/kg followed by a ﬁnal dose of 2 mg/kg). After each dose 2-3
DEF runs were performed (starting about 15 min after the infusions) to analyze the eﬀects of
the agent on respiratory control (see below). Finally, 0·1 mg/kg iv naloxone was administered
to these animals and again two DEF-runs were performed and analyzed.
Group 2: In these animals we determined the eﬀect of an initial treatment with naloxone (0·1
mg/kg, iv) by performing DEF runs both before and after its administration. Thereafter, a sin-
gle dose of 4 mg/kg tramadol was given intravenously and during the next two hours DEF runs
were performed each 15 min to analyze the respiratory eﬀects.
Group 3: In these animals a similar protocol as in group 2 was followed but without the nalox-
one pretreatment.
The ventilatory response to CO2 was studied with the dynamic end-tidal forcing technique
(DEF). We applied the DEF technique by imposing step-wise changes in the end-tidal CO2 ten-
sions at a constant normoxic background (PETO2 ∼15 kPa). Each DEF-run started with a steady
state period of about 2 minutes, in which the end-tidal PCO2 was maintained about 0·1–0·2 kPa
above the resting value. Thereafter, the PETCO2 was elevated by about 1-1·5 kPa within one or
two breaths, maintained at a constant level for about 7 min and then lowered to the previous
value and kept constant for a further 7 min.
Data Analysis
The steady-state relation of inspiratory ventilation to PETCO2 at constant PETO2 can be de-
scribed by:54,55
V˙i = (SP + SC)(PETCO2 − Bk)
where SP is the carbon dioxide sensitivity of the peripheral chemoreﬂex loop, SC the carbon
dioxide sensitivity of the central chemoreﬂex loop, and Bk the apnoeic threshold or extrapolated
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PETCO2 at zero. The sum of SP and SC is the overall or total carbon dioxide sensitivity (GT ).
For the analysis of the dynamic response of ventilation to a step-wise change in PETCO2 we
used a two-compartment model:54
τc
d
dt
V˙c(t)+ V˙c(t) = Sc[PET ,CO2(t − Tc)− Bk]
τp
d
dt
V˙p(t)+ V˙p(t) = Sp[PET ,CO2(t − Tp)− Bk]
Where τP and τC are the time constants of the peripheral and central chemoreﬂex loops, re-
spectively, V˙c(t) and V˙p(t) are the outputs of the central and peripheral chemoreﬂex loops.
PETCO2(t - Tc) is the stimulus to the central chemoreﬂex loop delayed by the central transport
delay time (Tc), PETCO2(t - Tp) the input to the peripheral chemoreﬂex loop delayed by the
peripheral transport delay time (Tp).
To allow the time constant of the ventilatory on transient to be diﬀerent from that of the oﬀ
transient τC is written as:
τC = x · τON + (1− x) · τOFF
τON is the time constant of the ventilatory on transient, τOFF the time constant of the oﬀ
transient, and x = 1 when PETCO2 is high, while x = 0 when PETCO2 is low. In most experi-
ments a small drift in ventilation was present. We therefore included a drift term (C · t) in our
model. The total ventilatory response, V˙i(t), is made up of the contributions of the central and
peripheral chemoreﬂex loops, the trend term and measurement noise (W ):
V˙i(t) = V˙c(t)+ V˙p(t)+ C · t +W(t)
The parameters of the model were estimated by ﬁtting the model to the breath-by-breath data
with a least-squares method. To obtain optimal time delays a ‘grid search’ was applied, and
all combinations of Tp and Tc , with increments of 1 s and with Tc  Tp, were tried until a
minimum in the residual sum of squares was obtained. The minimum time delay was chosen,
arbitrarily, to be 1 s, the τP was somewhat arbitrarily constrained to be at least 0·3 s.
Statistical Analysis
Results are presented as means ± SD. Diﬀerences between the obtained parameters in the con-
trol condition and after the three diﬀerent doses of tramadol and after naloxone, respectively
(group 1), were analyzed by performing a two way analysis of variance using a ﬁxed model.
The level of signiﬁcance was set at 0·013. Control and naloxone data in group 2, and control
and tramadol data in group 3 were compared with paired t-tests (P = 0·05).
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Table 1. Respiratory variables from ﬁve animals obtained from the optimal model ﬁts in the control
conditions, after three cumulative iv doses of tramadol and after naloxone. Tramadol data were col-
lected 15, 30 and 45 min after infusion and averaged. After naloxone, DEF runs were performed 15
and 30 min after administration and the obtained parameters from the optimal ﬁts were averaged.
control 1/mg/kg 2 mg/kg 4 mg/kg 0·1 mg/kg
tramadol tramadol tramadol naloxone
No. of DEF runs 26 15 14 14 10
GC 0·67 ± 0·27 0·45 ± 0·24 0·28 ± 0·17 0·21 ± 0·13 0·69 ± 0·13 ∗
GP 0·15 ± 0·04 0·11 ± 0·05 ∗ 0·05 ± 0·03 0·05 ± 0·03 0·18 ± 0·08 ∗
GT 0·82 ± 0·31 0·56 ± 0·29 0·34 ± 0·20 0·27 ± 0·16 0·86 ± 0·18 ∗
GP/GC 0·27 ± 0·10 0·27 ± 0·06 ∗ 0·21 ± 0·07 ∗ 0·28 ± 0·10 ∗ 0·26 ± 0·09 ∗
Bk (kPa) 3·77 ± 0·64 4·11 ± 0·86 4·31 ± 0·76 4·89 ± 0·95 3·44 ± 0·81 ∗
MAP (mmHg) 134 ± 18 136 ± 13 ∗ 131 ± 13 ∗ 125 ± 15 ∗ 130 ± 30 ∗
GP , GC and GT : peripheral, central and total CO2 sensitivity. Units L min−1 kPa−1;
MAP mean arterial pressure; Values are means of the individual mean values ± SD;
∗ not signiﬁcantly diﬀerent from control. All other values are diﬀerent vs. control at P < 0·013.
RESULTS
Examples of individual DEF runs in one animal from group 1 are shown in ﬁgure 1. In
this example, 2 and 4 mg/kg tramadol reduced the CO2 sensitivities of the peripheral
and central chemoreﬂex loops and increased the apneic threshold indicating depres-
sant eﬀects on ventilatory output. The last panel in ﬁgure 1 shows that after infusion
of 0·1 mg/kg naloxone these inhibiting eﬀects were completely reversed. The results
in all animals from group 1 are summarized in table 1. The total (= peripheral + cen-
tral ) CO2 sensitivity in these animals (control value: 0·82 ± 0·31 L min−1 kPa−1) was
reduced by 31, 59 and 68% by 1, 2 and 4 mg/kg tramadol, respectively, and these ef-
fects were caused by proportionally equal reductions in sensitivities of the peripheral
and central chemoreﬂex loops (see unchanged GP over GC ratios in table 1). Also in a
dose-dependent way, the apneic threshold increased from 3·77 ± 0·64 kPa in the con-
trol situation to 4·89 ± 0·95 kPa after the highest dose (P-values in legends of table
1). Lung-to-chemoreceptor time delays and time constants were not inﬂuenced by both
agents (data not shown). After each tramadol dose we calculated the minute ventilation
at a ﬁxed PCO2 of 6 kPa using the obtained values for the slope (GT ) and intercept (Bk)
of the ventilatory CO2 response curve. Figure 2 displays the dose-dependent decrease
in minute ventilation at this PCO2 level in the animals of group 1, ranging from a de-
pression of about 45% after 1 mg/kg (mean V˙iTRAMADOL/V˙iCONTROL = 0·55 ± 0·16) to about
84% after the total dose of 4 mg/kg (mean V˙iTRAMADOL/V˙iCONTROL = 0·16 ± 0·12).
The last column in table 1 shows the mean results of two DEF runs recorded 15
and 30 min, respectively, after a ﬁnal administration of 0·1 mg/kg naloxone to the
animals of group 1. Control and naloxone parameter values did not diﬀer from each
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other indicating a complete reversal by naloxone of the depressant eﬀects induced by
tramadol. Neither tramadol nor naloxone caused signiﬁcant changes in blood pressure
(table 1). The reversal by naloxone of the tramadol-induced respiratory depression may
indicate an action of tramadol on opioid receptors, and to investigate this further we
investigated whether naloxone would be able to prevent respiratory depression from
naloxone. Five animals (group 2) were pre-treated with 0·1 mg/kg naloxone (iv); 15
and 30 min later two DEF runs were performed and analyzed. The eﬀects of naloxone
on the respiratory variables in these ﬁve animals are shown in table 2. Thirty-ﬁve (35)
min after the initial treatment with naloxone, a single dose of 4 mg/kg tramadol was
administered and its respiratory eﬀects were followed for two hours by performing and
analyzing DEF runs each 15 min. To calculate V˙i at a ﬁxed PCO2 of 6 kPa at these time
points, we used the optimal values obtained for the apneic threshold B and the CO2
sensitivity GT . Then, at these 15 min intervals, we determined the ratios of after and
before the tramadol infusion at this ﬁxed PCO2. The results are displayed in ﬁgure 2
(open symbols).
Figure 1. Examples of the DEF runs in one animal from group 1 showing the eﬀects of control,
2 and 4 mg/kg tramadol, and (last panel) the total reversal of tramadol eﬀect after naloxone (0·1
mg/kg) infusion. The top diagram in each panel is the PETCO2 input function. The line through the
V˙i data is the sum of V˙c , V˙p and a trend term. V˙c and V˙p are the outputs of the central and peripheral
chemoreﬂex loops, respectively.
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Table 2. Eﬀects of 0·1 mg/kg naloxone (iv) on mean (± SD) respiratory variables in ﬁve animals.
Values after naloxone are means of two DEF runs performed 15 and 30 min after infusion.
control 0·1 mg/kg
naloxone
No. of DEF runs 22 10
GC (L min−1 kPa−1) 0·41 ± 0·12 0·57 ± 0·44
GP (L min−1 kPa−1) 0·09 ± 0·05 0·10 ± 0·06
GT (L min−1 kPa−1) 0·50 ± 0·17 0·67 ± 0·49
GP/GC 0·20 ± 0·08 0·20 ± 0·12
Bk (kPa) 4·21 ± 0·50 3·62 ± 0·75 ∗
∗ signiﬁcantly diﬀerent from control at P < 0·05.
Five other cats (group 3) received the same single dose of tramadol but were not pre-
treated with naloxone (closed symbols in ﬁg. 3). At each 15 min interval we calculated
the ratios of after and before the tramadol infusion in the same way as in the animals of
group 2. The eﬀects of tramadol on the respiratory variables in these animals are shown
in table 3. From ﬁgure 3 two ﬁndings are obvious. First, without naloxone pretreatment
tramadol exerted its full depressant eﬀect already 15 min after its administration (note
that the data in table 3 show the means of all DEF runs performed in two hours). Sec-
ond, after naloxone pretreatment the full depressant eﬀect of tramadol developed much
slower than without pretreatment, although naloxone did not prevent a rapid or suba-
cute (as measured after 15 min) depression. The data in ﬁgure 3 strongly suggest hat
the increasingly depressant eﬀect of tramadol in the naloxone pretreated animals over
time are caused by a gradually declining eﬀect of the opioid antagonist. At least part
of the initial depression by tramadol (ﬁrst data collection 15 min after tramadol i.e., 15
min after naloxone, see ﬁg. 3) may be caused by non-opioid mechanisms.
DISCUSSION
In this study we found that in the dose range of 1–4 mg/kg tramadol caused a dose-
dependent depressant eﬀect on ventilatory control consisting of a decrease in CO2 sen-
sitivity of the peripheral and central chemoreﬂex loops and an increase in the apneic
threshold. In addition, in a dose of 0·1 mg/kg, naloxone completely reversed the de-
pressant eﬀect of a cumulative dose of 4 mg/kg tramadol, and prevented more than
50% of the depressant eﬀect of an equal acute tramadol dose.
The reputation of tramadol as an analgesic lacking respiratory depression has con-
tributed to its incremental clinical use in the intra- and postoperative period.5 The ab-
sence, however, of changes in end-tidal or arterial PCO2 and/or ventilation does not
preclude possible depressant eﬀect on ventilatory control. Single respiratory variables
such as respiratory frequency, tidal volume, oxygen saturation, etc. do not have any
predictive value as to a patient’s ability to respond adequately to hypercapnia and hy-
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Figure 2. The dose-dependent decrease in relative ventilation at a ﬁxed PETCO2 of 6 kPa (◦) in 5
animals. The triangle depicts the eﬀect of naloxone given after 4 mg/kg tramadol.
poxia. Our data conﬁrm and extend previous data obtained from humans,131 and show
a clear dose-dependent increase in the apneic threshold and decrease in CO2 sensitivity.
Our ﬁnding that the respiratory depressant eﬀect of tramadol could be completely
reversed by naloxone contrast with results obtained in clinical tests in which the opioid
antagonist only partially inhibited tramadol’s analgesic eﬀect.35. In humans, only about
one-third of the antinociceptive action of tramadol, for which the parent compound
is probably responsible can be reversed by naloxone.35 The α2-adrenergic antagonist
yohimbine, however, greatly reduced the antinociceptive action of 100 mg oral tramadol
in healthy volunteers.59,60 In most animal tests, tramadol-induced antinociception was
only partially reversed by naloxone.153,75In contrast, intravenous yohimbine appeared
to inhibit the antinociceptive eﬀect of spinally administered tramadol but not morphine
on the tail-ﬂick response in the rat.153 These results led to the hypothesis that the anal-
gesic eﬀect of tramadol is produced by both opioid and non-opioid i.e. monoaminergic
mechanisms. The opioid eﬀect may be mediated via µ-opioid receptors because tra-
madol’s aﬃnity at κ- and δ-opioid receptors is even lower than at the µ-receptor.153,88
Tramadol is a racemic mixture of two enantiomeres and the opioid action is exerted
by the + enantiomer and its metabolite O-desmethyltramadol (M1) which has a greater
aﬃnity at the µ-receptor than its parent compound.153 The monoaminergic mode of
action may consist of an inhibition of the reuptake of serotonin and noradrenaline.
This occurs mainly by the – enantiomer of tramadol and acts synergistically with the
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Table 3. Eﬀects of a single iv infusion of 4 mg/kg tramadol on respiratory variables in ﬁve animals.
After tramadol, DEF runs were performed each 15 min during 2 hours.
control 4 mg/kg
tramadol
No. of DEF runs 22 37
GC (L min−1 kPa−1) 0·59 ± 0·25 0·29 ± 0·11
GP (L min−1 kPa−1) 0·14 ± 0·07 0·05 ± 0·03 ∗
GT (L min−1 kPa−1) 0·73 ± 0·25 0·34 ± 0·12
GP/GC 0·27 ± 0·14 0·18 ± 0·13 ∗
Bk (kPa) 4·20 ± 0·37 4·77 ± 0·40
∗ not signiﬁcantly diﬀerent from control.
All other values P < 0·05 vs. control.
analgesic eﬀect of the + enantiomer.7,30,63,64,88,153,154
It is unknown whether respiratory depression by tramadol is also mediated via opi-
oid and monoaminergic mechanisms. Our ﬁnding that naloxone completely reversed
tramadol’s depressant eﬀects indicates an important contribution of opioid –probably
µ-receptors, but does not necessarily imply that these eﬀect were solely due to an opi-
oid mechanism of action: we can not exclude that part of the relieve by naloxone from
the tramadol-induced depression was caused by blockade of a tonic inhibitory inﬂuence
of endogenous opioid peptides on ventilatory control in our animal preparation. For
this reason we tested the eﬀect of naloxone in a separate group of animals (group 2)
without any pretreatment with tramadol; subsequently, these animals were given tra-
madol to see whether a respiratory depression developed. The ventilatory eﬀects of
these animals were then compared with those in animals receiving the same acute dose
of tramadol but without being subjected to a pretreatment with naloxone. The ﬁnding
that naloxone caused a moderate stimulatory eﬀect on ventilatory control (an insignif-
icant increase in CO2 sensitivity and a signiﬁcant decrease in the apneic threshold of
∼0·6 kPa - table 2) indicates indeed a tonic inhibitory inﬂuence of endogenous opioid
peptides in our animal preparation, which, however, is much too small to account for the
very large stimulation that was seen in the animals in which the ventilation was greatly
depressed by tramadol (table 1). Comparison of the respiratory behavior after tramadol
infusion between animals with and without naloxone pretreatment (ﬁg. 3) clearly shows
that naloxone prevented more than 50% of tramadol’s depressant eﬀect. Figure 3 shows
that tramadol exerts its eﬀect rapidly: 15 min after administration the full depressant
eﬀect had already developed. We attribute the increasing respiratory depression with
time in the naloxone-pretreated animals to a diminishing action of the opioid antago-
nist, which has a known half-time of ∼90 min. By extrapolating the ﬁtted curve in ﬁgure
3 back to the moment just after the tramadol infusion, we estimate that in our animals
the pretreatment with naloxone prevented ∼70% of tramadol’s depressant eﬀect. From
these ﬁndings we conclude that, in contrast to its analgesic eﬀects, the respiratory ef-
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Figure 3. Open symbols: Inﬂuence of naloxone pretreatment (0.1 mg/kg, given at time=0) on venti-
lation at a ﬁxed PETCO2 of 6 kPa after infusion of 4 mg/kg tramadol (arrow) in ﬁve animals. Closed
symbols: The same single dose of tramadol in ﬁve animals not pretreated with naloxone. The con-
tinuous line is an exponential function of time vs. ventilation relative to pre-tramadol in animals
pretreated with naloxone from time t = 50 min on. The dashed line is an extrapolation to time t =
35 min (the time tramadol was given).
fects of tramadol are mainly due to an action on opioid receptors. The remainder of the
eﬀect may be due to the inhibition of serotonin and/or noradrenaline reuptake (or by
stimulation of their release), but experimental evidence for this is lacking. Generally, an
increase in brain stem noradrenaline concentration has inhibitory eﬀects on V˙i.30 The
eﬀect of serotonin on ventilatory control is more complex and depends on the speciﬁc
respiratory neuron and type of 5-HT receptor subtype involved.17
Because the eﬀect of tramadol on the CO2 sensitivity was caused by proportionally
equal reductions in the sensitivities of the peripheral and central chemoreﬂex loops
(unchanged ratio GP/GC – table 1) we suggest that the agent acts at the respiratory
integrating centers within the brain stem, and in this respect tramadol does not diﬀer
from other agents acting at µ-opioid receptors. The eﬀect of 1 mg/kg tramadol to
reduce the CO2 sensitivity by about 30% is about equal to that of 0·15 mg/kg morphine
in the same animal preparation,16 indicating that as a respiratory depressant, in the
cat morphine is 6–7 times more potent than tramadol. Although we are cautious to
extrapolate our ﬁndings to men, the facts that in humans tramadol possesses about
1/6–1/10 of the analgesic potency of morphine,112 an analgesic oral dose of 100 mg in
healthy volunteers reduced the CO2 response by about 30%,131 and intravenous doses
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of 1 and 1·5 mg/kg clearly caused a decrease in CO2 sensitivity,180 indicate that in
clinical doses tramadol may have similar respiratory depressant eﬀects as we report
here. Since in humans tramadol is often used in doses higher than 1 mg/kg, it would be
useful to assess its possible depressant eﬀect on the ventilatory CO2 response curve and
its reversibility by naloxone at these doses. In this way it could be anticipated whether a
patient may be at increased risk during the occurrence of sleep apnea’s or other events
resulting in abnormal blood gas tensions.
SECTION 3
Postoperative Care

9 The Edinburgh Ward 9 Study or Ventilatory responses
after major abdominal surgery and intensive care
IN THE FIRST few nights after major surgery, most patients have frequent episodes of
airway obstruction and hypoxaemia.156 These events cause cardiovascular responses
which may contribute to the cardiovascular complications that occur at this time. The
factors that cause these respiratory disturbances are not clear, but opioid analgesia,
sleep deprivation, other centrally active medications, and the stress of major surgery
may all play a part.3,85,101,120 We have recently shown that hypoxaemia can be reduced
by oxygen therapy, but nasal continuous airway pressure, which might reduce episodic
airway obstruction, does not improve either oxygenation or the quality of sleep in pa-
tients after major surgery.66 Indeed we felt that such patients, even when judged ‘ﬁt
to leave’ the high dependency or intensive care unit, appeared not well recovered from
the impact of surgery and the postoperative period, with breathing still depressed by
postoperative analgesics. If respiratory responses are impaired, then an obstructive
episode might persist longer, causing more profound and prolonged hypoxaemia.152
In this study, we set out to assess how well patients after major abdominal surgery
and intensive care were able to respond to episodes of airway obstruction, by simulat-
ing the changes in chemosensory input that they would experience during an episode
of obstruction. To assess the response to obstruction, we devised a method to simulate
the changes that would occur in the lung gases. We used a computer-controlled gas
forcing system to increase CO2 and reduce O2 in the way these changes occur during
obstruction. If the patient is in fact breathing clearly, then the changes in ventilation
(V˙e) caused by this stimulus can be used as an index of the response the patient gen-
erates, although in a real obstructive episode increased breathing force would lead to
increased muscle eﬀort but not necessarily increased breathing. We also studied how
the inﬂammatory response (indicated by the C-Reactive Protein (CRP) concentration),
opioid medication, and opioid metabolites might be related to these responses.
METHODS
We studied respiratory responses to a combined hypoxic/hypercapnic stimulus in patients
after abdominal surgery and 2 to 3 days intensive care (IC) in the high dependency unit (HDU)
of the hospital (Ward 9 at the Royal Inﬁrmary in Edinburgh; study period March - September
2000). Permission was obtained from the local ethics committee to recruit these patients before
surgery and all subjects gave consent. Since the patients had to be moved to the respiratory
laboratory, we were only allowed to do this when the patient was judged ready to leave the
high dependency unit and return to the general surgical ward.
There were no restrictions in the use of drugs for induction and maintenance of general
anesthesia. After surgery all patients were extubated. Initially, postoperative analgesia was
106 Chapter 9 •
either epidural infusion of bupivacaine and morphine, or patient controlled intravenous anal-
gesia (PCA) with morphine, according to the preferences of the attending anaesthetist. At the
morning of discharge from the ICU all epidurals were removed and the patients set on PCA
with morphine. All patients were asked to return for a review session 6 to 8 weeks after their
discharge from the hospital.
Apparatus and Measurements
Patients were studied sitting in bed after discharge from the HDU in a semi-recumbent position,
and in a comparable bed at their review visit. They breathed through a face mask (Vital Signs,
Totowa, NJ) connected to a low resistance one way valve (Hans Rudolf model 2700). The exhaled
gas from the valve passed through a heated pneumotachograph (Fleisch no. 2) and drying
chambers to a dry gas meter (Parkinson Cowan CD4) modiﬁed to give a digital signal. This
signal was used to calibrate the integrated expiratory ﬂow signal and give an accurate breath
by breath exhaled tidal volume. Gas was sampled at the mask and analyzed for O2 and CO2
concentrations by a mass spectrometer (VG Spectralab M, Winsford, UK) calibrated regularly
with four standard gas mixtures. Breath by breath values for tidal volume (VT ), respiratory
frequency (RR), instantaneous minute volume (RR × VT ) and inspired and end-tidal partial
pressures of O2 and CO2 were digitized (Dell 425 s/L computer, Dublin, Ireland) and stored on
disc. The inspiratory side of the one-way breathing valve drew gases from a T piece with an open
wide bore reservoir and a closed mixing compartment fed with O2, CO2 and N2. These gases
were delivered from mass ﬂow controllers (Bronkhorst Hi-Tech, Veenendaal, The Netherlands)
supplied with gas from precision regulators (RS components), and controlled by a computer
(Elonex PT-5120/l) with a D to A converter (Amplicon PC24). This computer was supplied with
data from the data acquisition computer. Custom written software calculated a rolling mean of
the end-tidal O2 and CO2 from the last n breaths, where n could be adjusted between 1 and 10,
and adjusted the mass ﬂow controllers so that the inspired concentrations of the O2 and CO2
were the same as this mean end-tidal value. This caused a gradual decrease in inspired O2 and
concomitant increase in inspired CO2. The value of n was adjusted so that a fall in SPO2 of 6%
and an increase in end-tidal PCO2 (PETCO2) of 1 kPa occurred over 1-min. Sighing or swallowing
cause sudden changes in the end-tidal concentrations, so breaths which diﬀered from the target
value by more than 5% were ignored. A pulse oximeter using an ear probe (Ohmeda 3700 set
to an averaging time of 2 s, Ohmeda, Helsinki, Finland) and ECG (HP 78351A) were recorded
throughout the study. We observed the patients carefully as well as monitored the EEG (A2000,
Aspect Medical Systems, Newton, MA) for any evidence of sleep.
On both study occasions the patients ﬁrst inhaled a normoxic gas mixture (Fi = 0·21) for
at least 2 minutes until ventilation was stable. Next, one to three combined ramp-like hy-
poxic/hypercapnic stimuli (see above, duration 1–2 min) were administered. Subsequently the
inspired oxygen fraction was increased (Fi = 0·3) and another one to three O2/CO2 stimuli
(duration 1–2 min) applied. Each run was separated by at least two minutes of steady-state
ventilation. If the baseline SPO2 was less than 95%, the inspired oxygen was increased (Fi >
0·3) at the beginning of the study to increase the SPO2 to a value > 95%, and 3 to 6 stimuli were
applied.
After the respiratory study was completed, venous blood was sampled and stored for assays
of morphine (MOR), morphine-3-glucuronide (M3G), morphine 6 glucuronide (M6G) by HPLC,121
and for C-reactive protein (CRP) measurement using the FPIA method on an Abbott FLX appara-
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Table 1. Patient characteristics, types of surgery and baseline parameters in the initially recruited
group of 40 patients
Age (years) 66 (53, 68) Heart rate (beats/min) 78 (67, 87)
Female/male ratio 16/24 –CRP (mg/dl) 17·6 (9·4, 24·0)
Type’s of surgery: –Morphine (nM) 34 (12, 86)
–Abdominal aorta reconstruction 10 –M6G (nM) 29 (19, 54)
–Bowel surgery 11 –M3G (nM) 526 (250, 767)
–Liver surgery 6 SPO2 (%) 93 (92, 95)
–Whipple procedure 5 Ventilation (L/min) 9·6 (8·0, 11·1)
–Gastrectomy 4 RR (breaths/min) 15 (13, 19)
–Other abdominal procedures 3 VT (ml) 613 (532, 762)
Length of stay in HDU (days) 2 (2, 3) PETCO2 (kPa) 5·3 (4·4, 6·3)
BIS 97 (95, 98) PETO2 (kPa) 13·3 (11·7, 15·7)
Values are median (25, 75 % quartiles); CRP, C-reactive protein; HDU, high dependency unit.
tus. Morphine and its metabolites were measured after leaving the high dependency unit only,
CRP values were measured on both test occasions.
Data Analysis
Baseline parameters were averaged over one minute at the start of the measurements but prior
to any change in inspired gas concentrations. The ventilatory response to the combined hy-
poxic/hypercapnic stimulus was analyzed using a non-parametric approach. Initially, we per-
formed a linear regression of V˙e on PETCO2 on the linear part of the V˙e-CO2 response (as judged
by the eye). Next, the resultant slope (G) was divided by the measured drop in SPO2. A delay in
SPO2 was taken into account because of the instrumentation and physiological delays.182 This
yielded the value S. However, due to the fact that we applied ramps in inspired gas concen-
tration (end-tidal gas values and SPO2 were outcome parameters), especially in runs in which
the inspired oxygen fraction was increased, no decrease in SPO2 occurred or the decrease was
4 % or less. In these cases we decided not to divide G by the drop in SPO2 and perform the
statistical analysis on G rather than S.
Comparisons were made by non-parametric analysis (Kruskal-Wallis and Wilcoxon tests).
Linear regression analysis was used to examine the relationships between variables (Sigmaplot
2001 for Windows, SPSS Inc.). P-values < 0·05 were considered signiﬁcant. All values are ex-
pressed as median (25, 75 % quartiles).
RESULTS
A ﬂow chart of the data acquisition and analysis is given in ﬁgure 1. Initially a total
of 40 patients were recruited and tested (table 1). Only 26 patients returned for a
second session (table 2). The ventilatory responses in seven of these 26 were so irregular
or unreliable that an analysis of the data was not possible. In eight other subjects
additional inspired oxygen was given prior to the application of the respiratory stimuli.
Although all subjects completed the studies without major side eﬀects, some of them
did feel uncomfortable during the studies. We consider this the main reason for the
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Postoperative response dataReview response data
29 studies with a drop in Sat > 4%
26 studies with a drop in Sat < 4%
Postoperative study
n = 40 patients
return for review?
NO
YES
n = 14 patients
n = 26 patients
reliable and regular 
response data?
NO
n = 7 patients
n = 19 patients
YES
27 studies with a drop in Sat > 4%
24 studies with a drop in Sat < 4%
paired comparison
of response data
paired comparison of baseline variables
Figure 1. Flow chart of the data acquisition and data analysis of baseline variables and response
data sets with and without drop in saturations.
rather disappointing return rate (26/40) and large number of curves that could not be
analyzed (all curves in 7/26 patients). At the end of the study, response data from 19
patients were included in the analysis (48%).
In the initial studies, we noticed in none of the 40 subjects any subjective or EEG-
related signs of sleep. Baseline parameters and blood concentrations of CRP, morphine
and its metabolites are given in table 1. Note the large range of values (coeﬃcients
of variation were 78% (CRP), 149% (MOR), 70% (M3G) and 71% (M3G)). The variation in
hospital PETCO2 values but in none of the other variables could be partly explained by
the plasma morphine concentration (r2 = 0·34, P < 0·05). CRP, M6G and M3G values
did not correlate signiﬁcantly with any of the measured baseline variables.
After surgery and intensive care, patients showed evident signs of respiratory depres-
sion relative to the values obtained 6 to 8 weeks after hospital discharge (table 2), with
greater PETCO2 values, lower SPO2’s, lower tidal volumes and lower V˙e levels (18 patients
had greater V˙e levels on review). Although respiratory rate did not diﬀer between the
two test occasions, analysis of the pattern of breathing revealed that the duration of
inspiration was 1·3 (1·1, 1·5) s in postoperative patients, while on return for review this
value was signiﬁcantly longer (1·6 (1·5, 1·9) s, P < 0·001). The duration of expiration
was similar in postoperative and review studies (postoperative 2·7 (1·9, 3·0) s versus
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Figure 2. Example of the combined hypoxic/hypercapnic stimulus (A) and resultant changes in
ventilation V˙e and O2-Hb saturation (SPO2) (B) of one subject. On the right (C), a plot of PETCO2
versus V˙e and the linear regression on the linear part of the curve. Open symbols denote date
points used in the regression analysis. The slope of the response curve (i.e., parameter G, which
equals 4·4 L·min-1·kPa-1) was subsequently divided by the drop in SPO2 (see diagram B) of 11% (S
= 0·4 L·min-1·kPa-1·%-1).
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Figure 3. Box plots of the values of parameters S (left) and G (right). Values depicted are median
(continuous lines), mean (dashed lines), 25 and 75% quartiles (top and bottom of boxes) and 10 and
90% quartiles (error bars) in data obtained postoperatively (hospital) and on review (6 to 8 weeks
post hospital discharge) ∗ P < 0·02; ns not signiﬁcantly diﬀerent (Kruskal-Wallis test).
review 2·4 (2·1, 2·8) s, ns).
An example of an O2/CO2 stimulus and resultant ventilatory response of one subject
is given in ﬁgure 2. In 19 patients, a total of 27 responses with a fall in SPO2 > 4% and 24
with a fall< 4 % were obtained after surgery and intensive care. On review the respective
number of studies was 29 and 26. Values of the changes in SPO2 and PETCO2 are given
in table 3. On review, respiratory responses to an increase in CO2 and decrease in SPO2
were about 25% greater than those obtained after surgery (S hospital = 0·69 (0·30, 0·85)
L·min-1·kPa-1·%-1 versus review = 0·90 (0·80, 1·20) L·min-1·kPa-1·%-1, P < 0·02; ﬁg. 3),
while no diﬀerence was observed for the responses to an increase in CO2 with little to
no change in SPO2 (G hospital = 4·0 (1·9, 4·7) L/min per kPa versus review = 4·1 (3·4,
5·0) L/min per kPa, P = 0·09; ﬁg. 3).
The distribution of values for C reactive protein in the ward and on return for review
(table 2) show that the patients had a considerable inﬂammatory response at the time of
discharge from the ward, which had returned to normal when they attended for review.
We observed no correlation between CRP, morphine or its metabolites and degree of
respiratory depression as determined from the ventilatory response to hypercapnia ±
hypoxia (ventilatory depression expressed as the proportion of the responses obtained
at follow up (G(hospital)/G(review) and S(hospital)/S(review)).
• Breathing Responses after Surgery and Intensive Care 111
Table 2. Hospital versus review baseline variables in 26 patients
Hospital data Review data P-value∗
CRP (mg/dl) 18·6 (7·0, 21·0) 0·9 (0·0, 2·2) < 0·001
Morphine (nM) 32 (19, 84) —
M6G (nM) 29 (21, 54) —
M3G (nM) 580 (300, 760) —
BIS 96 (95, 98) 97 (95, 98) ns
V˙e (L/min) 10·4 (8·0, 11·2) 10·6 (8·3, 12·6) = 0·04
RR (breaths/min) 15 (13, 10) 16 (14, 18) ns
VT (ml) 629 (534, 817) 691 (611, 854) < 0·05
PETCO2 (kPa) 5·3 (4·0, 6·3) 4·7 (4·2, 5·1) < 0·02
PETO2 (kPa) 13·7 (11·9, 17·1) 14·1 (13·5, 14·7) ns
SPO2 (%) 93 (92, 94) 97 (95, 98) < 0·001
Heart rate (beats/min) 76 (66, 85) 74 (69, 88) ns
Values are median (25, 75 % quartiles); ∗ Student-t-tests; ns = not-signiﬁcantly diﬀerent;
See legend of table 1 for explanation of abbreviations.
Table 3. Median values of the changes in oxygen saturation (SPO2) and end-tidal CO2 concentrations
(PETCO2) observed at the end ofO2 and CO2 ramps in hospital and review studies. Data are grouped
according to the fall in SPO2.
n ∆SPO2 (%) ∆PETCO2 (kPa)
hospital ∆SPO2 > 4 % 29 8·0 (6·1, 8·8) 0·8 (0·7, 1·0)
hospital ∆SPO2 < 4 % 26 2·8 (1·4, 3·5) 1·0 (0·9, 1·1)
review ∆SPO2 > 4 % 27 7·0 (5·0, 10·3) 1·1 (0·9, 1·3)
review ∆SPO2 < 4 % 24 0·7 (0·5, 1·1) 1·0 (0·9, 1·1)
Values are median (25, 75 % quartiles). n is the number of runs.
DISCUSSION
In this study we compared respiratory variables and ventilatory pseudo-rebreathing
responses in patients after abdominal surgery and intensive care and these same pa-
tients six to eight weeks after discharge from the hospital. The stimuli we used were
intended to mimic changes in arterial oxygen saturation and CO2 concentrations that
occur once gas exchange has stopped due to upper airway obstruction. Due to the par-
ticular making of these stimuli (we used inspired control rather than end-tidal control
of gas concentrations) a drop in saturation > 4% did not always occur, especially not
when the study started with an increased inspired O2 fraction. The oxygen reserve in
the lungs and reduced oxygen metabolism are among the most likely causes for the
absence in saturation fall in these patients during pseudo-rebreathing. Both kinds of
stimuli do occur clinically in patients that develop upper airway obstruction for the
same reasons as in our study. During upper airway obstruction, patients on oxygen de-
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velop often high arterial CO2 levels without any desaturations for many minutes, while
patients that breathe air develop concomitant hypercapnia and hypoxemia.152
Because of our study design (see ﬁg. 1) each patient served as its own control. Ini-
tially but not on review, all patients showed elevated C-reactive protein levels, a sign
of inﬂammatory response (table 2).85 We observed that relative to review, respiratory
depression was modest in postoperative patients: PETCO2 was 11% greater, the ventila-
tory response to a CO2 stimulus and drop in oxygen > 4% was about 25% reduced. No
diﬀerence was observed in the ventilatory response to a CO2 stimulus when saturation
did not fall > 4%, although an evident trend towards postoperative depression is visible
in the data (ﬁg. 3). While the low SPO2 value after surgerymay be an indicator of reduced
ventilatory drive, it must be remembered that oxygen saturation reﬂects the eﬃcacy of
gas exchange in the lungs and is not a measure of ventilation. The reduced values of
SPO2 (∼93%) may further be caused by atelactasis, a reduction in cardiac output, and/or
increased oxygen metabolism.
The large number of patients that did not return for a review session and the relatively
large number of data runs that could not be analyzed due to breathing instabilities may
have under/overestimated the eﬀect of surgery and analgesia on the response data. The
median values of the O2/CO2 responses with and without fall in SPO2 in the 14 subjects
that did not return for review were 0·61 (0·33, 1·1) L·min-1·kPa-1·%-1 and 3·9 (2·4,
4·2) L/min per kPa, respectively. These values are not diﬀerent from the 19 subjects
that were included in the paired comparison. Hence we do not believe that the low
return rate and sometimes poor data quality did inﬂuence our results signiﬁcantly. Poor
quality and increased variability of responses, relative to responses obtained in healthy
volunteers, is inherent to the collection of clinical respiratory data. The large variability
in the postoperative data may have been one of the reasons for not ﬁnding a signiﬁcant
eﬀect on G between hospital and review (ﬁg. 3). A post-hoc power analysis revealed
that at this level of variability at least 30 patients were needed to get a signiﬁcant 25%
diﬀerence between studies.
Taken into account the complexity of the stimulus and resultant responses (see ref.
38 on the diﬃculties in the interpretation of CO2 pseudo-rebreathing responses), we
felt that it was necessary to develop a non-parametric method of describing the ven-
tilatory response to the simultaneous hypoxic/hypercapnic stimulus. However, this
non-parametric method will require some normalization by the level of the stimulus
since the degree of hypercapnia and/or desaturation was not identical in all subjects
and runs. In contrast to the gains of the peripheral and central chemoreﬂex loops as de-
termined from single CO2 steps (which represent the V˙e-CO2 sensitivity of the peripheral
and central chemoreceptors),36,38 one has to be cautious in assigning physiological to G
or S in our analysis. However, since the drop in SPO2 > 4% at the background of mild
hypercapnia must have stimulated the carotid bodies,45 we believe that S in contrast
to G incorporates respiratory responsiveness mediated via the peripheral chemoreﬂex
loop (part of which may be O2-CO2 interaction at the carotid bodies).45
We observed a diﬀerence in PETCO2 of 0·6 kPa between the hospital and review visits.
A similar value was observed in healthy volunteers who were without pain or inﬂamma-
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tion and had similar estimated plasma levels of morphine.43 We relate the increase in
PETCO2 in both studies to the respiratory depressant eﬀect of morphine. Furthermore,
in postoperative patients respiratory muscle function is often impaired due to a de-
crease in phrenic motoneuron output, which may be (vagal) reﬂex related to minimize
irritation of the peritoneum after abdominal surgery.213 This may be the cause of the
reduced tidal volume we observed after surgery. The M6G levels were relatively low and
most probably did not contribute to the respiratory eﬀects of morphine. M6G concen-
trations> 300 nM are required for signiﬁcant respiratory eﬀect.∗ Our ﬁnding that S was
depressed while G remained unaﬀected suggests that the peripheral chemoreﬂex loop
was aﬀected more than the central chemoreﬂex loop in our group of postoperative pa-
tients. This observation is in agreement with an earlier observation that the ventilatory
response to a hypercapnic/hypoxic stimulus is aﬀected at lower anesthetic and opioid
concentrations that the response to a CO2 stimulus when no fall in SPO2 is allowed.†
A Comparison with Volunteer Data
The depressant eﬀect of morphine on respiration in healthy volunteers is well docu-
mented. For example, 0·1 mg/kg morphine bolus dose, followed by 30 µg/kg per h
continuous infusion (median steady-state morphine plasma levels estimated to be >
100 nM),174 caused sex-dependent respiratory depression with about 50% depression
of the ventilatory response to CO2 steps in female volunteers and no eﬀect on the step
response in male volunteers but a parallel shift of the response slope to greater PETCO2
values.43 In another study, 0·07 and 0·20 mg/kg iv morphine depressed the ventila-
tory response to a ramp increase in PETCO2 by 40% and 50%, respectively.24 Although
care has to be taken in comparing patient data with volunteer data and plasma mor-
phine concentrations were considerably higher in some of the volunteer studies (see
above), our results suggest that depression in postoperative patients on morphine was
signiﬁcantly less than depression observed in volunteers on morphine.24,43 This is not
surprising taken into account the fact that respiration in perioperative patients is re-
lated to the balance between stimulation from pain, stress and activated chemoreﬂexes
and depression resulting from sedation, the direct eﬀect of analgesics and anaesthetics
on respiratory neurones and the eﬀect of surgery (see above). In our study depression
of ventilatory responses occurred due to morphine (via its eﬀect on µ-opioid recep-
tors at central and peripheral sites),6,44,171 while stimulation of the responses may have
occurred due to pain,21,23,172 stress, inﬂammation and discomfort. Interestingly, pain
may both cause respiratory depression (patients that change their pattern of breathing
to minimize diaphragmatic descent; the reduced inspiratory times may be the relec-
tion of such a mechanism (table 2)),213 or stimulate breathing, often but not always via
chemoreﬂex-independent mechanisms.21,23,172
∗Unpublished observation.
†See Chapter 6.
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Clinical Considerations
Postoperative patients on opioid analgesics titrated to eﬀect, seldom require interven-
tion for apneic or periodic breathing. However, several studies showed frequent occur-
rence of upper airway obstruction and hypoxic episodes related and unrelated to upper
airway obstruction in both awake and sleep states.61,66,155,156,189 We did not measure
sleep-related breathing in our patients. But there is no reason to doubt that these pa-
tients did not experience upper similar airway patency problems and hypoxic events like
those patients reported in the literature. Whether the mild to moderate depression of
the ventilatory control system as observed in our group of patients plays some causative
role in the occurrence of upper airway obstruction remains unknown but is plausible.152
A more important question is whether the ventilatory responses set at the restoration
of blood gases in between episodes of upper airway obstruction remain suﬃciently ef-
fective. The mild reduction in response data observed in our patients seems to suggest
that this may indeed be the case. However, the ample data showing sometimes severe
nocturnal hypoxemia after major abdominal surgery, which in some studies remains
unaﬀected by oxygen or nasal continuous positive airway pressure therapy, suggests
the contrary.66,189 Evidently, further studies on the eﬀect of surgery and pain relief and
their interaction on (hypoxia and CO2 stimulated) breathing are required to improve our
insight in this important part of postoperative patient care.
APPENDIX: A Modeling Approach to the Data Analysis
While a simultaneous ramp increase in PETCO2 and a decrease in SPO2 provides a stimulus that is similar
to clinical conditions (e.g., airway partial obstruction), it does present some practical and theoretical
problems with analysis. The physiological response to hypercapnia (at a constant saturation) is a
linear increase in ventilation arising from both peripheral and central chemoreceptors.36 As saturation
is decreased (at a constant PETCO2) there is also a linear increase in ventilation arising from stimulation
of the peripheral chemoreceptors.45 The interaction between saturation and CO2 has been expressed
as the change in the slope of the hypercapnic response for a decrease in saturation. The dynamics of
both these response (hypoxic and hypercapnic) have generally beenmodeledwith diﬀerential equations
and given an appropriate input all these gains can be determined (along with the associate time delays
and time constants).40 With some reasonable assumptions, it is possible to modify our previously
used two compartment dynamic CO2 model used for parameter estimation and to obtain estimates of
physiological parameters from this clinical data.
The relative slow changes in both the PETCO2 and SPO2 does not provide an input that is ‘persistently
exciting’ and the central and peripheral time constants cannot be estimated with any conﬁdence. How-
ever, from past experience we can assume the peripheral time constant to be ∼10 s and the central time
constant to be ∼120 s.40 However, we can assume that the change in the saturation only eﬀects the pe-
ripheral input. This allows us to modify our parameter estimation program to assume that the central
and peripheral inputs are known signals (SC and SP ) and the steady state ventilation is determined by
a central and peripheral gain on these two signals:
SC = PETCO2
SP = (α · SPO2 + β) · PETCO2
V˙i = GC · (SC − Bk)+GP · (SP − Bk)+ C · t
The saturation data needs to be time shifted (and interpolated) to match the breath-by-breath CO2
and ventilation data. Bk is the so called apneic threshold and a trend term, C, is also included. These
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Figure 4. Example of amodel ﬁt in six sequential ramps in hypoxia/hypercapnia (initial three ramps)
and hypercapnia. The data are from a patient returning for review. The upper panel shows the end-
tidal CO2 and saturation waveforms. The bottom panel shows the measured V˙e (open circles) and
the model ﬁt (the solid line going through the circles). The bottom two curves show the estimated
central (V˙c ) and peripheral (V˙p) components. Note that the peripheral component responds much
faster and is altered by the level of saturation.
equations represent the steady state form of the model and in the parameter estimation program ﬁrst
order dynamics, with the assumed time constants given above, are included on each of the signals.
The factors α and β are scaling factors that are chosen such that the value of the estimated GP is of
similar magnitude to that estimated in step hypercapnic experiments. The values chosen result in the
hypoxic factor equal to 1 for 98% saturation and equal to 2 at 80% saturation. Note that these values
are arbitrary in that they function only as scale factors and do not eﬀect the ﬁnal parameters estimated
from the data set. Thus for this model the total CO2 gain (change in ventilation for a change in CO2 at
100% saturation) is:
GT = GC +GP · (100 ·α+ β)
and the percentage increase in the total gain for a 10% decrease in saturation:
%∆GT = 10 ·αGT · 100%
Figure 4 illustrates the curve ﬁt of this model utilizing the whole data set which included 6 ramps, the
ﬁrst three are combined O2/CO2 stimuli, the last three hypercapnic stimuli. The data set was obtained
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Figure 5. Example of a model ﬁt in three sequential ramps in hypoxia/hypercapnia (ﬁrst two ramps)
and hypercapnia. The data are from a patient after surgery and intensive care. See Figure 4 for
explanation of the symbols.
in a patient returning for review. Due to the absence of a hypoxic stimulus, the lasts three ramps elicit
a much smaller peripheral signal. Note that the large increase in V˙e for the third ramp is apparently
due to the deeper desaturation and the resulting larger peripheral component is seen in the ﬁgure.
The parameters estimated for this data set was a total CO2 gain of 7·05 L min−1 kPa−1 and a change in
total hypercapnic gain with a 10% decrease in saturation of 21%. These values are comparable to those
found in normal subjects.
Figure 5 illustrates another ﬁt, this time to three ramps, two combined hypoxic/hypercapnic ramps
and one hypercapnic one. This data set was obtained in a patient upon discharge from the high de-
pendency unit. Note that for the third ramp the increase in CO2 was greater than for the ﬁrst two CO2
ramps and even though there was no of desaturation, the resulting ventilatory increase was larger.
This indicates that there is only a small amount of hypoxic-hypercapnic interaction. In fact, when this
data set was curve ﬁtted, we found that the total CO2 gain was 7·15 L min−1 kPa−1 but the change in
total gain with a 10% decrease in saturation was only 6%.
This dynamic parameter estimation technique requires a data set with little ventilatory instability
or noise. As can be seen by the ventilation instability between the second and third ramps in ﬁgure
5, there can be signiﬁcant ventilatory alterations that cannot be modeled as resulting from changes in
CO2 or saturation. Unfortunately, due to the clinical nature of our data sets, these types of ventilation
changes were frequent and prevented us from applying this model to most of the data.
Summary and Conclusions

10 Summary and Conclusions
ANESTHESIA and surgery have profound eﬀects on the control of breathing, which is
best observed postoperatively. Ventilation is depressed, hypercapnia may occur, and
recurrent hypoxic episodes are common in the ﬁrst few postoperative days, especially
when asleep. The patient may continue to breathe during a hypoxemic episode, but
hypoxia and hypercapnia have further eﬀects. They cause sympathetic nervous system
activity, which can lead to tachycardia, hypertension and ischemic ECG changes. Af-
ferent input from the peripheral chemoreceptor is an important stimulus to arousal,
the clearing of upper airway obstruction and the subsequent hyperventilatory response
to correct any hypoxia, hypercapnia and acidosis. Therefore it is of importance to un-
derstand the eﬀect of anesthetics and analgesics on cardiorespiratory control and the
mechanism of action of these agents. In this thesis, the results of experiments are
described which improve our insight in the complex of factors that determine the car-
diorespiratory control of perioperative patients. Studies were performed in animals,
volunteers and patients.
In Chapter 2, the ventilatory responses to carbon dioxide (CO2) and to hypoxia were
examined in adult human subjects after bilateral and unilateral carotid body resection
(CBR) for carotid body tumors, and compared with results obtained in (age-, and sex-
matched) healthy volunteers. In humans, the ventilatory response to a step change in
end-tidal CO2 yields a fast (τ ∼10 s) and a slow component (τ ∼120 s). It is thought that
the fast component arises from the peripheral chemoreceptors located in the carotid
bodies. This study was an attempt to validate this hypothesis in humans. The results
showed that in patients after bilateral CBR the ventilatory response to CO2 was satis-
factory ﬁtted with a one-compartment model and and an improvement of the ﬁt was
not obtained with a two-compartment model. When a signiﬁcant improvement in ﬁt
did occur, with the introduction of a second fast component, it was associated with
the presence of a peripheral chemoreﬂex response. This occurred in unilaterally CBR
patients and control subjects. Our data validates the hypothesis that the fast compo-
nent of the ventilatory response to CO2 arises from the peripheral chemoreceptor at the
carotid body.
In Chapter 3, we studied the eﬀect of an antioxidant cocktail (ascorbic acid and α-
tocopherol) on halothane-induced depression of the ventilatory response to brief ex-
posures to hypoxia (3 min) in healthy volunteers. Halothane, at already subanesthetic
concentrations (0·05–0·1 end-tidal %) causes profound depression of the carotid bod-
ies and consequently of the ventilatory response to hypoxia. The precise mechanism of
oxygen sensing at the carotid body remains elusive, but the involvement of free radical
species has been proposed, and halothane, under hypoxic conditions, produces free
radical species. The results showed that 0·1 MAC halothane-induced depression of the
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hypoxic ventilatory response (halothane reduced the response by more than 50%), was
completely prevented by pretreatment with the antioxidant cocktail, but not by placebo.
This observation is important as it sheds light on the mechanism of oxygen sensing at
the carotid bodies, improves our insight in themechanism of halothane-induced depres-
sion of breathing at the carotid bodies, and, most importantly, opens new perspectives
for therapeutic intervention to prevent potentially serious and life-threatening adverse
eﬀects in the postoperative period, following the use of inhalational anesthetics.
The inﬂuence of the intravenous anesthetic propofol on cardiorespiratory control was
investigated in Chapters 4 and 5. Experiments, in healthy volunteers, were performed
on the eﬀect of propofol on various cardiorespiratory and EEG parameters, such as
resting ventilation, resting end-tidal carbon dioxide partial pressure (PETCO2), heart rate,
bispectral index of the EEG (BIS), the acute and sustained hypoxic ventilatory response,
and the dynamic ventilatory CO2 response.
In Chapter 4, the results of the inﬂuence of low dose propofol (plasma concentration
0.6 µg/ml) on the acute (3 min) and sustained (15 min) hypoxic ventilatory response
are reported. The results showed that propofol decreased the acute hypoxic response
(AHR) by∼50% and the ventilatory response to sustained hypoxia by∼25%. Further, the
magnitude of the slow ventilatory decline in ventilation from min 3 to min 15 of hypoxia
was increased relative to the acute response by more than 50%. Interestingly, exposure
to ﬁve consecutive 3-min hypoxic pulses did not generate any ventilatory decline in
control or propofol studies. Since we did not perform CO2 studies in this protocol, the
mechanism behind the observed ﬁndings remain unclear: ventilatory depression due
to propofol may be due an eﬀect at peripheral or central sites involved in respiratory
control or secondary to the sedation or hypnosis by propofol.
In Chapter 5, the possible site of action of propofol within the chemical ventilatory
control system was investigated. We studied the inﬂuence of two concentrations of
propofol (blood concentrations 0.5 and 1.3 µg/ml) on the dynamic ventilatory response
to CO2 in healthy volunteers. The results showed that sedative concentrations of propo-
fol (mean BIS 67) caused a dose related depression of the dynamic response to CO2
which was attributed to an exclusive eﬀect within the central chemoreﬂex loop. In other
words, the peripheral chemoreﬂex loop remained unaﬀected by propofol. This is an im-
portant observation, and contrast sharply with the ﬁnding that all volatile anesthetics
cause an selective depression of the CO2 responses via the peripheral chemoreceptor.
We relate these diﬀerences to the distinct mechanism by which the inhalational anes-
thetics and propofol act. It may very well be related to the antioxidant eﬀect of propofol
versus the prooxidant eﬀect of inhalational anesthetics.
In Chapters 6 and 7, the eﬀect of combining opioids and anesthetics on cardiorespira-
tory control is investigated. The combined administration of opioids and anesthetics
for induction and maintenance of anesthesia (but also for Monitored Anesthesia Care
and Conscious Sedation) is common practice. Therefore, knowledge on the quantita-
tive and qualitative (additive versus synergistic) nature of their interaction is clinically
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important and may lead to dosing regimens aimed at the titration of sedation or anal-
gesic versus respiratory eﬀect. The anesthetic–opioid interaction on cardiorespiratory
control was assessed by response surface modeling. This approach enables us to con-
struct three-dimensional representations of the concentration-response relation among
inﬁnite combinations of anesthetic and opioid concentrations and assess the nature of
interaction (additive, synergistic, or antagonistic) over the whole surface area.
In Chapter 6, the inﬂuence of the combined administration of the inhalational anes-
thetic, sevoﬂurane, and the opioid, alfentanil, was investigated in healthy volunteers.
The experiments consisted of step decreases in end-tidal partial pressure of oxygen
from normoxia into hypoxia at constant PETCO2. The experiments were performed at
various concentrations of alfentanil and sevoﬂurane ranging from 0 to 50 ng/ml for
alfentanil and from 0 to 0.4 end-tidal concentration (ET%) for sevoﬂurane, and at var-
ious combinations. The results were as follows: alfentanil and sevoﬂurane, when ad-
ministered separately, depressed ventilation, HR, and the ventilatory and HR responses
to acute hypoxia in a dose-dependent linear manner; when combined, their depressant
eﬀect on ventilation and HR was synergistic, whereas their eﬀect on the hypoxic re-
sponses was additive; relative to normoxic baseline parameters (V˙i, VT , RR, and HR)
the responses to hypoxia showed greater sensitivity to the eﬀects of alfentanil and
sevoﬂurane (i.e. depression occured at lower drug concentrations) when the drugs are
administrated separately and when combined; the BIS was sensitive to sevoﬂurane but
not to alfentanil, even when these agents were combined (inert interaction).
In Chapter 7, the eﬀect of steady state concentrations of intravenous anesthetic,
propofol, and short acting opioid, remifentanil, given separately and in combination, on
cardiorespiratory control and BIS was assessed in 22 healthy volunteers. In each sub-
ject one control, one remifentanil, one propofol, and at least one propofol-remifentanil
combined study were obtained (measured arterial blood concentration range for propo-
fol 0-2·6 µg/ml, and for remifentanil 0-2·0 ng/ml). Respiratory studies consisted of
ventilatory responses to three to ﬁve increases in PETCO2. The results show the follow-
ing: remifentanil and propofol caused a dose dependent depression of respiration, as
observed by an increase in resting PETCO2 and decreases in resting ventilation, slope
of the ventilatory response to CO2 (S), and ventilation at a ﬁxed PETCO2 of 55 mmHg
(V˙55); whereas remifentanil shifted the V˙i-CO2 response curve in a parallel manner to
higher PETCO2 levels, propofol reduces the slope of the response rather than shift-
ing its position; When combined, their depressant eﬀect on resting V˙i, resting PETCO2,
S, and V˙55 was synergistic, with the greatest synergy observed for resting V˙i; the de-
pressant eﬀect of remifentanil and propofol, when administered separately, on blood
pressure and heart rate was modest, when combined their depressant eﬀect was addi-
tive; the BIS is sensitive to propofol but not to remifentanil, even when these agents
are combined. Furthermore, these results indicate that in the clinical situation, when
combining remifentanil and propofol in a spontaneous breathing patients, it might be
safer to titrate the propofol dose with a constant remifentanil background if more or
less sedation is needed, since there should be little change in the amount of respiratory
depression, but if less respiratory depression is required, then remifentanil would need
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to be reduced.
The inﬂuence of tramadol on ventilatory control was investigated in Chapter 8. Tra-
madol is an analgesic with putative opioid and non-opioid modes of action. The respi-
ratory eﬀects of tramadol are not clear, with studies showing conﬂicting results. The
contribution of the µ-opioid receptor to tramadol induced respiratory depression, as
measured by its eﬀect on the V˙i-CO2-response, was determined in the anesthetized cat.
Respiratory depression by tramadol was reduced by∼70% after naloxone pretreatment,
indicating that at least 70% of tramadol‘s respiratory eﬀect is related to its action at
opioid receptors.
In Chapter 9, the complex of factors that interact on the cardiorespiratory control sys-
tem in postoperative patients is examined. In this study we assessed how well patients
after major abdominal surgery and intensive care were able to respond to episodes of
airway obstruction, by simulating the changes in chemosensory input that they would
experience during an episode of obstruction. We used a computer-controlled inspired
gas forcing system to increase CO2 and reduceO2 in the way these changes occur during
airway obstruction. The eﬀect of 1 to 3 ramp-like combined hypoxic and hypercapnic
stimuli, without initial added O2 and 1 to 3 with initial increased inspired O2 (Fi = 0.3)
on ventilation was assessed in 40 patients after major abdominal surgery and 3 days
of intensive care (IC) in a high dependency unit (Ward 9 of the former Royal Inﬁrmary
of the University of Edinburgh). Six to eight weeks after discharge from the hospital
the patients were asked to return for a review study, and so each patient served as its
own control. The results show that initially but not on review, all patients showed el-
evated C-reactive protein levels, a sign of inﬂammatory response. Furthermore, while
morphine blood concentrations were relatively high (> 50 nM), respiratory depression
was modest with only ∼30% depression of ventilatory responses to the combined hy-
percapnic and hypoxic stimuli and 11% increase in resting PETCO2. Our results suggest
that depression seen in patients was about half of the depression seen after morphine
in volunteers. This is not surprising taken into account the fact that respiration in pa-
tients is related to the balance between stimulation from pain, stress, the inﬂammatory
response, and activated chemoreﬂexes and depression resulting from sedation, the di-
rect eﬀect of analgesics and anesthetics on respiratory neurones. This seems to suggest
that the ventilatory responses set at the restoration of blood gases in between episodes
of upper airway obstruction remain suﬃciently eﬀective.
In Conclusion, the data collected in this thesis show that:
• The fast component of the ventilatory response to CO2 arises from the peripheral
chemoreceptor at the carotid body;
• Halothane-induced depression of the ventilatory response to hypoxia is prevented
by pretreatment with antioxidants;
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• A sedative dose of propofol decreases the acute hypoxic ventilatory response by
∼50%;
• Propofol, at a bispectral index value of 60 to 70, causes depression of the dynamic
response to CO2 via an exclusive eﬀect within the central chemoreﬂex loop;
• Alfentanil and sevoﬂurane, when administered separately, depress ventilation,
heart rate, and the ventilatory responses to acute hypoxia in a dose dependent
linear manner, when combined, their depressant eﬀect on ventilation and heart
rate is synergistic, whereas their eﬀect on the hypoxic responses is additive;
• Remifentanil and propofol cause, when administered separately, a dose depen-
dent depression of respiration. When combined the depressant eﬀect of remifen-
tanil and propofol on resting V˙i, resting PETCO2, S, and V˙55 is synergistic, with the
greatest synergy observed for resting V˙i. The depressant eﬀect of remifentanil
and propofol, when administered separately, on blood pressure and heart rate is
modest, when combined their depressant eﬀect is additive;
• The bispectral index is unable to extract the sedative eﬀects of opioids, alone or
in combination with anesthetics;
• Tramadol depresses the ventilatory response to CO2. This eﬀect is at least for 70%
related to its action at opioid receptors;
• In patients after major abdominal surgery and Intensive Care on PCA morphine,
respiratory depression is modest and about half of what is seen after morphine in
volunteers.
Valuable information regarding the cardiorespiratory control in perioperative patients
in this thesis was obtained. The precise mechanism and complex of factors that play
a role in perioperative respiratory depression remain unknown. Elucidation of these
mechanisms is of evident clinical importance. Future studies should focus on the com-
plex way the eﬀects of genetic and acquired risk factors (e.g., sex, congenital hypoven-
tilation syndrome, obesity, sleep apnea syndrome, age), pain and pain relief, arousal
state, upper airway obstruction, oxygen therapy, surgery and direct depressant eﬀects
of residual anesthetics on respiratory sensors and neurons interact and together de-
termine respiratory eﬃcacy (breathing and breathing responses to hypoxia and hyper-
capnia) in perioperative patients. A ﬁrst attempt was made in the study described in
Chapter 9. In this study we found a modest respiratory depression despite relative
high morphine blood concentration. Suggesting that the ventilatory responses set at
the restoration of blood gases in between episodes of upper airway obstruction remain
suﬃciently eﬀective. However, the ample data showing sometimes severe nocturnal
hypoxemia after abdominal surgery suggest the contrary. Evidently, further studies are
required to resolve this matter.

10 Samenvatting en Conclusies
ZOWEL ANESTHESIE als de operatie beïnvloeden het ademregelsysteem. De eﬀecten
zijn in de eerste twee tot drie dagen na de operatie duidelijk aantoonbaar. In deze pe-
riode is het ademminuutvolume gereduceerd, er kan sprake zijn van hypercapnie en
frequente en kortdurende perioden van soms diepe hypoxie komen voor. Dit laatste
doet zich met name voor tijdens de slaap. Ook treden perioden van bovenste luchtweg-
obstructie (obstructieve apneu’s) frequent op. Tijdens een hypoxische periode blijft
de patiënt ademen, maar hypoxie en hypercapnie hebben verdere eﬀecten. Het sym-
pathische zenuwstelsel wordt geactiveerd en dit kan weer leiden tot tachycardie, hy-
pertensie en ischaemische ECG veranderingen. Om hypoxie, hypercapnie en acidose
al dan niet veroorzaakt door bovenste luchtwegproblematiek te bestrijden zijn goed
functionerende perifere chemoreceptoren noodzakelijk, niet alleen voor de noodzake-
lijke hyperventilatoire respons, maar ook om de bovenste luchtwegmusculatuur aan te
spannen en aldus bovenste luchtwegobstructies op te heﬀen of te voorkomen. Het is
daarom van belang om de interactie en het werkingsmechanisme van anesthetica en
analgetica op het respiratoir regelsysteem te bestuderen en te begrijpen. In dit proef-
schrift worden experimenten beschreven die het inzicht in het complex van factoren die
samen het (cardio)respiratoir regelsysteem bepalen en beïnvloeden bij perioperatieve
patiënten, vergroot. De experimenten werden uitgevoerd bij proefdieren, vrijwilligers
en patiënten.
In hoofdstuk 2 wordt de ademrespons op hypercapnie (verhoogde arteriële koolzuur-
spanning) en hypoxie (verlaagde arteriële zuurstofspanning) beschreven bij gezonde
vrijwilligers en patiënten bij wie het glomuslichaampje (glomus caroticum, carotid body),
enkel- of dubbelzijdig, operatief is verwijderd vanwege een glomustumor. In het glo-
mus caroticum bevinden zich de perifere chemoreceptoren. De ventilatoire respons op
een stapsgewijze verhoging van de eind-expiratoire koolzuurspanning (PETCO2) is te
verdelen in een snelle (τ ∼10 s) en een langzame (τ ∼120 s) component. Aangenomen
wordt dat de snelle component z’n origine heeft in de perifere chemoreﬂexlus (met als
sensoren de perifere chemoreceptoren in het glomus caroticum), terwijl de langzame
component afkomstig is van de centrale chemoreﬂexlus (met als sensoren de centrale
chemoreceptoren in de ventrale medulla). Deze studie is een poging om bij de mens de
hypothese te valideren dat het glomus caroticum de sensoren bevat waaruit de snelle
ventilatoire component voortkomt (tijdens stimulatie met koolzuur). De resultaten
laten zien dat bij personen, die een dubbelzijdige glomus caroticum resectie hebben
ondergaan de dynamische V˙i-CO2 respons het best te beschrijven is met één (langzame)
component en dat er geen verbetering optreedt na toevoeging van een tweede compo-
nent. Doet zich een verbetering voor met de introductie van een tweede (snelle) com-
ponent, dan wordt dit geassociëerd met de aanwezigheid van een perifere chemoreﬂex
respons. Dit was alleen het geval bij de groep éénzijdig geopereerde patiënten en bij de
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controle groep. Onze resultaten valideren de hypothese dat de snelle component van
de ventilatoire respons op hypercapnie afkomstig is van de perifere chemoreceptoren
in het glomus caroticum.
Het eﬀect van een antioxidantencombinatie (vitamine C en E) op de door halothaan
geïnduceerde depressie van de ventilatoire acute hypoxische respons (AHR) wordt in
hoofdstuk 3 beschreven. Halothaan veroorzaakt, reeds in zeer lage concentraties (0·05–
0·1 eind-expiratoir (ET) %), een uitgesproken depressie van het glomus caroticum en
daardoor van de AHR. Het mechanisme dat verantwoordelijk is voor ‘O2-sensing’ in
het glomus caroticum (en dus voor de AHR) is niet bekend, maar de literatuur geeft
aan dat de betrokkenheid van vrije radicalen goed mogelijk is. Van halothaan is het
bekend dat het onder hypoxische omstandigheden vrije radicalen produceert. De resul-
taten tonen aan dat een halothaan concentratie van 0·11 ET % de AHR deprimeert met
meer dan 50%. Deze depressie werd volledig voorkomen door een voorbehandeling met
de vitaminecocktail, maar niet door voorbehandeling met placebo. Deze opmerkelijke
bevinding vergoot ons inzicht niet alleen in het mechanisme van ’O2-sensing’, maar ook
in het mechanisme van halothaan-geïnduceerde ademdepressie. Tenslotte bieden deze
bevindingen nieuwe mogelijkheden voor therapeutisch ingrijpen om potentiëel levens-
bedreigende situaties in de postoperatieve periode, na gebruik van inhalatie anesthetica,
te voorkomen.
Onderzoek naar de eﬀecten van het populaire intraveneuze anestheticum propofol op
het ademregelsysteem wordt beschreven in de hoofdstukken 4 en 5. Het eﬀect van
propofol op tal van cardio-respiratoire parameters wordt bestudeerd tijdens lucht ade-
men (rust V˙i), hypercapnische stimulatie, kort- en langdurige hypoxie bij gezonde vrij-
willigers.
In hoofdstuk 4 wordt aangetoond dat propofol (in een zeer lage plasmaconcentratie
van circa 0·6 µg/ml) de acute hypoxische respons deprimeert met ∼50%. Een interes-
sante bevinding is de afwezigheid van de ontwikkeling van secundaire depressie van de
ventilatie door hypoxie (hypoxische ventilatoire depressie of HVD) gedurende 5 opeen-
volgende korte (3 min) perioden van hypoxie, terwijl eenzelfde periode aaneengesloten
hypoxie (15 min) wel HVD doet onstaan. Dit fenomeen is propofol-onafhankelijk. Om-
dat in dit protocol de V˙i-CO2 onbestudeerd bleef, is het aangrijpingspunt van propofol
binnen het ademregelsysteem niet duidelijk geworden. De door propofol veroorzaakte
ademhalingsdepressie kan tot stand zijn gekomen door een eﬀect op de perifere of
centrale chemoreﬂexlus, of secundair zijn aan de door propofol veroorzaakte sedatie.
De lokatie van het aangrijpingspunt van propofol binnen het ademregelsysteem wordt
verduidelijkt in hoofdstuk 5. Het eﬀect van propofol op de dynamische V˙i-CO2 res-
pons werd gemeten. Sedatieve propofolconcentraties veroorzaken een exclusieve de-
pressie van de centrale chemoreﬂexlus (de perifere chemoreﬂexlus blijft onaangetast
door propofol). Dit is een bijzondere bevinding die in contrast staat met het feit dat
inhalatieanesthetica een selective depressie geven van de perifere chemoreﬂexlus. We
schrijven dit toe aan het verschil in het werkingsmechanisme van propofol en inhala-
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tieanesthetica. Het is zeer goed mogelijk dat het waargenomen verschil gerelateerd is
aan de antioxidatieve werking van propofol tegenover de pro-oxidatieve werking van
inhalatie anesthetica (zie hoofdstuk 3).
In de hoofdstukken 6 en 7 wordt het eﬀect van de gecombineerde toediening van opio-
iden en anesthetica onderzocht. Dit gebeurt met behulp van de techniek van respons-
oppervlak-analyse. Deze techniek stelt ons in staat om 3D representaties van de con-
centratie-respons relatie te construeren alsmede de wijze van interactie (additief, syn-
ergistisch of antagonistisch) vast te stellen over het gehele responsoppervlak. Omdat
het gecombineerd toedienen van anesthetica en opioiden gemeengoed is in de anesthe-
siologie, ook in spontaan ademende patiënten, geven deze studies ons informatie die
kan leiden tot het maken van doseringsschema’s voor optimale analgesie of sedatie met
minimale ademdepressie.
Initieel is het eﬀect van het gecombineerd toedienen van een opioid, alfentanil, en
een inhalatieanestheticum, sevoﬂuraan, onderzocht (hoofdstuk 6). De invloed van ver-
schillende concentraties van alfentanil alleen (0–50 ng/ml) en sevoﬂuraan alleen (0–0·4
ET%) en meerdere concentratiecombinaties werd gemeten op CO2-gestimuleerde ven-
tilatie en de acute hypoxische respons. Alfentanil en sevoﬂuraan hebben een dosis
afhankelijk deprimerend eﬀekt op beide parameters. In combinatie was het eﬀect op
de CO2-gestimuleerde ventilatie synergistisch, op de AHR additief. De depressie van de
AHR treedt op bij veel lagere concentraties van beide middelen (zowel indien separaat
toegediend als in de combinatie).
Vervolgens werd de interactie van een intraveneuze anestheticum, propofol, en een
opioid, remifentanil, bestudeerd (hoofdstuk 7 ). Remifentanil en propofol gaven een
dosis afhankelijke respiratoire depressie. Tijdens de gecombineerde toediening is het
deprimerende eﬀect uitgesproken synergistisch. De resultaten duiden er verder op dat
indien de anesthesioloog tijdens de anesthesie met de combinatie remifentanil/propofol
meer of minder sedatie wenst hij of zij er verstandig aan doet de propofolconcentratie
te wijzigen. Dit zal weinig tot geen additioneel eﬀect op de ademhaling hebben. Is
echter toch minder ademdepressie gewenst dan heeft het slechts zin de remifentanil
concentratie te wijzigen. Dit zal weinig eﬀect hebben op het sedatie/hypnose niveau
van de patient.
In hoofdstuk 8 wordt het eﬀect van tramadol op het ademregelysteem onderzocht in
een experimenteel kat model. Tramadol is een analgeticum met zowel opioide als non-
opioide werkingsmechanismen. Het resultaat van deze studie is dat minstens 70% van
het ademdeprimerende eﬀect van tramadol tot stand komt via opioid-receptoren.
De ademregulatie in de postoperatieve fase werd gemeten in patiënten na uitgebreide
abdominale chirurgie en twee tot drie dagen intensieve zorg (hoofdstuk 9). Het doel
van de studie is te bestuderen of deze patiënten in staat zijn om adequaat te reageren
op perioden van bovenste luchtwegobstructie. Veranderingen in de inspiratoire gascon-
centraties werden toegediend alsware het veranderingen in de chemische samenstelling
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van het bloed tijdens een bovenste luchtwegobstructie. Dit resulteerde in een geleide-
lijke toename in de PETCO2 al dan niet gecombineerd met een geleidelijke daling van
de arteriële zuurstofsaturatie. De ventilatiereactie werd vervolgens gemeten. Patiënten
werden zowel direct postoperatief als 6 tot 8 weken later onderzocht. De resultaten
laten zien dat initieel maar niet tijdens de vervolgstudie, alle patiënten een verhoogde
bloedspiegel van het C-reactief eiwit hadden (een teken van een actief onstekingspro-
ces). Terwijl de morﬁne plasmaconcentratie relatief hoog was bleek de respiratoire
depressie bescheiden te zijn in de postoperatieve fase. Dit staat in schril contrast tot
de bevinding bij gezonde proefpersonen die ernstige ademdepressie tonen na toedien-
ing van morﬁne (leidend tot plasmaconcentraties zoals bij onze patiënten gemeten). Dit
is niet verbazingwekkend als men in ogenschouw neemt, dat de ademhaling bij patiën-
ten bepaald wordt door de balans tussen stimulatie door pijn en stress, het ontstek-
ingsproces en geactiveerde chemoreﬂexen enerzijds en depressie door sedatie en de
direct deprimerende eﬀecten van anesthetica en analgetica op respiratoire neuronen in
het perifere en centrale zenuwstelsel anderzijds. Onze data suggereren dat de ademre-
spons, die nodig is om hypoxie en hypercapnie te herstellen na of tijdens een bovenste
luchtwegobstructie redelijk intact is.
IN CONCLUSIE, de data beschreven in dit proefschrift tonen het volgende aan:
• De snelle ventilatoire component tijdens koolzuurstimulatie is afkomstig van de
perifere chemoreceptoren in het glomus caroticum;
• De depressie van de hypoxische ventilatoire respons door lage concentraties ha-
lothaan is te voorkomen door voorbehandeling met antioxidanten;
• Een lage dosis propofol deprimeert de acute hypoxische ventilatorie respons met
50%;
• Propofol deprimeert de dynamische V˙i-CO2 respons via een exclusief eﬀect binnen
de centrale chemoreﬂexlus;
• Het combineren van lage doses opioiden en anesthetica leidt veelal tot synergis-
tische interacties met forse ademdepressie die het best wordt tegengegaan door
de opioidconcentratie te verlagen;
• Ademdepressie door tramadol wordt voor minstens 70% bepaald door interactie
met opioidreceptoren;
• Bij patiënten na een grote buikoperatie en intensieve zorg lijkt de ademhalingsde-
pressie bescheiden te zijn.
In de studies beschreven in dit proefschrift is waardevolle informatie over het (car-
dio)respiratoir regelsysteem bij de perioperatieve patiënt verkregen. Het preciese mech-
anisme en het complex aan factoren dat een rol speelt bij de perioperatieve veranderin-
gen in het ademregelsysteem blijft grotendeels onduidelijk. Opheldering hiervan is
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van grote waarde voor de klinische praktijk. Toekomstige studies zullen zich moeten
richten op de interactie van de chirurgische stress, postoperative pijn en pijnstilling,
bovenste luchtwegobstructie, zuurstoftherapie en de eﬀecten van anesthetica en anal-
getica op dit belangrijke regelsysteem. Een eerste poging door ons ondernomen wordt
beschreven in hoofdstuk 9. In deze studie vonden we een bescheiden eﬀect op de
ademhaling na uitgebreide abdominale chirurgie, ondanks relatief hoge morﬁneconcen-
traties. Dit suggereert dat de ventilatoire respons, die nodig is om de bloedgaswaarden
te herstellen na of tijdens een bovenste luchtwegobstructie, redelijk suﬃciënt zou func-
tioneren in de postoperatieve patiënt. Echter het ruime aantal studies in de literatuur,
dat laat zien dat bij postoperatieve patiënten frequente perioden van soms diepe hy-
poxie voorkomen, suggereert het tegenovergestelde. Verder onderzoek zal nodig zijn
om ons inzicht in deze materie te vergroten.
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List of Abbreviations and Symbols
Main Respiratory Terms Modifiers
AHR acute hypoxic response a arterial
Bk apneic threshold C central loop related
CO2 carbon dioxide e expired
F fraction ET end-tidal
G chemoreﬂex gain i inspired
HVD hypoxic ventilatory decline n parallel noise
O2 oxygen P peripheral loop related
P partial pressure T total
RR respiratory rate
S ventilatory CO2 sensitivity
SPO2 oxygen saturation
T time delay
τ time constant
V˙i inspired minute ventilation
VT tidal volume
W measurement noise
Modeling Terms of Chapters 6 and 7
AIC Akaike’s information criterion
C25 concentration causing 25% eﬀect
C50 concentration causing 50% eﬀect
E eﬀect
E0 baseline eﬀect
γ shape parameter
λ scaling parameter
Miscellaneous Terms
AOX antioxidant
BIS bispectral index
CBF cerebral blood ﬂow
CBR carotid body resection
DEF dynamic end-tidal forcing
EEG electroencephalogram
GABA γ amino butyric acid
HR heart rate
MAP mean arterial pressure
MFBS multifrequency binary sequence
OR opioid receptor
ROS reactive oxygen species
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Stellingen behorende bij het proefschrift
CardioRespiratory Control in the Perioperative Patient: from bench to bedside
1. Ademhalingsdepressie, veroorzaakt door het eﬀect van subanesthetische concen-
traties van inhalatieanesthetica op de perifere chemoreceptoren (gelocaliseerd in
het glomus caroticum), is eﬀectief te antagoneren door de toediening van antiox-
idanten.
Hoofdstuk 3 van dit proefschrift.
2. In tegenstelling tot de inhalatieanaesthetica heeft propofol geen selectief ademha-
lingsdeprimerend eﬀect op de perifere chemoreceptoren. Dit is hoogstwaarschijn-
lijk gerelateerd aan de antioxidatieve eigenschappen van propofol.
Hoofdstuk 5 van dit proefschrift.
3. De ademhaling bij patiënten, na een grote buikoperatie en postoperatieve pijnstil-
ling door morﬁne, is gedeprimeerd, ondanks stimulerende invloeden van pijn en
stress.
Hoofdstuk 9 van dit proefschrift.
4. De bispectrale index van het EEG is niet in staat de sedatieve eﬀecten van opioïden
aan te tonen, zelfs niet indien deze worden gecombineerd met een anestheticum.
Hoofdstuk 6 en 7 van dit proefschrift.
5. In tegenstelling tot morﬁne heeft morﬁne-6-glucuronide nauwelijks eﬀect op de
isocapnische hypoxische ventilatoire respons. Dit is een belangrijke aanwijzing
dat deze opioïden hun werking hebben via een separaat receptorsysteem.
6. Ondanks het gunstige bijwerkingsproﬁel van morﬁne-6-glucuronide zal het alleen
dan een acceptabel alternatief voor morﬁne zijn indien de gebruiksprijs vergelijk-
baar is aan die van morﬁne.
7. De ’bootstrap’ techniek is geschikt om het meest adequate model uit een serie niet
geneste modellen te selekteren.
8. De bloed-biofase equilibratie constante (keo) is groter voor de eﬀecten op de adem-
haling dan voor de analgetische eﬀecten van intraveneus toegediende opioïden.
Dit kan duiden op een verzadigingsfenomeen in de banen die betrokken zijn bij
de ademhalingseﬀecten.
9. Ontdekken is zien wat iedereen heeft gezien en denken wat niemand heeft gedacht.
Albert Szent-Györgyi.
10. Budgettering van de gezondheidszorg en het wegwerken van wachtlijsten gaan
niet samen.
11. Vernieuwing in de politiek : de "sorry" cultuur van Paars is veranderd in de "zo
had Pim het gewild" cultuur van LPF.
12. Om iemands wind uit de zeilen te nemen, moet het diegene wel voor de wind gaan.
Diederik Nieuwenhuijs Leiden, 4 september 2002

 
  
        
